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Summary  
Exploring the genomic and phenotypic diversity of the Vibrio cholerae species 
Matthew James Dorman 
Vibrio cholerae is the aetiological agent of cholera, an acute diarrhoeal disease which 
is estimated to result in up to 143,000 deaths per annum. Cholera is a considerable public health 
concern because it can spread rapidly in and explosive pandemics. Current pandemic cholera 
is caused by a highly-clonal phylogenetic lineage of V. cholerae serogroup O1, which spreads 
across the globe in periodic ‘waves’. However, V. cholerae is a species rich in diversity, and 
although much is known about the population structure of the pandemic lineages, the biology 
and pathogenicity of non-pandemic and non-O1 V. cholerae has been comparatively neglected. 
In this dissertation, I have studied the biology, genome dynamics, and diversity of non-
pandemic V. cholerae, in comparison to the current pandemic lineage.  
I first present an analysis of the 1992-1998 cholera epidemic in Argentina, a country 
which had been free of pandemic cholera for nearly 100 years before 1992. I use the genome 
sequences of 490 V. cholerae from Argentina to study the micro-evolution of the pandemic 
lineage upon its introduction into a naïve population. I use these data to describe the 
progression of the Argentinian cholera epidemic using genomic epidemiology approaches, and 
to contrast this pandemic lineage to the non-epidemic V. cholerae that were present in 
Argentina at the same time as the pandemic lineage.   
I then present a study of important recent and historical V. cholerae isolates, sequenced 
to completion using long-read technologies. I describe aspects of these genomes that could 
only be resolved using closed assemblies, and present functional validations of several in silico 
observations. Having performed this forensic, manual study of a small number of genomes, I 
then extrapolate those insights into a wider context, by mapping the distribution of key genetic 
determinants of important V. cholerae phenotypes across a phylogenetic tree of 651 highly-
diverse V. cholerae. Finally, I integrate the knowledge gained in this research to make a rational 
selection of V. cholerae isolates for transcriptomic analysis, based on their phylogenetic 
position and gene content, to investigate whether differential gene expression might explain 
the stark differences between pandemic and non-pandemic V. cholerae.  
The data presented here add substantially to our understanding of the diversity of V. 
cholerae. They emphasise the stark differences in genome flux and evolution between 
pandemic and non-pandemic lineages. They also show that many of the genetic and phenotypic 
markers of epidemic and pandemic lineages are misleading, and do not describe that which 
they were originally chosen to describe.   
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Chapter 1 
 
Introduction 
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1.1 – Initial overview: Cholera, cholera incidence, and case definitions  
 
1.1.1 – Clinical presentation and incidence  
 
Cholera is an acute diarrhoeal disease transmitted via the faecal-oral route, caused by the Gram-
negative bacterium Vibrio cholerae [1–3]. Cholera leads to very rapid dehydration, and is 
characterised by the profuse production of ‘rice-water’ stools flaked with mucus [2]. 
Incomplete international reporting of cholera cases means that estimates of the global burden 
of cholera disease are underestimates [4]. Nonetheless, it has been estimated that there are 2.8-
2.9 million cases of cholera annually [4, 5], and up to 143,000 deaths from cholera per annum 
[4, 6]. Without intervention, global cholera cases have been projected to rise to ~3.7 million 
cases per annum by 2030 [7]. It has also been estimated that 1.3 billion people in endemic 
countries are at risk of contracting cholera [4]. Cholera is considered by some to be a disease 
of the poor, and low-income countries have been shown to be more affected by cholera than 
middle- or high-income countries [8]. The World Health Organisation (WHO) and Global 
Taskforce for Cholera Control (GTFCC) have published a strategic roadmap which aims to see 
cholera eliminated by the year 2030 [9].  
 
1.1.2 – Treatment and vaccines 
 
The principal treatment for clinical cases of cholera is the administration of rehydration 
therapy, either oral rehydration if no or some dehydration has occurred, or intravenous 
rehydration for cases of severe dehydration or shock [10]. Although cholera is caused by a 
bacterial pathogen, the administration of antibiotics is only recommended to occur in 
conjunction with, rather than instead of, oral rehydration [11]. Historically, tetracycline was 
the antibiotic of choice for treatment of severe cholera cases [12], and current guidance from 
the Centers for Disease Control and Prevention (CDC) is that doxycycline and tetracycline are 
useable in the treatment of cholera although azithromycin, erythromycin, and other 
antimicrobials are also recommended [11]. Based on data collated by the CDC [11], 
doxycycline is recommended as the first-line antimicrobial of choice for cholera treatment by 
the WHO [13], the Pan-American Health Organisation (PAHO) [14], the International Centre 
for Diarrhoeal Disease Research, Bangladesh (icddr,b) [15], and Médecins Sans Frontières 
(MSF) [16].  
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Vaccines are available for cholera, which are principally either whole-cell/toxoid vaccines, or 
composed of live-attenuated vaccine strains of V. cholerae [1, 17], strains which may be 
genetically engineered [18, 19]. At the time of writing, at least seven oral killed cholera 
vaccines and four live-attenuated oral vaccines are either licenced or under development [20]. 
Three vaccines have been pre-qualified by the WHO – Dukoral®, ShancholTM and Euvichol®  
– and of these, ShancholTM and Euvichol® are included in the global oral cholera vaccine 
(OCV) stockpile created by WHO and funded in part by GAVI, the Global Alliance for 
Vaccines and Immunisation [17, 20]. This vaccine stockpile has been reactively deployed to 
reduce cholera transmission in settings of humanitarian crisis, such as amongst the Rohingya 
refugee population in Bangladesh [21]. The development of new cholera vaccines and vaccine 
strains is an area of active research, and strains such as HaitiV have been designed to be 
intrinsically recalcitrant to becoming toxigenic [22]; these strains have shown evidence of 
conferring protection against infection with toxigenic V. cholerae in mouse models [23, 24].  
 
1.1.3 – Epidemiology and case definitions 
 
One of the most distinct and notorious epidemiological features of cholera is the ability of its 
aetiological agent to spread rapidly and to cause explosive outbreaks. These transmissions and 
outbreaks are exemplified by the Haitian cholera epidemic of 2010, associated with an 
intercontinental transmission event [25–27], and more recently, outbreaks in Yemen in mid-
2017 [28]. In addition to causing acute community outbreaks and national epidemics, V. 
cholerae also has the capacity to spread internationally in multi-continent cholera pandemics 
[1]. The epidemiology of cholera outbreaks and epidemics is traditionally associated with the 
work of John Snow, an English anaesthetist who mapped cholera cases in Broad Street and 
adjacent areas in London between 1849 and the 1850s [29, 30]. Snow’s observations identified 
contaminated water sources as the sources of cholera transmission within and around Broad 
Street, and were published in 1855 [30]. These are regarded as seminal examples of 
epidemiological practice [31].  
 
In order to track internationally the incidence and spread of cholera, common clinical 
definitions of a cholera case are required. The WHO and GTFCC, in the Roadmap to ending 
cholera by 2030 [9], define a confirmed cholera case as: 
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“A suspected case with Vibrio cholerae O1 or O139 confirmed by culture or PCR 
polymerase chain reaction and, in countries where cholera is not present or has 
been eliminated, the Vibrio cholerae O1 or O139 strain is demonstrated to be 
toxigenic” [9]. 
 
The same cholera case definition is used by the CDC [3, 32]. The definition for suspected 
cholera cases, which is also shared by the WHO and CDC [3, 9, 32], depends on whether or 
not a country is defined as suffering currently from an outbreak of cholera (defined as “the 
occurrence of at least one confirmed case of cholera and evidence of local transmission” [9]). 
In countries where cholera outbreaks have not been declared, a suspected cholera case is 
defined as:  
 
“Any patient 2 years old or older presenting with acute watery diarrhea and severe 
dehydration or dying from acute watery diarrhea” [3, 32].  
 
Acute watery diarrhoea (AWD) is defined as “three or more loose or watery (non-bloody) stools 
within a 24-hour period” [9]. In countries where cholera outbreaks have been declared, a 
suspected cholera case is defined as:  
 
“Any person presenting with or dying from acute watery diarrhea” [3, 32]. 
 
These definitions are fundamental to assessing the success of cholera elimination campaigns 
such as that of the WHO: a country which has successfully eliminated cholera is defined as one 
which has: 
 
“...no confirmed cases [of cholera] with evidence of local transmission for at least 
three consecutive years and has a well-functioning epidemiologic and laboratory 
surveillance system able to detect and confirm cases” [9]. 
 
1.1.4 – This chapter 
 
In this Introduction, I will first present the mechanisms by which V. cholerae is known to cause 
clinical cholera, as defined above. I will also introduce the genetic determinants that are 
responsible for this canonical disease, and frame these molecular details in the context of 
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historical and current cholera pandemics. I will then summarise key microbiological 
phenotypes that are intimately linked to our understanding of these pandemics, as well as some 
additional genetic determinants that have been hypothesised to enable certain bacteria to cause 
pandemic cholera. Finally, I will introduce the understanding gleaned from the application of 
genome sequencing to studying V. cholerae, in order to identify the key aims of this thesis.  
 
1.2 – Vibrio cholerae  
 
1.2.1 – V. cholerae microbiology 
 
Since its first description by Pacini in 1854 [33, 34], V. cholerae has been recognised as the 
aetiological agent of cholera. Pacini’s original description of V. cholerae is considered to be 
that of the type species of the Vibrio genus [35]. During the 1880s, Robert Koch also observed 
V. cholerae in clinical specimens while studying cholera in Egypt, which he termed 
‘Kommabazillen’, or ‘Vibrio comma’, on the basis of the cellular morphology of the bacterium 
(reviewed by [36]).  
 
V. cholerae is a comma-shaped Gram-negative bacterium, and typically expresses a 
monotrichous polar flagellum which can be observed microscopically (Figure 1.1). The species 
is highly-diverse, exemplified by the fact that more than 200 discrete serogroups of V. cholerae 
have been described [37]. As well as this multitude of antigenic profiles, the species’ diversity 
has also been highlighted by various taxonomic and biochemical studies, which have 
demonstrated that V. cholerae can display numerous phenotypes, ranging from the capacity to 
utilise certain sole carbon compounds to the ability to secrete haemolysins and other toxins 
(e.g., [38–41]). These variable phenotypes have been used to assign V. cholerae to specific 
biotypes (section 1.3.1.4). The natural environment for many V. cholerae is that of estuarine 
waters, and can involve the colonisation of chitinous copepods or shellfish (e.g., [42–45]). The 
species can tolerate a moderate range of salinity and temperature compared to other members 
of the genus [46], and can metabolise a number of carbon compounds [38] including chitin 
[47].  
 
Horizontal gene transfer (HGT) is a fundamental aspect to V. cholerae genome biology and to 
the evolution of the species, and will be explored in detail later (section 1.2.5). V. cholerae is 
naturally competent when exposed to appropriate inductive signals or cultured on chitinous 
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materials [48], harbours a large chromosomal integron (gene capture apparatus) [49], and can 
employ a type VI secretion system (T6SS) with which to kill adjacent prey bacteria and liberate 
free DNA into its environment which it can access, using natural competence, to avail of novel 
genetic material [50, 51]. Bacteriophages, genomic islands, and integrative/conjugative 
elements also all have roles to play in the evolution of this species [52–56], and will be 
discussed in subsequent sections. 
 
V. cholerae is an unusual enteric bacterial pathogen because, like other Vibrio spp., this species 
normally has two chromosomes [57]. The chromosome biology of this pathogen is an area of 
current research, and this species has been used as a model for studying the regulation of 
chromosomal replication timing and dynamics in bacteria with multiple chromosomes [58, 59]. 
For example, V. cholerae was used to elucidate the role for the crtS locus in coupling the 
replication of chromosome 2 to that of chromosome 1 in Vibrio spp., such that chromosome 1 
must replicate as far as crtS before chromosome 2 replication is initiated [58, 60]. Some rare 
exceptions have been reported or engineered in vitro in which both chromosomes have fused 
into one macromolecule [61, 62], and in V. cholerae in which chromosomes 1 and 2 are fused, 
the replication origins from both chromosomes may, or may not, be active [63, 64]. It has also 
been hypothesised that the second V. cholerae chromosome, on which the V. cholerae integron 
is located [65], was originally co-opted from a plasmid [66].  
 
 
Figure 1.1 – Scanning electron micrograph of V. cholerae. SEM produced from fixed V. cholerae colonies 
grown on LB agar plates. Several comma-shaped bacteria can be seen in this image, amongst extracellular 
polysaccharide (biofilm). A cell producing a polar monotrichous flagellum is indicated (white arrow). Image 
captured by Claire Cormie. 
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The specific mechanistic details of how this bacterium causes canonical cases of clinical 
cholera, and how it acquires the capacity to do this via HGT, will now be discussed.  
 
1.2.2 – Mechanism of bacterial pathogenesis in cholera cases 
 
The acute watery diarrhoea that is characteristic of cholera cases is caused by the cholera toxin 
(CT). This toxin was first discovered as a component produced by V. cholerae that was retained 
in cell-free filtrates produced from bacterial cultures, and produced a strongly-positive reaction 
in a rabbit ileal loop assay for diarrhoea [67]. CT is an AB5 exotoxin encoded by the operonic 
ctxA and ctxB genes, which are homologous to the ltA and ltB genes of enterotoxigenic 
Escherichia coli that express the heat-labile enterotoxin, LT [68–70]. CT can be only 
elaborated by toxigenic V. cholerae – that is to say, V. cholerae which harbour ctxAB. This 
operon is encoded by a filamentous, lysogenic bacteriophage dubbed CTXφ, the genome of 
which integrates into the V. cholerae chromosome after CTXφ infects the bacterium [52, 71] 
(section 1.2.3).  
 
CT consists of five identical CtxB subunits and one CtxA protein, and the three-dimensional 
structure of this hetero-hexamer has been determined [72]. After transcription and translation 
of ctxAB, CT is assembled in the bacterial periplasm [73], from where it is then secreted via a 
type II secretion system (T2SS), as part of the general secretory pathway (Gsp) [74–76]. It has 
been suggested very recently that specific mutations in the signal peptide sequence of ctxB can 
influence the efficiency by which pre-CtxB is processed and secreted from V. cholerae, thereby 
altering the amount of CT secreted and the relative toxigenicity of an isolate of V. cholerae 
[77].  
 
Once CT is secreted from V. cholerae, it is capable of binding to host receptors expressed by 
the epithelial cells of the small intestine. The primary binding site for CT is the GM1 ganglioside 
[78], which contains galactose and sialic acid residues with which CtxB interacts directly [79]. 
It should be noted that secondary receptors have been identified to which CtxB5 or the CtxAB5 
can bind, including the LewisX histo-blood group antigen, L-fucose, and other fucosylated 
glycoproteins [80–82]. The significance of these secondary receptors in the context of in vivo 
disease is the subject of current research.  
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Once CT has bound to its receptors, endocytosis occurs, which may take place via multiple 
clathrin-dependent and clathrin-independent pathways [83]. Following endocytosis, CT is 
trafficked via the trans-Golgi network and endoplasmic reticulum, where the CtxA protein is 
unfolded and proteolysed into the A1 and A2 subunits [83–86]. CtxA1 causes the ADP-
ribosylation of adenylate cyclase [87–89]. This “locks” adenylate cyclase into a state in which 
it is bound to GTP, dramatically elevating the rate at which the enzyme converts ATP to cyclic 
AMP, and increasing the intracellular concentration of cAMP. cAMP-responsive protein 
kinase (protein kinase A) is stimulated by increased cAMP levels, leading to an activation of 
the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel and a loss 
of chloride ions to the lumen of the intestine [90]. This altered ion gradient means that water is 
lost from the cell into the intestinal lumen, which is rapidly excreted, forming the ‘rice-water’ 
stool that is characteristic of cholera cases. A model of these steps is presented in Figure 1.2.      
 
 
Figure 1.2 – Model of V. cholerae pathogenesis leading to the diarrhoea characteristic of cholera. Drawn 
from steps outlined in section 1.2.2. CT receptors (GM1 or others) are indicated as a green circle on the epithelial 
membrane. TCP is elaborated by V. cholerae and acts as a colonisation factor in the intestine. Not to scale.  
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1.2.3 – Molecular genetics of the CTXφ bacteriophage 
 
The CTXφ bacteriophage infects V. cholerae via its receptor, the toxin co-regulated pilus, TCP 
[55, 91, 92]. Possession of the genes encoding this type IV pilus is therefore canonically 
necessary for CTX- V. cholerae to be lysogenised by CTXφ, though there is some evidence 
that other transducing phages can mobilise CTXφ prophages independently of the requirement 
for TCP [93, 94]. The genes encoding TCP were found to be encoded on a pathogenicity island, 
initially dubbed the Vibrio pathogenicity island (VPI) [55] and now referred to as VPI-1 [54]. 
VPI-1 contains the tcp gene cluster (encoding the TCP receptor) as well as genes encoding an 
accessory colonisation factor (acf cluster) and toxT, which encodes a master regulator of 
virulence gene expression [55] (section 1.2.4).  
 
Upon infection of V. cholerae, the CTXφ genome circularises into a replicative form and can 
then integrate into the bacterial chromosome in an XerCD-catalysed recombination between 
the CTXφ attP site and bacterial attB site, producing hybrid attL and attR sequences [95, 96]. 
CTXφ typically integrates into the larger V. cholerae chromosome, at an attB site located near 
to the dif site on chromosome 1. However, it can also occasionally integrate into the smaller 
chromosome – again, at a site equivalent to the dif site on that molecule [97, 98]. The nature 
of this integration usually sees the integration of CTXφ prophages into the bacterial 
chromosome in tandem repeats [99]; multiple copies of CTXφ have been suggested to render 
it impossible for  CTXφ to be deleted from certain bacterial strains [69].  
 
CTXφ can replicate itself by producing ssDNA from chromosomal tandem arrays of CTXφ 
that are integrated in the bacterial chromosome. This is dependent on the product of the CTXφ-
encoded rstA gene – the RstA protein nicks the CTXφ replication origin located in the Ig-1 
intergenic region of the prophage [99, 100]. The exposed 3' site at this nicked site enables 
synthesis of CTXφ DNA up until the second, tandem CTXφ replication origin is encountered. 
This second Ig-1 site is also a substrate for RstA cleavage; this second nick creates a free CTXφ 
genome [99, 100]. Circularisation of this DNA and second-strand synthesis then forms an 
active replicative phage genome, which can then proceed to be packaged, forming infectious 
phage particles [101].  
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1.2.4 – Regulation of ctxAB and virulence gene expression 
 
Although CTXφ prophages and their complement of genes are necessary for the production of 
CT, work in heterologous systems has shown that possession of ctxAB alone is not sufficient 
to express high levels of CT [102]. In order for toxigenic V. cholerae to cause the production 
of rice-water stool, CT must be produced at high levels by the bacterium at an appropriate time 
for the toxin to bind to receptors on the luminal surface of the human gut epithelium (section 
1.2.2). Since V. cholerae is a non-invasive pathogen [103], ctxAB expression must therefore be 
activated at an appropriate point in the V. cholerae life cycle – i.e., for this to happen, V. 
cholerae must be ingested, survive exposure to environmental stresses in the stomach and 
upper intestine, and migrate through the mucus layer of the small intestine, to the epithelial 
cells of the intestine [104]. Consequently, the expression of ctxAB and other virulence genes is 
tightly regulated, the regulatory mechanism of which has been dissected by molecular 
biologists.  
 
The regulatory decision to activate transcription of ctxAB and other V. cholerae virulence genes 
is governed by the activity of the ToxT and ToxR transcription factors. ToxR was first 
described as a trans-factor that positively regulated the synthesis of CT, both in V. cholerae 
and when cloned into E. coli harbouring ctxAB [102]. ToxR was subsequently shown to be a 
transmembrane protein with a DNA binding domain [105]. In contrast, ToxT is an AraC-family 
transcriptional regulator [106] which binds to a specific sequence dubbed the ‘toxbox’ in the 
promoters of genes which it regulates [107]. The toxT gene is located on VPI-1 and therefore 
is only present in those isolates which harbour this horizontally-transferred genomic island 
[55], unlike toxR, which is a gene that is found in nearly all V. cholerae [108].  
 
The virulence regulon governed by ToxR encompasses the ctxAB and toxT genes, along with 
the tcp genes required to produce the toxin co-regulated type IV pilus TCP, so named because 
these genes are co-regulated with ctxAB [91]. ToxR also regulates the genes encoding two 
major V. cholerae outer membrane proteins, ompU and ompT [109]. ToxR can form 
homodimers with other ToxR proteins, and heterodimers with the ToxS protein [110]. The 
ToxT protein can activate ctxAB and tcp promoters independently of ToxRS [109], and also 
regulates the acf genes located on VPI-1 [111]. Expression of toxT is directly regulated by 
ToxRS [112], and TcpP, enhanced by TcpH, also activates toxT [113, 114]. TcpH acts by 
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preventing degradation of TcpP [115]. The tcpPH operon, also located on VPI-1, is regulated 
by other transcription factors such as AphA [116] (see Figure 1.3 for a summary).   
 
Although the cascade which activates CT expression is well-characterised, the integration of 
extracellular signals that must occur in order to make the ‘decision’ to activate this cascade is 
complex, and integrates perception of signals such as pH [117], bile (via TcpPH) [118, 119], 
and the secondary metabolite cyclo(L-phenylalanyl–L-proline) (cyclo(Phe-Pro)), via LeuO 
[120]. The intracellular concentration of cyclic di-nucleotides such as cyclic-di-GMP, 
modulated by systems such as the VieSAB three-component system, various 
phosphodiesterases and diguanylate cyclase enzymes [121–124], have been implicated in 
governing the regulation both of virulence gene expression and of the genes required for V. 
cholerae to switch between environmental and human-virulent behaviours [125, 126]. There is 
also evidence that global gene expression profiles in V. cholerae differ at the early and late 
stages of infection [127], and that bacteria which have exited a patient in stool have increased 
fitness and exist in an ‘hyper-infectious’ state [127–129]. Ablation of the ability of V. cholerae 
to respond to stress, such as by disrupting alternative sigma factors RpoE and RpoS [130, 131], 
has been shown to attenuate its pathogenicity, and to reduce its ability to reach high titres in 
the human gut [132]. Taken together, it is clear that the regulation of pathogenicity in V. 
cholerae is complicated, and involves multiple inputs as well as the utilisation of genes 
encoded both by the core and the accessory genome of the bacterium (summarised in Figure 
1.3).  
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1.2.5 – Importance of horizontal gene transfer in V. cholerae biology and pathogenicity 
 
As mentioned previously (section 1.2.3), the principal V. cholerae virulence determinants are 
encoded on mobile genetic elements, either CTXφ or VPI-1. These are mobile genetic elements 
that either actively engage in HGT (CTXφ) or engaged in this process ancestrally (VPI-1). 
Genomic islands other than VPI-1 also play important roles in V. cholerae biology. Following 
the identification of genes specific to classical and El Tor V. cholerae by Dziejman et al. [133], 
VPI-2 was formally characterised [134]. This genomic island encodes V. cholerae 
neuraminidase (sialidase, now NanH; EC 3.2.1.18), an enzyme which was first described in 
1947 as a protein which destroyed the receptor for influenza virus – hence, the protein was first 
known as the ‘receptor destroying enzyme’ [135]. The nanH gene was first cloned in 1988 
[136], and its product has been shown to be capable of hydrolysing higher-order gangliosides 
to that of GM1, [137]. However, purified sialidase does not appear to change the profile of toxin 
binding sites in the intestine of multiple species, in vitro or in vivo [78]. It remains uncertain 
whether this hydrolysis is to increase the number of potential receptors for CT during an 
infection or for growth, since it is known that V. cholerae can utilise sialic acid as a sole carbon 
source [138].  
 
Other V. cholerae genomic islands and prophages have also been identified, and their 
distribution amongst limited numbers of diverse V. cholerae have been described (e.g., [54, 
139–141]). Two important genomic islands, VSP-1 and VSP-2, have been identified from 
microarray data and comparative genome sequencing which have been purported to be found 
exclusively in those V. cholerae that cause current cholera pandemics [54, 133]. The function 
of these is not completely understood, though some work has been done on VSP-1 function 
[142]. Small RNAs (sRNAs) regulated by ToxT, such as TarB, modulate the expression of 
genes within VSP-1, including those genes encoding dinucleotide cyclase, which produces 
cyclic AMP-GMP (c-AMP-GMP) [142] (Figure 1.3). These cyclic dinucleotides and VSP-1 
have been implicated in modulating the ability of V. cholerae to colonise the intestine [142]. 
The function of VSP-2, and its variants, remains uncertain [143].  
 
Recombination has been shown to be important to V. cholerae evolution. For instance, 
recombination within the chromosomal region encoding the O-antigen has been postulated to 
be a mechanism by which V. cholerae may have undergone serogroup conversion [144, 145] 
(discussed further in section 1.3.2). Conversion of serotype is of particular clinical significance 
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because of the important immunogenic properties of specific O-antigens in cholera vaccine 
efficacy [146] (section 1.3.1.3).  
 
The evolution in recent years of many bacterial pathogens has been driven in part by the 
increased use of antimicrobials, and the emergence of antimicrobial resistant pathogens is a 
consequence of the selective pressures imposed by these drugs [147]. There is evidence of V. 
cholerae O1 acquiring multidrug resistance plasmids [148, 149] and resistance genes within 
the chromosomal integron [150–152], including resistance to fluoroquinolones both by 
acquisition of qnr genes [150, 153, 154] and by mutation in parC and gyrA [155]. Resistance 
determinants can also be encoded by a conjugative ICE-type element, dubbed SXT, which was 
first described as an element conferring resistance to multiple antibiotics in V. cholerae O139 
[156]. The SXT element is conjugative and self-transmissible, integrating into the V. cholerae 
chromosome in a RecA-dependent manner specifically within the VC_0659 locus [54, 59, 156].  
 
Unusually for a pathogenic bacterium, V. cholerae evolution does not appear to be driven by 
the need to acquire antimicrobial resistance (AMR) in response to direct therapeutic antibiotic 
usage; it should be noted that the antimicrobials to which these determinants render V. cholerae 
resistant (e.g., sulfamethoxazole, trimethoprim and streptomycin as in the case of SXT [156]) 
are not drugs which are used to treat cholera (section 1.1.2). There are, however, some 
examples of drug resistance being acquired by V. cholerae in response to therapeutic use of 
antimicrobials – for instance, as a consequence of the use of tetracycline to control a sensitive 
strain in Tanzania, V. cholerae O1 became resistant to tetracyclines upon the acquisition of an 
IncA/C resistance plasmid [157, 158]. It should also be emphasised that our understanding of 
antimicrobial resistance amongst V. cholerae is largely limited to the study of pandemic V. 
cholerae lineages, as the aetiological agents of pandemic cholera; we know much less about 
the distribution of resistance determinants amongst more diverse or non-pathogenic members 
of the species. This is a topic which will be addressed in this thesis (see Aims, section 1.5). 
 
1.3 – Pandemic and non-pandemic cholera 
 
1.3.1 – Pandemic cholera 
 
The discussion of Asiatic cholera above (sections 1.1, 1.2) describes a disease which is 
canonically caused by specific clones of V. cholerae serogroup O1 [1, 36], and it is dependent 
 
   15 
on the activity of CT on epithelial cells of the human intestine. However, when considering 
pandemic cholera, it is useful to recall that a pandemic of a disease, such as influenza, can be 
defined as: 
 
“an epidemic occurring worldwide, or over a very wide area, crossing 
international boundaries and usually affecting a large number of people” [159, 
160]. 
 
It is therefore important to bear in mind that for a clone of V. cholerae to be both the aetiological 
agent of cholera and of pandemic cholera, it must be capable of causing the disease described 
in section 1.1.1, as well as spreading rapidly across the globe. This point will be emphasised 
by several historical epidemics of cholera and cholera-like disease that were not caused by 
pandemic V. cholerae (sections 1.3.2 and 1.4.3). 
 
1.3.1.1 – History of cholera pandemics 
 
Seven pandemics of cholera have been described in recorded history [36, 161], the first six of 
which are believed to have been caused by V. cholerae of the classical biotype (a set of 
phenotypic tests used to identify certain V. cholerae - details of biotyping will be presented in 
section 1.3.1.4). It is important to state that although there is direct evidence that the sixth, fifth, 
and second pandemics were caused by classical biotype V. cholerae [97, 162, 163], it is inferred 
that the remaining historical pandemics were caused by classical V. cholerae. Snow’s work, 
carried out during the second pandemic [30], would therefore have described cholera caused 
by classical biotype V. cholerae. Hereafter, the term ‘classical’ is used to describe the biotype, 
and ‘Classical’ is used to denote the phylogenetic lineage comprised of classical biotype V. 
cholerae (see section 1.4).  
 
The twentieth century saw the transition from the sixth to the seventh cholera pandemic. The 
sixth pandemic occurred between 1899 and 1923 [36, 97, 163], and the seventh cholera 
pandemic began in 1961 [36, 164]. The onset of the seventh pandemic caused alarm because 
the V. cholerae which caused this pandemic were of the El Tor biotype rather than the classical 
biotype [161, 164, 165]. Consequently, and due in part to confusion in the nomenclature in use 
at the time, these El Tor biotype V. cholerae were referred to as “Vibrio paracholera” [165, 
166] (discussed further in section 1.3.2).  
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A detailed recapitulation of the history of the seventh cholera pandemic is beyond the scope of 
this thesis, but has been presented by several groups [25, 161, 164, 167–169]. Briefly, the 
seventh pandemic began in Sulawesi, Indonesia, in 1961 [161] and spread into Southeast Asia 
[165, 170], from where it subsequently spread to Africa by the early 1970s [158]. Cholera 
spread within the continent between 1970 and the early 1990s (reviewed by [167, 171, 172]), 
prior to its transmission into Latin America in the early 1990s. In 1991, cholera broke out in 
Lima, Peru, following a period of nearly 100 years in which South America was free of cholera 
epidemics [168, 173]. This epidemic proceeded to spread to other countries within Central and 
South America [174], though the highest case/fatality rates were associated with countries in 
Central America [175].  
 
More recently, cholera epidemics have been the subject of intense coverage by the popular 
press. In October 2010, an outbreak of cholera in Haiti began [176], which led to over 170,000 
infections and 3,600 deaths by December 2010 [177, 178]. Cholera cases continued to be 
reported between 2010 and 2017 [179]. The cholera epidemic in Yemen, which began in late 
2016 and continues today, was a similarly high-profile event [28, 180] and led to considerable 
numbers of disease cases – by 12th March 2018, 1,103,683 suspected cholera cases and 2,385 
deaths from cholera had been reported in Yemen [28]. These statistics underline the fact that 
pandemic cholera remains a serious and current public health concern.  
 
1.3.1.2 – The cholera paradigm 
 
As mentioned earlier (section 1.2.1), V. cholerae is capable of living in estuarine and brackish 
water, often in association with copepods and crustaceans with chitinous exoskeletons [45, 
181–183]. It has been observed repeatedly that cholera outbreaks are correlated with 
seasonality and rainfall (e.g., [184]). It has also been reported that V. cholerae, and other 
bacteria, can enter a ‘viable but non-culturable’ state of dormancy [185], in which bacteria 
were shown to be metabolically active (viable) but could not be cultured using standard 
microbiological methods [185, 186].  
 
Taken together, these observations led to the hypothesis that V. cholerae is autochthonous to 
estuarine environments [29, 187], and to the proposition of the ‘cholera paradigm’ [29]. In 
practical terms, this model assumes that environmental reservoirs harbour local populations of 
V. cholerae in an estuarine environment in which the bacterium is known to live [188]. Upon 
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exposure to favourable environmental or climactic conditions, including temperature, salinity, 
etc., these bacterial populations expand in size and can be ingested by humans, causing 
outbreaks of cholera [29]. This model suggests that cholera outbreaks result from the expansion 
of local populations of V. cholerae that reside within an area or environment which are then 
ingested by humans, and that climactic factors are the principal driving force behind cholera 
outbreaks (rather than human-to-human transmission of V. cholerae).  
 
Many of the data upon which the cholera paradigm was formed were carried out in the Bay of 
Bengal, and their applicability to other environments (particularly inland areas) which 
experience cholera epidemics and hotspots has been contested [167]. Genomic analysis of the 
V. cholerae lineage causing the current cholera pandemic also indicates that the cholera 
paradigm, and its reliance on local populations of V. cholerae seeding cholera outbreaks, is not 
consistent with the observation that a single lineage of toxigenic V. cholerae has caused 
pandemic cholera since 1961 (section 1.4.2; [158, 189]).  
 
1.3.1.3 – V. cholerae serogroups and serotypes 
 
As mentioned throughout section 1.3.1, cholera pandemics are caused by V. cholerae of 
serogroup O1. Nonetheless, over 200 serogroups of V. cholerae have been described on the 
basis of variation in the O-antigen of the bacterial lipopolysaccharide (LPS) [37, 190]. The V. 
cholerae LPS is highly immunogenic, and antibodies against LPS have been shown to mediate 
near-exclusive immunity to V. cholerae in both humans and animals [103]. In rabbit 
immunisation experiments, a highly synergistic immunity was conferred by purified LPS 
(serogroup O1) and CT when simultaneously administered to animals [103, 191]. Although all 
pandemic cholera to date has been caused by V. cholerae O1, it is important to state that some 
large-scale outbreaks in Southeast Asia have also been caused by V. cholerae O139; the details 
of these outbreaks and how they are related to pandemic V. cholerae O1 will be discussed in 
section 1.3.2.1.   
 
As early as the 1930s, when Gardner and Venkatraman studied the “original, varied, and 
middle” phenotypes of V. cholerae agglutination to specific O1 sera, it was recognised that 
there was additional subtlety to the serogrouping of pandemic V. cholerae O1 [192]. This was 
subsequently found to be due to Inaba/Ogawa serotype variation. “Inaba” and “Ogawa” were 
the names of two cholera patients in 1921 from whom the strains used to describe these 
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serotype variants were obtained [193]. A rare third serotype variant, Hikojima, has also been 
described – this is an unstable mixed phenotype in which an isolate simultaneously expresses 
Ogawa and Inaba antigens, though Hikojima isolates will ultimately type as Inaba [194–196].  
 
Ogawa serotypes are a result of wild-type activity of the WbeT protein (formerly named RfbT 
[197, 198]), which methylates the terminal perosamine sugar on the O1 lipopolysaccharide 
chain [197–199]. In the absence of this methyl group, an Inaba phenotype results, and V. 
cholerae will be agglutinated by Inaba rather than Ogawa antisera [197–199]. Mutations in 
wbeT that lead to an abolition of WbeT activity result in seroconversion of V. cholerae O1 
from Ogawa to Inaba serotype [197–200]. There is evidence that Ogawa to Inaba mutations 
occur frequently amongst V. cholerae, and also that reversion from Inaba to Ogawa serotype 
can occur in vivo, albeit rarely [197, 201, 202]. 
 
Inaba and Ogawa serotypes are significant because both elicit different immunological 
responses [20, 203]. Thus, they are both included in the formulation of cholera vaccines, such 
as DukoralTM [204]. Co-expression of the Inaba and Ogawa antigens by a stable Hikojima 
strain has also been exploited for vaccinology purposes [196, 205]. Serotyping of V. cholerae 
O1 continues to be a clinically relevant microbiological test performed on bacterial isolates [3, 
32], and diagnostic laboratories [206] and epidemiologists [207] also serotype V. cholerae O1 
as a matter of routine. Outbreaks of cholera are often described in terms of the serotype of V. 
cholerae O1 that is associated with the outbreak – for instance, the initial cholera epidemic in 
Peru, 1991 was associated with Inaba isolates and with Ogawa isolates in subsequent years 
[208]. Thus, both the serogroup and serotype of V. cholerae have historically been important 
phenotypes for understanding cholera epidemiology. This point will be re-visited later in this 
thesis (section 3.4.6). 
 
1.3.1.4 – Classical and El Tor biotypes 
 
The first six cholera pandemics were caused by serogroup O1 V. cholerae of the classical 
biotype (section 1.3.1.1). Thus, toxigenic V. cholerae isolated during the sixth pandemic were 
those used to establish the biochemical, taxonomic, and microbiological criteria needed to 
classify a bacterium as “V. cholerae” and the aetiological agent of cholera [209]. In contrast, 
the seventh cholera pandemic, which began in 1961, is caused by an El Tor biotype V. cholerae 
O1 [164]. The taxonomic relationship between El Tor and classical biotype V. cholerae has 
 
   19 
been disputed, and it had been proposed that both comprised separate species [36, 164]. This 
was subsequently overturned, and both biotypes were re-classified as distinct members of the 
same species on the basis of their microbiological and biochemical properties [164, 210].  
 
In 1905, Gotschlich made the first report of V. cholerae which displayed a different 
biochemical phenotype to the strains now referred to as being of the classical biotype [211]. 
These unusual V. cholerae were isolated from patients at the El Tor quarantine camp in Egypt 
leading to bacteria displaying this phenotype being dubbed ‘El Tor biotype’ V. cholerae. There 
are also reports from the early twentieth century of “El Tor” vibrios distinct from the “vibrio 
of cholera” having been isolated from patients suffering from dysentery and colitis [212]. The 
term “paracholera” was used to describe cases of disease associated with these El Tor vibrios, 
not least because patients suffering from cholera sensu stricto (caused by classical V. cholerae) 
were subject to quarantine [213]. Paracholera was a term used historically to describe cases of 
disease which resembled cholera, but were not caused by V. cholerae as described by Koch 
(e.g., [214, 215]). However, there were inconsistencies in the bacteriological reports describing 
infections giving rise to cholera and cholera-like disease [216]; as noted by Mackie: 
 
“The paracholera vibrios comprise a group which is not serologically 
homogenous, but ... represents a considerable number of serological races...” 
[217].  
 
The importance of the ability to discriminate between V. cholerae associated with pandemic 
cholera, and those causing sporadic disease, was also recognised in historical reports. de Moor, 
in 1949, cites and translates a quote from as early as 1913 [218]: 
 
“with the same necessity with which paratyphoid is distinguished from typhoid, 
an ‘El Tor disease’ should be distinguished from true cholera” [218]. 
 
These observations have also been recapitulated in recent years – Salim and colleagues noted 
in 2005 that many environmentally-isolated V. cholerae displayed El Tor phenotypes, stating: 
 
“The properties that characterise the El Tor biotype are those of environmental 
strains” [163].  
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Although “El Tor” has come to be synonymous with the pathogen of the seventh pandemic [2, 
164], the above quotations and discussion illustrates the fact that the phenotypes associated 
with El Tor V. cholerae both describe the bacterium which causes current pandemic cholera as 
well as other V. cholerae, which may cause sporadic infections or be non-pathogenic. V. 
cholerae are biotyped on the basis of a set of biochemical and microbiological tests, detailed 
below (Table 1.1).  
 
 Biotype 
Test Classical El Tor 
Haemolysis Negative Positive 
Voges-Proskauer test Negative Positive 
Haemagglutination 
(chick or sheep erythrocytes) Negative Positive 
Polymyxin B, 50 units Susceptible Resistant 
Classical phage IV Susceptible Resistant 
El Tor phage 5 Resistant Susceptible 
Table 1.1 – Summary of V. cholerae O1 biotyping phenotypes. Scheme modified from [40, 206].  
 
The molecular basis of each of these phenotypes will be discussed in detail in Chapter 5. 
However, it is useful to note at this juncture that microbiologists have sought to explain the 
molecular basis of the variation in these phenotypes amongst strains. For instance, haemolysis 
in V. cholerae is mediated by the HlyA haemolysin, encoded by hlyA. This gene is truncated 
in strains of classical biotype V. cholerae, such that the C-terminal domain of HlyA cannot be 
produced [219]. Although the N-terminal domain of HlyA can be produced by classical V. 
cholerae and is cytotoxic to mammalian cells, the C-terminal domain has been shown to be 
necessary for haemolysis [219, 220]. Recently, pandemic V. cholerae have been isolated which 
exhibit “hybrid” biotypes – i.e., a mixture of classical and El Tor phenotypes, including a loss 
of haemolysis [221, 222]. However, sequencing of the hlyA locus has demonstrated that these 
hybrid phenotypes can be due to multiple independent hlyA mutations, not due to the 
acquisition of the same hlyA mutation as found in classical isolates [221].  
 
1.3.2 – Non-pandemic cholera  
 
A fundamental issue in the study of cholera and V. cholerae has been expressed succinctly by 
Kaper et al.: 
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“V. cholerae is a well-defined species on the basis of biochemical tests and DNA 
homology studies. However, this species is not homogeneous with regard to 
pathogenic potential.” [1].  
 
Although cholera pandemics are associated with serogroup O1 V. cholerae (section 1.3.1), 
there are historical examples of outbreaks and epidemics caused by non-O1 V. cholerae. The 
most well-described of these are the epidemics caused by V. cholerae of serogroups O139 and 
O37. 
 
1.3.2.1 – V. cholerae O139   
 
In 1992, the dogma that V. cholerae O1 was the exclusive agent of epidemic cholera was 
challenged by the sudden occurrence of cholera epidemics in South Asia caused by serogroup 
O139 V. cholerae, which caused a large cholera outbreak across Bangladesh and India [223–
225]. The substantial numbers of cholera cases caused by V. cholerae O139 in Southeast Asia 
during the early 1990s led to fears that this serotype would emerge as the aetiological agent of 
an eighth cholera pandemic [226–228]. However, these fears were ultimately unfounded. After 
the initial 1992-93 epidemic, V. cholerae O139 was only associated with low numbers of 
cholera cases, and did not proceed to cause a global pandemic. However, a second outbreak 
associated with V. cholerae O139 occurred in Bangladesh during early 2002 [229]. The re-
emergence of this serogroup renewed fears of an eighth cholera pandemic driven by V. cholerae 
O139 [230], but once again, this clone did not proceed to cause a cholera pandemic. 
 
The disease caused by V. cholerae O139 is clinically indistinguishable from that caused by V. 
cholerae O1 [224]. Molecular evidence also indicated that V. cholerae O139 was closely 
related to epidemic V. cholerae O1 [231], and data were subsequently obtained that showed 
that natural competence and homologous recombination enabled the in vitro exchange of the 
O1 and O139 operons, suggesting that such an event had occurred to seroconvert pandemic V. 
cholerae O1 to serogroup O139 [144]. Early genetic and biochemical studies demonstrated that 
O139 strains were closely related to O1 seventh pandemic El Tor strains, and it was suggested 
that V. cholerae O139 had arisen from an O1 El Tor ancestor [223, 231–233]. Whole-genome 
sequencing later confirmed this hypothesis, showing that toxigenic V. cholerae O139 were 
closely related to the V. cholerae O1 El Tor clone causing the seventh cholera pandemic [54, 
234, 235]. This clone is described more fully in section 1.4.2. 
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As well as serogroup, there are other notable differences between V. cholerae O139 and V. 
cholerae O1. For instance, V. cholerae O139 expresses a polysaccharide capsule, which V. 
cholerae O1 isolates do not [236]. The capsule is encoded by genes absent from the V. cholerae 
O1 causing current pandemic cholera, and these genes are located adjacent to the locus 
encoding LPS biosynthesis genes in V. cholerae O139 [145, 230, 237–240]. The complement 
of genomic islands in V. cholerae O139 is also different to that of pandemic V. cholerae O1, 
an observation first made using the genome sequence of MO10, a V. cholerae O139 isolated 
in India during 1992 [54, 133, 241].  
 
V. cholerae O139 remains an important organism to study and to monitor, not least because 
this serogroup has continued to be isolated since 2002. Recently, non-toxigenic V. cholerae 
O139 have been isolated in Thailand [242]. Toxigenic V. cholerae O139 have been isolated in 
China as recently as 2013 [243], and continue to be isolated in Bangladesh [244]. Accordingly, 
V. cholerae O139 continues to be the subject of surveillance in Southeast Asia. Crucially, it 
has been demonstrated in animal models that immunisation with serogroup O1 vaccine strains 
of V. cholerae does not confer cross-protection against infection with V. cholerae O139 [146]. 
Both serogroups therefore continue to be included in killed whole-cell vaccines [245–247], 
including ShancholTM, EuvicholTM, mORC-VaxTM, and CholvaxTM [20].  
 
1.3.2.2 – V. cholerae O37   
 
Another key example of epidemics caused by non-O1 V. cholerae are the outbreaks caused by 
V. cholerae O37. In November 1968, a severe outbreak of gastroenteritis occurred in Idd Eltin, 
Kassala Province, Sudan [248]. The outbreak was associated with a newly-opened well, around 
which tens of thousands of people were reported to have gathered without sanitation provisions 
[248]. Cholera was suspected, and non-agglutinable Heiberg group I Vibrios (metabolising 
mannose and saccharose, but not arabinose [40, 249], which is a definition now known to 
encompass pandemic V. cholerae O1 [41]) were isolated from stool and rectal swab samples 
[248]. During 1965, a similar outbreak of gastroenteritis occurred in Czechoslovakia amongst 
individuals at an automobile training centre [250]. Patients were described as producing stool 
that contained neither blood nor mucus [250]. A vibrio was isolated from these specimens 
which was not agglutinated by V. cholerae Inaba or Ogawa sera [250]. Subsequently, an isolate 
from this outbreak, “280 NAG” [251], was deposited in the American Type Culture Collection 
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under accession number ATCC 25872. The ATCC metadata and its initial report for this strain 
lists it as having been isolated from a ‘patient with clinical cholera’ [251, 252]. 
 
Isolates from the Sudanese and Czechoslovakian outbreaks have been shown to be V. cholerae 
of serogroup O37 [144, 253]. The O37 serogroup was first defined in 1970 [254], the type 
strain for which was isolated in India in 1969 [190, 255, 256]. ATCC 25872 was used in the 
original characterisation of VPI-1, and is both CTXφ and VPI-1 positive [55], though different 
tcpA alleles have been shown to be harboured by VPI-1 in various V. cholerae O37 [257]. 
Allelic variants of ctxB have similarly been reported amongst toxigenic V. cholerae O37 [189]. 
It has been demonstrated that genomic DNA prepared from O37 serogroup strain ATCC 25872 
could transform naturally-competent V. cholerae O1 and convert them to serogroup O37, just 
as was shown for V. cholerae O139 (section 1.3.2.1) [144]. ATCC 25872 and other V. cholerae 
O37 have also been shown to have a constitutively-active T6SS, making it a useful strain for 
the study of intra- and inter-strain competition [258].  
 
Several studies have found that these toxigenic V. cholerae O37 are closely-related to pandemic 
V. cholerae O1 [255, 259–265] and this has been supported by whole-genome sequencing data 
[54, 189, 234]. However, Bik et al noted that V. cholerae O37 ‘exemplifies the pitfalls of using 
phenotypic methods to discriminate V. cholerae strains’ [259]. Although multiple clinical and 
environmental isolates of serogroup O37 V. cholerae have proven to be both toxigenic and 
phylogenetically-related to O37 isolates from the Sudanese and Czechoslovakian outbreaks 
and, therefore, to pandemic V. cholerae [253], other V. cholerae O37 have been isolated which 
are distantly related, or are non-toxigenic and lack VPI-1 [259–261, 266–268]. 
 
1.3.2.3 – Cholera on the Gulf Coast  
 
During the 1970s and 1980s, toxigenic V. cholerae O1 El Tor were isolated from cases of 
cholera in Texas and Louisiana, USA [269, 270]. Non-O1 V. cholerae were also recovered 
from patients with diarrhoea in Louisiana, which were toxigenic and produced detectable CT 
[269]. In 1981, a cholera outbreak occurred on an oil rig south of Port Arthur, Texas, USA 
[271]. Toxigenic, haemolytic V. cholerae O1 Inaba was isolated from the stool of the index 
patient [271]. These outbreaks led to the hypothesis being proposed that V. cholerae is endemic 
on the US Gulf Coast [272], though it has also been recognised that the low frequency at which 
this clone can be isolated from the environment means that the relative contribution of human-
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to-human transmission and environmental reservoirs in the dynamics of this Gulf Coast clone 
remain unclear [269]. 
 
Molecular data have shown that this Gulf Coast clone is distinct from the classical and El Tor 
biotype pandemic clones [273, 274]. Isolates from this outbreak were first sequenced in 2009, 
which were shown to be related to the classical and El Tor biotype pandemic clones [54]. This 
phylogenetic positioning was corroborated in 2011, using both toxigenic and non-toxigenic V. 
cholerae O1 isolates from the Gulf Coast [234]. These isolates harbour VPI-1 and VPI-2, but 
not VSP-1 or VSP-2 [189].  
 
It should be noted that as well as these V. cholerae O1, isolates of V. cholerae O75 have also 
been reported to cause sporadic cases and outbreaks of cholera in the vicinity of the Gulf Coast 
in the USA [275, 276]. These V. cholerae O75 were toxigenic, and harboured VPI-1 (with the 
classical tcpA variant), a VPI-2 variant harbouring a T3SS, and a VSP-2 variant [276].  
 
1.3.2.4 – Non-O1/O139 V. cholerae infections and virulence determinants 
 
Thus far, consideration has been given to the aetiological agents of current and historical 
pandemics (section 1.3.1) and to bacteria that have caused epidemics of cholera but did not 
proceed to cause global pandemic disease (sections 1.3.2.1 – 1.3.2.3). All of the V. cholerae 
considered up until now have been toxigenic, causing disease by virtue of expressing CT and 
inducing choleraic diarrhoea (section 1.2.2). However, although toxigenic V. cholerae is 
notorious for causing cholera epidemics and pandemics, sporadic cases of disease can also be 
caused by this species. Approximately 40 cases of disease caused by non-O1/O139 V. cholerae 
are reported annually to the CDC [277]. These non-O1/O139 V. cholerae may cause 
gastroenteritis, extraintestinal infections (such as wound and skin infections) or septicaemia 
[277–282], and have been identified as causing sporadic outbreaks in studies that focus on 
epidemic cholera (e.g., [189, 235, 283]). Crucially, these non-O1/O139 V. cholerae have never 
been observed to proceed to cause epidemic cholera. It is important to state that there are rare 
examples of non-O1/O139 V. cholerae being toxigenic and harbouring CTXφ [54, 189, 276]. 
 
Several accessory virulence determinants can be expressed by V. cholerae, the most important 
of which will be discussed below. Some of these are encoded as part of the V. cholerae 
accessory genome, either on genomic islands or on bacteriophages. Others are part of the core 
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genome and are common to nearly all V. cholerae which have been characterised. For instance, 
possession of TCP, and the VPI-1 genomic island which encodes it, is necessary to render a 
strain of V. cholerae susceptible to infection by CTXφ, the generalised transduction of CTXφ 
by other bacteriophages notwithstanding [93]. However, TCP is itself a virulence determinant, 
and the TcpA pilus acts as a colonisation factor, enabling V. cholerae to adhere to the intestinal 
epithelium [284]. Other elements act as virulence determinants, such as the accessory 
colonisation factor Acf (also encoded by VPI-1), and play important roles in V. cholerae 
colonisation and chemotaxis [111, 285, 286]. 
 
The heat-stable enterotoxin of non-agglutinable V. cholerae, NAG-ST, was first observed in 
the early 1980s [263, 287] and the gene encoding this toxin was sequenced in 1990 [288]. 
NAG-ST is similar to the heat-stable toxin produced by enterotoxigenic E. coli [288, 289], and 
V. cholerae encoding this virulence determinant have been associated with causing severe 
diarrhoea in volunteer studies [290]. Strains of non-O1 V. cholerae encoding this toxin have 
been isolated from environmental sources and seafood farms [291, 292], and there are some 
reports of V. cholerae O1 encoding NAG-ST [293, 294]. Other Vibrios, including Vibrio 
mimicus, have been shown to encode NAG-ST [295].  
 
V. cholerae can produce a multifunctional autoprocessing RTX (MARTX) toxin, encoded by 
a  gene cluster adjacent to the CTXφ integration site on chromosome 1 [59, 296, 297]. This 
toxin is cytotoxic, and can affect cytoskeletal structure in target eukaryotic cells by interfering 
with actin crosslinking [298, 299]. Thus, this toxin is believed to contribute to the diarrhoeal 
and inflammatory symptoms occasionally experienced by human subjects when exposed to V. 
cholerae vaccine strains [297] and to lethality in mouse models of infection [300]. The rtx gene 
cluster typically contains two divergently-transcribed operons – rtxHCA, where rtxA is a long 
gene encoding the toxin (the longest gene in the V. cholerae genome [59]), and the rtxBDE 
operon which encodes a type I secretion system (T1SS) [299, 301]. RtxA is exported from the 
bacterial cytosol via this T1SS [299]. The RtxA toxin is produced by nearly all clinically- and 
environmentally-isolated V. cholerae [297, 299], though certain environmental isolates may 
encode RtxA variants [302], and a deletion of rtxC and the 5' sequence of rtxA has been 
described in classical isolates [297].  
 
Certain V. cholerae harbour gene clusters that encode type III secretion systems (T3SS) 
integrated into the same chromosomal location as VPI-2 [141]. A T3SS is a macromolecular 
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apparatus capable of translocating and injecting potentially-cytotoxic effector proteins from V. 
cholerae into adjacent prokaryotic and eukaryotic cells [303], unlike the mechanism of action 
of CT (section 1.2.2). These systems are common virulence determinants in other Vibrio, such 
as V. parahaemolyticus [303], but are present in certain non-O1/O139 V. cholerae [141]. There 
have been reports of serogroup O1 V. cholerae harbouring T3SS genes, but these have not yet 
been characterised in detail [304]. These systems are linked to causing rapid-onset 
inflammatory diarrhoea caused by CTXφ-negative V. cholerae in the infant rabbit model [305]. 
The first V. cholerae strain harbouring a T3SS to be characterised in detail was AM-19226, 
which was shown to encode a T3SS similar to that of V. parahaemolyticus [266]. It has been 
noted that T3SS in V. cholerae and V. parahaemolyticus are more similar to one another than 
the two species are to one another, strongly suggesting that these systems can be exchanged 
amongst Vibrio species [303].  
 
1.4 – Insights from V. cholerae genomics 
 
1.4.1 – Comparative V. cholerae genomics 
 
The comparative genomics of V. cholerae have been studied using several approaches in the 
past. For example, microarray hybridisation technology has been used to describe variations in 
gene content amongst small numbers of pandemic and non-pandemic V. cholerae. The V. 
cholerae microarray, designed using the N16961 reference sequence, has been used for this 
comparative work [133]. However, microarray hybridisation cannot identify or describe 
genetic novelty – the approach can only detect the presence and absence of genes that were in 
the genome sequence used to generate the array [306]. Comparative genomic approaches have 
also been used to analyse the genome sequences of key fully-sequenced strains of V. cholerae, 
including O395, an isolate representing the classical biotype, pre-seventh pandemic reference 
sequences M66 [97, 307] (see section 1.4.2), and other isolates of particular importance to 
researchers (e.g., [98]). Whole-genome sequencing of V. cholerae has allowed for comparative 
genomics analyses to be performed, yielding similar results to these microarray experiments 
[54]. However, most of these studies implement short-read sequencing (e.g., Illumina) with 
read lengths of 150 bp, up to a maximum of 300 bp.  
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1.4.2 – V. cholerae genomics and genomic epidemiology 
 
Prior to the implementation of whole-genome sequencing, the phylogenetic analysis of 
housekeeping genes had indicated that the classical biotype V. cholerae clone and the El Tor 
clone causing the seventh cholera pandemic were distinct from one another [163]. In that study, 
the relationship between M66, and the classical and El Tor epidemic clones, was also 
investigated (M66 was isolated in Makassar, Indonesia in 1937). Consistent with its time and 
place of origin (section 1.3.1.1), M66 was shown to represent a “pre-pandemic” ancestor of the 
current El Tor pandemic clone [163, 213, 234]). The relationships of other El Tor clones to the 
seventh pandemic clone was also described [163]. 
 
The V. cholerae reference genome was published in 2000 [59]. This reference sequence was 
produced from N16961, a toxigenic, serogroup O1 Inaba, biotype El Tor V. cholerae isolated 
from a patient in Bangladesh in 1975 [234]. Closed genome sequences for a classical V. 
cholerae (O395), and for M66 were subsequently reported [97]. Comparative genomics 
between these two genome sequences and that of N16961 illustrated the gain and loss of genes 
as units in these isolates [97], consistent with previous reports [133].   
 
Work by Chun et al. was one of the first studies to characterise V. cholerae population 
structures using whole-genome sequencing and comparative genomics [54]. Here, the authors 
described the phylogenetic relationships between 23 V. cholerae isolates, which corroborated 
the conclusions drawn from molecular studies that M66 was closely-related to the El Tor clone 
causing the seventh cholera pandemic, and that classical V. cholerae were more closely related 
to the pandemic El Tor clone than were environmental V. cholerae [54, 163]. The authors 
included non-O1 V. cholerae in their study, and also included details such as characterising the 
genes present and absent in each genome, the structures of the CTXφ prophages, and a 
proposed sequence of genomic island acquisition and loss in the course of the emergence of 
the clades of El Tor and classical pandemic clades (dubbed pandemic groups, PGs) [54]. 
 
Several global phylogenetic studies of cholera epidemiology have since been conducted to 
describe the routes by which epidemic V. cholerae is transmitted globally [158, 189, 234, 235, 
308, 309]. Inherent to performing such analyses is the fact that pandemic V. cholerae appears 
to evolve with a very stable molecular clock rate of ≈ 6 substitutions per site per year [158]. 
This facilitates the calculation of dated phylogenies with which to infer transmission events 
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between continents and countries [158, 189, 309]. One of the first such studies was published 
in 2011, using the genome sequences of 136 V. cholerae and dated phylogenies to show that 
the seventh cholera pandemic had been transmitted globally in three waves [234]. These results 
built upon molecular and epidemiological data to show that the seventh pandemic of cholera 
was caused by a single lineage of V. cholerae O1 El Tor, and that this lineage appeared to 
reside in Southeast Asia (circa the Bay of Bengal) and to be transmitted in these waves [234]. 
This V. cholerae lineage has since been re-named “7PET”, for seventh pandemic El Tor [189].  
 
Other studies, including recent analyses, have explored the contributions of other countries in 
Asia to these dynamics [308, 310, 311], as well as the micro-evolution of the pandemic lineage 
in India [200]. Whole-genome sequencing data have been used to provide strong corroborative 
evidence that the Haitian cholera epidemic had its origin in Nepal [26, 27, 312]. Two studies 
reported in 2017 demonstrated that since 1970, pandemic cholera in both Africa and Latin 
America was caused by sub-lineages of 7PET [158, 189]. These data also provided additional 
phylogenetic support for the transmission of cholera from Nepal or surrounding countries into 
Haiti in 2020 [189]. Most recently, genomics [309] coupled to epidemiological data [28] have 
contributed to our understanding of how cholera entered into and spread within Yemen during 
the ongoing outbreak.  
 
Building on these global analyses, the transmission of 7PET within and amongst households 
in Dhaka, Bangladesh, a city hyper-endemic for cholera, has been studied. This work found 
that multiple sub-lineages of 7PET co-existed with one another over the course of four years 
[235]. This was unlike the dynamics observed in Africa and in global transmission studies [158, 
234, 309], which saw sub-lineage replacements rather than the co-circulation of sub-lineages, 
and it was hypothesised that this reflected the unique setting of a hyper-endemic environment 
[235]. However, due to insufficient sampling in a single non-endemic country or setting, data 
were unavailable with which to contrast the observations made in Dhaka, and sub-lineage 
dynamics in non-hyper-endemic settings remain uncertain. Studying how pandemic V. 
cholerae evolves upon introduction into a naïve setting was a strong focus of the research in 
this PhD (Aims; section 1.5).  
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1.4.3 – Patterns of disease and local lineages 
 
For this PhD, one of the most significant observations from the above genomic studies was 
made as part of the work carried out in Latin America, which led to the identification of 
lineages of V. cholerae O1 El Tor that were distinct from 7PET, but were associated with low 
levels of disease [189]. These were dubbed ‘local lineages’; all were serogroup O1, biotype El 
Tor, and some (but not all) were of clinical origin and were toxigenic, harbouring CTXφ and 
ctxAB. These local lineages were detectable in Latin America because countries in this region 
benefitted from surveillance systems which captured cholera epidemics in parallel with 
sporadic outbreaks of disease caused by V. cholerae which were not part of 7PET and did not 
cause global disease [189]. Outbreaks of disease caused by these local lineages would satisfy 
the WHO definitions of suspected and confirmed cholera cases (section 1.1.1); however, the 
patterns of disease caused by these lineages and by bacteria causing sporadic outbreaks of 
disease are starkly different (Table 1.2): 
 
Pattern of disease Description 
Number of 
cases Aetiological agents 
Sporadic outbreaks 
Can be caused by non-O1/O139 as 
well as O1 V. cholerae 
Very few 
Very diverse V. 
cholerae, might be either 
toxigenic or non-
toxigenic 
Local epidemics 
May cause relatively large numbers 
of cases, but does not transmit as 
rapidly as pandemic cholera. May be 
serogroup O1, but not always (e.g., 
O37, O75, O1 Gulf Coast) 
Variable 
Local lineages, may be 
serogroup O1, but not 
always 
Pandemic cholera 
Characterised by rapid transmission, 
large numbers of cases. Cholera, in 
the epidemiological sense 
Hundreds of 
thousands 
7PET and Classical 
Table 1.2 – A summary of the three patterns of disease caused by virulent V. cholerae. Scheme after [189], 
and integrating the discussions in this Introduction.  
 
1.5 – Open questions and aims of this thesis 
  
This Introduction has sought to highlight a number of open questions in our understanding of 
V. cholerae biology. Acknowledging that there is more complexity to the V. cholerae species 
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than can be captured by examining pandemic cholera alone, this PhD project was designed to 
explore the diversity of V. cholerae by addressing the following open questions: 
 
a. Although a lot is known about how pandemic 7PET V. cholerae evolves on a global 
scale, we know little about how this pathogen evolves during an epidemic in a single 
country that is not endemic for cholera.  
b. We also have limited information about the genomics of the V. cholerae that are present 
in a country during an outbreak or an epidemic caused by the introduction of 7PET.  
c. The relative paucity of non-O1/O139 V. cholerae genomes means that we know 
comparatively little about how virulence genes, drug resistance determinants, plasmids, 
and other genetic factors of interest are distributed across the V. cholerae species more 
generally than just within 7PET.  
d. As local V. cholerae O1 lineages begin to be recognised and identified, opportunities 
begin to present themselves to study why the 7PET (and Classical) lineages cause 
pandemics, and other lineages do not, even though they might harbour CTXφ and many 
of the other genetic determinants associated with pandemic cholera.  
 
The aims of this PhD research were framed around these open questions. In order to study these 
questions, appropriate collections of V. cholerae were required. These are described in each of 
the chapters in this thesis, which has the following four aims: 
 
1. Using nearly 500 strains collected during the 1992-1998 Argentinian cholera epidemic, 
to characterise how 7PET evolves during an epidemic, and to compare and contrast this 
to the background of non-epidemic V. cholerae isolated from the same places and times 
as 7PET (Chapter 3).  
2. Using long-read sequencing and experimental approaches, to characterise a number of 
clinically- and historically-important non-O1 V. cholerae of clinical origin (Chapter 4).  
3. Using the genomes of ~650 diverse V. cholerae, to identify the distribution of 
antimicrobial resistance genes, plasmids, virulence genes, and key genetic determinants 
of biotype and pathogenicity across diverse V. cholerae (Chapter 5).  
4. Integrating the knowledge gleaned from Chapters 3-5, to use phylogenetic and genomic 
information to select rationally a number of live V. cholerae for transcriptomic 
profiling, beginning to examine global gene expression differences amongst pandemic 
and non-pandemic V. cholerae O1 (Chapter 6).   
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Chapter 2 
 
Methods 
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2.1 – Computational analyses 
 
2.1.1 – Bacteria sequenced in the course of this PhD research 
 
A list of V. cholerae that were sequenced in the course of this study is provided in Appendix 
1. Additional previously-published genomes were also collated for analyses in Chapters 3-5. If 
the short-reads for externally-sequenced genomes were available, these were included with the 
short-reads generated in this study for analysis. If these external genomes were only available 
as assemblies and short-reads were required (e.g., for mapping analyses), paired-end 100 bp 
Illumina reads were simulated from assemblies using wgsim v.0.3.2 1, part of SAMtools [313], 
and parameters '-e 0 -r 0 -X 0 -1 100 -2 100' (these settings assume a haploid genome and are 
appropriate for bacteria). Additional V. cholerae genomes were also downloaded from Refseq 
as assemblies. 
 
2.1.2 – Genome assembly  
 
2.1.2.1 – Short-read data 
 
Throughout this PhD research, short-read sequencing data generated at WSI were assembled 
using SPAdes v3.8.2 [314] as part of a WSI high-throughput analysis pipeline [315]. 
Externally-generated sequencing reads were assembled using the same pipeline.   
 
2.1.2.2 – Long read data 
 
The V. cholerae O139 long-read assemblies described in Chapter 4 (section 4.3.1) were 
produced using HGAP v3 and SMRT analysis software v2.3.0 [316]. The fold coverage to 
target when picking the minimum fragment length for assembly was set to 30 and the 
approximate genome size was set to 3 Mbp. Assemblies were circularised using Circlator 
v1.1.3 [317] and the pre-assembled reads (also known as corrected reads). Circularised 
assemblies were polished using the PacBio RS_Resequencing protocol and Quiver v1 [316]. 
Pilon v1.19 [318] did not identify any single nucleotide variants (SNVs) in any of the PacBio 
                                               
1 https://github.com/lh3/wgsim  
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assemblies using the corresponding short-read data – accordingly, no short-read corrections 
were made to these assemblies.  
 
The NCTC 30 genome (Chapter 4, section 4.3.7) was similarly assembled from PacBio RSII 
reads using HGAP v3 and the RS_HGAP_Assembly.2 protocol, performed using SMRT Portal 
and SMRT Analysis v2.3.0.140936.p5.167094 [316]. Minimum polymerase read quality and 
length were set to 0.8 and 100, respectively. A minimum length of 500 bases was used to filter 
sub-reads. The minimum seed read length for assembly was set to 6,000, with BLASR options 
'-noSplitSubreads -minReadLength 200 -maxScore -1000 -maxLCPLength 16', an expected 
genome size of 5 Mbp, and a target coverage of 30 X. Contigs were circularised using Circlator 
v1.5.3 [317] using both the assembly and the corrected reads, and a final assembly was obtained 
by using the circularised sequences as a reference to re-assemble the PacBio reads using the 
RS_Resequencing.1 protocol (minimum subread length = 50 bp, minimum polymerase read 
quality = 75%, minimum polymerase read length = 50 bp, BLASR maximum divergence = 
30%, minimum anchor size = 12). This assembly was then corrected using Quiver v1. The 
finished assembly was covered to an average depth of 148.01 X. To check the accuracy of the 
PacBio assembly, the corresponding Illumina short-reads were mapped to the assembly using 
SMALT v0.5.8 2 (maximum insert size = 1000, minimum insert size = 50). No SNVs were 
identified in the assembly upon mapping of these data.  
 
2.1.2.3 – Hybrid assemblies and data visualisation 
 
The hybrid assemblies described in Chapter 5 (section 5.3.7) were produced using both the 
long- and short-reads for each isolate and Unicycler v0.4.0 [319], with options '-t 4 --mode 
conservative'. The De Brujin graphs from these assemblies were visualised using Bandage 
v0.8.0 [320]. 
 
2.1.3 – Sequencing quality control 
 
Contamination of genome sequences was assessed using several methods. Kraken [321] was 
used to assess whether sequences belonging to bacterial species other than the species of 
interest were present in the sequencing data for an isolate. Additionally, the length of genome 
                                               
2 http://www.sanger.ac.uk/science/tools/smalt-0 
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assemblies was inspected and summarised using assembly-stats v1.0.1 3. Assemblies that were 
substantially larger than expected for a V. cholerae genome were treated as potentially-
contaminated (i.e., assembly length was ≥ 5 Mbp; the V. cholerae reference genome is 4.1 Mbp 
in length [59]). Phylogenetic trees were also inspected at the beginning of each analysis, to 
identify stark outliers (e.g., isolates on very long branches). Any sequences which were 
suspected to be of poor quality were excluded from downstream analyses.  
 
2.1.4 – Automated genome annotation 
 
All genome assemblies used in this research were uniformly annotated using Prokka v1.5 [322] 
and a genus-specific database for Vibrio [323]. This was either run as part of the WSI 
automated assembly pipeline (for all automatically-assembled genomes, for genomes 
downloaded from RefSeq, and for any assemblies that were produced from simulated reads), 
or manually (for hybrid and long-read-only assemblies generated in Chapters 4 and 5).  
 
2.1.5 – Pangenome calculations 
 
All pangenomes described in this thesis were generated using Roary v3.12.0 [324], run with 
options '-e --mafft -s -cd 97'. These settings prevent the splitting of paralogous genes into 
separate gene clusters to avoid the over-partitioning of orthologous genes into separate clusters, 
and impose a CD-HIT clustering cut-off of 97%. Prokka-annotated genome assemblies in 
GFF3 format were used as input for these calculations. Gene presence/absence matrices were 
visualised using roary_plots.py v0.1.0 4.  
 
2.1.6 – Short-read mapping and SNV detection 
 
High-quality SNVs, including small indels, were identified as described by Harris et al [325] 
using SMALT v0.7.4 5. Briefly, variant sites was identified from mapped sequence data using 
SAMtools mpileup v0.1.19 [313] and parameters '-d 1000 -DSugBf', and bcftools v0.1.19 
[313], to produce a BCF file of all variant sites from which high-quality SNVs were identified 
using previously-described quality thresholds [325]. For analyses of 7PET genomes, mapping 
                                               
3 https://github.com/sanger-pathogens/assembly-stats 
4 https://github.com/sanger-pathogens/Roary/tree/master/contrib/roary_plots 
5 http://www.sanger.ac.uk/science/tools/smalt-0 
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and SNV-calling were performed against the N16961 reference genome sequence (accession # 
LT907989/LT907990 [59]). For the analysis of LAT-1 described in Chapter 3 (section 3.4.5), 
mapping and SNV-calling were performed against the sequence of the LAT-1 isolate A1552 
(accession # CP025936/CP025937 [326]). 
 
2.1.7 – Detection of potentially-recombined chromosomal regions  
 
Potentially-recombined regions of V. cholerae genomes were identified using Gubbins v1.4.10 
[327] and a “pseudo-genome” multiple-sequence alignment of all variant and invariant sites 
relative to a reference genome sequence. This tool produced a variant-only alignment of SNVs 
which excluded all variants predicted to be located within recombined regions of the 
chromosome. This alignment was used for subsequent phylogenetic analyses, to avoid SNVs 
in recombined regions potentially interfering with the topology of phylogenetic trees.  
  
2.1.8 – Phylogenetic analyses and tree-building 
 
7PET and LAT-1 phylogenies were calculated from non-recombinant SNVs called against the 
N16961 and A1552 reference sequences by mapping, as described above (section 2.1.6 and 
2.1.7). V. cholerae species phylogenies were calculated from the core-gene alignment 
generated by Roary (section 2.1.5); core-gene alignments were trimmed using trimAl v1.4.1 
[328], and SNP-sites v2.4.1 and v2.5.1 [329] was used to extract the variant sites from this 
trimmed alignment. The sizes of alignments used for calculations are reported throughout the 
thesis.  
 
The maximum-likelihood phylogenetic trees presented in this thesis were calculated using IQ-
Tree v1.6.10 [330] unless otherwise stated in the text, and either the alignments of non-
recombinant SNVs produced by Gubbins (section 2.1.7) or the SNV-only alignments from a 
core-gene alignment, described above. Trees were calculated under the general time reversible 
(GTR) and ascertainment bias correction (ASC) models [331]. In order to assess the robustness 
of the computed phylogenies, five thousand approximate likelihood ratio tests [332] and 
ultrafast bootstrap approximations [333] were performed for each tree calculation.  
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2.1.9 – Data clustering and lineage assignment  
 
In order to identify clusters of similar sequences from multiple-sequence alignments, 
alignments of parsimony-informative SNVs were extracted from SNV-only alignments using 
extract_PI_SNPs.py 6 (i.e., any SNVs that were private to a single isolate were removed from 
the alignment). For alignments that were derived from V. cholerae species core gene 
alignments, sequence data for the Vibrio spp. outgroup were deleted from the alignment prior 
to running extract_PI_SNPs.py. 
 
Alignments of parsimony-informative SNVs were used for cluster analysis using the R 
implementation of Fastbaps v1.0.1 [334]. The Dirichlet Process Mixture model was used to 
cluster 7PET and LAT-1 genomes, whereas the Bayesian Hierarchical Clustering prior [335] 
was used to cluster sequences in V. cholerae species phylogenies.  
 
2.1.10 – Comparative genomics 
 
Synteny plots were generated using ACT v13 [336] and Easyfig v2.2.2 [337] to enable 
comparative genomics analyses. Both of these tools rely on BLASTn [338] comparisons 
between two genome assemblies. Cut-offs for Easyfig comparisons were set to a maximum e-
value of 0.001 and minimum length of 0; the minimum BLASTn identity percentage is 
specified in each comparison figure throughout the thesis. BamView [339] was used to 
visualise the mapping of Illumina reads to a genome sequence using the BAM file of mapped 
sequencing data. 
 
2.1.11 – Pairwise SNV and ANI calculation  
 
SNV distance matrices were calculated from SNV-only alignments using snp-dists v0.4 7. 
Average nucleotide identity (ANI) values were calculated using FastANI v1.0 [340] and a 
reference sequence as stated in the text. 
 
 
                                               
6 https://gist.github.com/jasonsahl/9306cd014b63cae12154 
7 https://github.com/tseemann/snp-dists 
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2.1.12 – Assessment of temporal signal in phylogenetic data 
 
Maximum-likelihood phylogenetic trees produced in section 2.1.8 were read into TempEST 
v1.5.1 [341] to assess whether a temporal signal could be detected within the phylogeny. The 
names of leaves on the phylogeny were amended to include the date of isolation, where known.  
 
2.1.13 – Detection of antimicrobial resistance genes, wbeT and ctxB variants, plasmid 
replicons and virulence determinants 
 
Antimicrobial resistance genes and plasmid replicons were detected in genomes using both 
ARIBA v2.12.1 [342] and ABRicate v1.0.1 8. ARIBA performs local assembly of sequence 
data against a reference database of genes of interest, and was therefore only used when short-
reads were available for all genomes of interest. In contrast, ABRicate screens assembled 
contigs for genes of interest, and was used when assemblies were available for all genomes of 
interest. The ResFinder database of antimicrobial resistance genes [343], and the 
PlasmidFinder database of plasmid replicon sequences [344] were used for ARIBA and 
ABRicate analyses (both databases accessed on 23/06/2019 and 11/05/2020 for ARIBA and 
ABRicate analyses, respectively). The VFDB database (accessed on 11/05/2020) was used for 
identifying virulence genes of interest using ABRicate. Default cut-offs for identity percentage 
and length were used throughout this thesis unless otherwise specified in the text.  
 
ARIBA was also used to assign wbeT and ctxB genotypes to V. cholerae isolates. This relied 
on a custom database consisting of the ctxB nucleotide sequence from N16961 (accession # 
LT907989/LT907990) and the intact wbeT sequence from NCTC 9420 [213] (accession # 
CP013319/CP013320). This wbeT sequence translates into a protein sequence which is 100% 
identical to the WbeT sequence from the Ogawa isolate VX44945 (AEN80191.1 [196]), which 
has been used for wbeT genotyping in previous studies [158, 189]. 
 
The NCTC 30 genome assembly was screened for antimicrobial resistance genes using the 
ResFinder web server [343] (database version 2018-02-19) using default cut-offs of 90% 
nucleotide identity and 60% minimum length.  
 
                                               
8 https://github.com/tseemann/abricate  
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2.1.14 – Confirming the presence of genomic elements 
 
The presence of the WASA-1 genomic island, a marker characteristic of the LAT-1 sub-lineage 
[234, 235], was confirmed in genome assemblies by using BLASTn to query the assembly for 
the presence of the WASA-1 sequence, as well as by using pangenome gene presence/absence 
matrices to check for the presence of WASA-1 gene orthologues in an assembly of interest. 
Similarly, the presence and absence of the V. cholerae serogroup O1 biosynthesis operon was 
confirmed using the pangenome gene presence/absence matrix, and by testing for the presence 
of the O1 biosynthesis operon sequence using BLASTn. 
 
2.1.15 – Construction of BLAST atlases  
 
BLAST atlas figures were generated using annotated genome assemblies (EMBL format) and 
the GView web server 9, which relies on CGView [345]. The GC% and GC skew calculation 
for each comparison was also carried out using GView.    
 
2.1.16 – Statistical tests 
 
Statistical tests and p-value cut-offs are listed and described in the text of the thesis. Unless 
otherwise specified, statistical tests were performed using the R package, v3.5.1 [346] 
 
2.1.17 – Promoter sequence analysis  
 
The tcpPH and aphA promoter sequences were extracted from genome assemblies using in 
silico PCR, a custom script at WSI which searches for the sequences of 5' and 3' “primers” 
within an assembly and reports the sequence between those as output. To “amplify” PtcpPH, the 
primer sequences 5'-cgtaaggggcaaaatgtcacaggaa-3' and 5'-
atagacttgattagtgcattcattc-3' were used (maximum amplicon length 1,500 bp, 
minimum length 100 bp), and for PaphA, 5'-gaatgcgcaatactggttaa-3' and 5'-
catcgacaggtttggcttgg-3' (maximum length 2,000 bp; minimum length 100 bp). Up to 
three mismatches were permitted between primer and assembly sequences. The extracted 
promoter sequences were concatenated into a multi-FASTA file and aligned using Clustal 
                                               
9 https://server.gview.ca/  
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Omega [347] and Seaview v4.6.1 [348]. trimAl v1.4.1 [328] was used to extract 50 bp 
sequences from this alignment which were then used to identify motifs and produce nucleotide 
usage frequency figures using MEME v5.1.1 [349] 
 
2.1.18 – RNA-seq data analysis and statistical cut-offs 
 
The Rockhopper 2 package [350, 351] was used to calculate expression of genes using the 
sequence and annotation of the N16961 isolate as a reference. Genes were determined to be 
differentially expressed if the log2(fold change) of a gene’s expression in one condition relative 
to a second condition was greater than or equal to 2, or less than or equal to -2. Additionally, 
the false discovery rate (FDR) q-value cut-off for each result was set to <0.01 – this was used 
rather than a p-value cut-off in order to account for multiple testing implicit in large RNA-seq 
comparisons. Principal component analyses (PCA) were calculated using prcomp in R v3.5.1 
and a matrix of normalised expression values per gene for all replicates in an experiment.  
 
2.1.19 – Additional data visualisation 
 
Incidence data reported in Chapter 3 (e.g., section 3.4.2) were visualised and annotated using 
Tableau Desktop 2018.31. Maps produced in Tableau made use of OpenStreetMap (© 
OpenStreetMap contributors) which is licenced under a CC-BY-SA licence 10. Phylogenetic 
trees were visualised and annotated using Figtree v1.4.3 11, iCANDY 12, iTOL v3 [352], and 
the Phandango web server [353]. Various graphs and plots were produced using Adobe 
Illustrator CC v23.0.4, or R v3.5.1 with the ggplot2 v3.1.1 package [354] and reshape v0.8.8 
[355] packages. Various comparative genomics figures were generated using Artemis v16 
[356], ACT v13 [336], DNAplotter v1.11 [357], and Easyfig v2.2.2 [337]. Where figures were 
edited manually, this was performed using Adobe Illustrator CC v23.0.4.   
 
  
                                               
10 https://www.openstreetmap.org/copyright 
11 http://tree.bio.ed.ac.uk/software/figtree/ 
12 https://github.com/simonrharris/iCANDY 
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2.2 – Experimental methods 
 
2.2.1 – Strains, plasmids and oligonucleotides 
 
The bacterial strains, plasmids, and oligonucleotide primers used in thesis chapters involving 
molecular and genetic experiments (Chapters 4 and 6) are listed in Table 2.1. This list excludes 
isolates which were exclusively used for whole-genome sequencing – these are listed in 
Appendix 1. 
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Internal ID Strain name Genotype/Details Source/Reference 
Vibrio cholerae   
MJD382 NCTC 30  
 
Non-O1/O139 (probably O2). Isolated in 1916; 
Alexandria, Egypt. AmpR  
NCTC 
 
MJD439 Second clone of NCTC 30. AmpR 
MJD367 NCTC 10732  Serotype O1 Inaba, classical biotype. Isolated in 1952; 
India. 
NCTC 
MJD1404 
MJD389 NCTC 5395  Serotype O1 Ogawa, El Tor biotype. Pre-seventh 
pandemic. Isolated in 1938; Iraq. AmpS 
NCTC. Sequenced  
in 2016 [213] 
MJD1402 NCTC 10256 O1 El Tor biotype. 7PET lineage. Toxigenic. Hong 
Kong, 1961.  
NCTC [358] 
MJD1403 MJD474 O1 El Tor biotype. 7PET lineage. Toxigenic. Traveller 
from Somalia, 2017. 
Claire Jenkins 
MJD1405 NCTC 5596 Classical lineage. O1 classical biotype. Pre-1939. NCTC 
MJD1406 A213 Gulf Coast. O1 El Tor biotype. Non-toxigenic. Georgia, 
1984. 
IVI [234] 
MJD1407 A219 Gulf Coast. O1 El Tor biotype. Toxigenic. Georgia, 
1986. 
IVI [234] 
MJD1408 MJD462 Non-O1. Related to MS-6 and Chinese non-7PET 
isolates. Traveller from Thailand, 2017.  
Claire Jenkins 
MJD1409 NCTC 9422 O1 El Tor biotype. Non-7PET. Non-toxigenic. Pre-
1955. 
NCTC 
Escherichia coli   
MJD839 ER2420 
pACYC184 
K-12 cloning strain harbouring pACYC184. CmR TcR Francesca 
Short/NEB 
MJD841 NEB® 5-alpha fhuA2 Δ(argF-lacZ)U169 phoA glnV44 Φ80 
Δ(lacZ)M15 gyrA96 recA1 relA1 endA1 thi-1 hsdR17 
NEB 
MJD842 NEB® 5-alpha 
pUC19 
K-12 cloning strain harbouring pUC19. AmpR This study 
MJD844 NEB® 5-alpha 
pACYC184 
K-12 cloning strain harbouring pACYC184. CmR TcR This study 
MJD847 MJD847 NEB® 5-alpha harbouring pMJD61. AmpR CmR TcS This study 
    
Plasmid name Genotype/Details Source/Reference 
pACYC184 Low-copy cloning vector. CmR TcR [359] 
pUC19 High-copy cloning vector, ampicillin resistance positive 
control. AmpR  
[360] 
pMJD61 pACYC184 Ω(tet::blaCARB-like). AmpR CmR TcS This study 
    
Primer ID Other name Sequence 5'-3' 
oMJD96 BamHI_blaCARB-like-
NCTC30_orf_5 
CCGGATCCGGTTTCAGTGCCTAATGCTTTAAGTTAAGATG 
oMJD97 blaCARB-like-
NCTC30_orf_SalI_3 
CCGTCGACATCAACGCGACTGTGATGTATAAACTTCAA 
oMJD88 blaCARB-like-
NCTC30_int _5 
TGGGGTCACATACATGAAGTCT 
oMJD89 blaCARB-like-
NCTC30_int _3 
CAGCAATACTCCACTTCACTG 
oMJD98 pACYC184_tet_seq_Pf GTTAAATTGCTAACGCAGTC 
oMJD99 pACYC184_tet_seq_Pr GTGAATCCGTTAGCGAGGTG 
oMJD135 VC_2135_check_Pf GTCAGGCAGATAGCTCAAACT 
oMJD136 VC_2135_check_Pr CTCATTGCTACCTCTGATGCC 
 
Table 2.1 – Strains, plasmids, and oligonucleotides. Restriction enzyme recognition sites are underlined. 
AmpR: ampicillin resistant; CmR: chloramphenicol resistant; TcR: tetracycline resistant. AmpS: ampicillin 
sensitive. TcS: tetracycline sensitive. 
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2.2.2 – Routine bacterial culturing 
 
V. cholerae and E. coli were cultured routinely on LB media (10 g/L tryptone, 5 g/L yeast 
extract, 5 g/L sodium chloride), supplemented with agar (1.5%) and antibiotics as appropriate 
(100 µg/ml ampicillin, 10 µg/ml chloramphenicol, or 10 µg/ml tetracycline). Pre-poured 
thiosulfate-citrate bile salt (TCBS) agar plates (Oxoid # PO0194) was used for selective culture 
of V. cholerae (on this medium, V. cholerae typically grows as yellow colonies). Plasmids were 
maintained in strains by culturing on LB media supplemented with antibiotics where required. 
All manipulations with live V. cholerae were carried out at Containment Level 3 (CL3) within 
a Class II microbiological safety cabinet (MSC).   
 
2.2.3 – Single-colony purification of strains received during this project 
 
Throughout this project, live V. cholerae were received from multiple sources, typically 
shipped on agar stabs or slopes. Upon receipt, these isolates were sub-cultured immediately on 
to LB agar plates and grown overnight at 37 ˚C (passage 1). At least two distinctly-isolated and 
representative colonies were streaked onto both TCBS and LB agar plates and grown overnight 
at 37 ˚C (passage 2). If bacteria recovered well on TCBS media, single colonies were taken 
from this plate and purified once more onto LB media (grown overnight at 37 ˚C). Colonies 
from these plates (passage 3) were then taken and mixed in a cryotube containing a 1:1 mix of 
50% v/v glycerol and sterile LB media. These were indexed and frozen at -80 ˚C. If growth on 
TCBS was poor on day 1, distinctly-isolated colonies were taken from the LB agar plates from 
day 1 and frozen similarly. At least two independent colonies were frozen per strain.  
 
2.2.4 – Recovery of lyophilised NCTC isolates 
 
V. cholerae were received from NCTC as lyophilised stocks, and were revived, sub-cultured, 
and frozen at -80 ˚C following the method published by Public Health England Culture 
Collections 13. Ampoules containing lyophilised bacterial culture were opened in a Class II 
MSC, and the contents were rehydrated at room temperature with 0.5 ml LB broth. After five 
minutes incubation, this suspension was mixed and spread over LB agar plates, which were 
incubated overnight at 37 ˚C (passage 1). Three well-isolated colonies from these plates were 
                                               
13 https://www.phe-culturecollections.org.uk/ 
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single-colony purified onto both LB and TCBS agar (passage 2). Colonies were taken from 
TCBS plates (or from LB plates if the strain grew poorly on TCBS plates) and were used to 
inoculate 3 ml LB liquid media in a disposable test-tube. This was incubated for 24 h with 
shaking (180 rpm) at 37 ˚C (passage 3). Cultures were mixed with glycerol (25% v/v final 
concentration) and frozen at -80 ˚C.  
 
2.2.5 – Extraction of gDNA from V. cholerae 
 
DNA extractions from V. cholerae were carried out using the Masterpure Complete DNA and 
RNA Purification kit (Epicentre, #MC85200), with modifications to the manufacturer’s 
protocol. An LB agar plate was lawned using a single isolated colony from each strain to be 
processed. This plate was grown overnight (37 ˚C). Five loopfuls of bacterial culture were 
taken from this plate and mixed with 300 µl Tissue & Cell Lysis Solution containing Proteinase 
K, vortexed (10 s), and then incubated at 65 ˚C for the shorter of 20-25 min or until the 
suspension had fully cleared. Samples were vortexed every ~ 5 min during this incubation to 
ensure even lysis of bacterial cells. RNAse A was then added to each sample, which were 
incubated at 37 ˚C for 30 min to ensure complete digestion of residual RNA before samples 
were chilled on ice for ≥ 5 min.  
 
Proteins were precipitated from each sample by adding MPC Protein Precipitation Solution 
(150 µl) and vortexing the sample immediately (10 s). Precipitated debris was collected by 
centrifugation (16,000 x g; 10 min; 4 ˚C). Additional MPC reagent was added to each cleared 
sample (30 µl) to remove residual protein contaminants. Samples were then vortexed and re-
centrifuged (16,000 x g; 10 min; 4 ˚C). Genomic DNA (gDNA) was precipitated from the 
cleared supernatant in a fresh 1.5 ml Eppendorf tube using room-temperature isopropanol (500 
µl). Precipitated gDNA was collected by centrifugation (16,000 x g; 10 min; 4 ˚C) and washed 
with room-temperature 70% v/v ethanol (2 x 1 ml). The pellet was dried and resuspended in 
80 µl nuclease-free water – ethylenediaminetetraacetic acid (EDTA) was excluded from the 
resuspension solution to avoid interfering with PacBio sequencing chemistry. Samples were 
then tested for sterility: 2 µl was spotted onto an LB agar plate which was incubated overnight 
at 37 ˚C; the absence of bacterial growth was interpreted as the sample being sterile. Sterile 
DNA samples were removed from containment and, where appropriate, submitted for 
sequencing.  
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2.2.6 – Next-generation DNA sequencing 
 
gDNA was sequenced using the Illumina X10 and the PacBio RSII platforms by the high-
throughput and long-read teams at WSI. Briefly, DNA fragments of approximately 450 bp were 
produced from 0.5 µg gDNA and used for Illumina library creation. Libraries were sequenced 
on a 150 bp paired-end run (target coverage 30 X; V. cholerae were multiplexed with up to 384 
samples per Illumina X10 lane). Approximately 10 µg gDNA was used for PacBio sequencing, 
using polymerase version P6 and C4 sequencing chemistry reagents. gDNA from NCTC 30 
batch 4 was sequenced on the PacBio Sequel platform.  
 
2.2.7 – High-throughput analysis of growth kinetics 
 
Single colonies of V. cholerae were picked and suspended in 0.5 ml LB broth by vortexing (10 
s). Two microlitres of this suspension were used to inoculate 150 µl LB in a 96-well flat-
bottomed microtitre plate (Corning CoStar #3595) and a gas-permeable seal was applied to the 
plate. Plates were incubated at 37 ˚C in a BMG Fluostar Omega microtitre plate reader for 24 
h, with shaking at 300 rpm using the ‘meander corner well shaking’ mode. Absorbance (λ = 
600 nm) was measured every 15 min (cycle time: 900 s); four readings were taken per well per 
timepoint in a square matrix and averaged. This was to minimise the risk that debris or 
aggregated cells passing through the light beam would artificially increase absorbance 
readings. Three colonies per strain (biological triplicate) were used to inoculate six technical 
replicate cultures each.  
 
2.2.8 – Transmission electron microscopy 
 
Bacterial colonies were picked and suspended in 0.5 ml sterile water. The suspension (4 µl) 
was applied to a glow-discharged Formvar carbon film copper TEM grid (FCF-100-Cu) and 
mixed with ammonium molybdate solution (2.5% final concentration). Following initial tests 
to confirm that this treatment killed V. cholerae, inoculated grids were removed from CL3 for 
microscopic analysis. Images were acquired using a FEI Tecnai G2 Spirit BioTWIN.  
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2.2.9 – Motility assays 
 
Clearly-isolated bacterial colonies were re-suspended in 0.5 ml LB media by vortexing in a 
Class II MSC. The suspension (2 µl) was used to inoculate motility LB agar plates (0.3% agar 
in 140 mm dishes). The pipette tip was pushed through the agar surface during inoculation. 
Plates were incubated face up at 37 ˚C for 18 h prior to being photographed. Each experiment 
was repeated in biological triplicate.  
 
2.2.10 – Amplicon sequencing of the flrC locus 
 
The flrC mutation was confirmed by amplifying flrC from V. cholerae gDNA using Phusion® 
high-fidelity DNA polymerase (NEB, # M0530S) and primers oMJD135 and oMJD136 
(annealing temperature: 55 ˚C; extension time: 60 s, 30 cycles). The resultant amplicon was 
purified using the QIAquick PCR Purification kit (Qiagen, #28104) according to the 
manufacturer’s instructions. The DNA concentration in each purified sample was estimated 
using a Nanodrop One instrument, and an appropriate amount of DNA and sequencing primer 
was sent for amplicon sequencing (GATC/Eurofins). All amplicons were sequenced in both 
directions (i.e., with both oMJD135 and oMJD136).  
 
2.2.11 – Chemical transformation of E. coli  
 
Chemically-competent E. coli were either purchased from New England Biolabs (NEB, 
#C2987I), or cultures of E. coli were treated with calcium chloride (CaCl2) to produce stocks 
of competent cells. Chemically-competent cells were produced from 100 ml cultures of E. coli 
which harboured no plasmids, cultured in LB media in a baffled 500 ml Erlenmeyer flask (220 
rpm, 37 ˚C) for 5 hours. The culture was then split into 2 x 50 ml Falcon tubes, and cells were 
pelleted by centrifugation (3,900 x g, 10 min, 4 ˚C). The supernatant was discarded and pellets 
immediately resuspended in 40 ml 0.1 M CaCl2 solution. These suspensions were incubated on 
ice for 30 min and were then centrifuged (3,900 x g, 10 min, 4 ̊ C). The cell pellets were washed 
twice in 20 ml 0.1 M CaCl2, centrifuging after both washes (3,900 x g, 10 min, 4 ˚C). Both 
pellets were resuspended in 2 ml of 0.1 M CaCl2 + 25% v/v glycerol, and this suspension was 
aliquoted into ice-cold 1.5 ml Eppendorf tubes (50 µl) before being frozen at -80 ˚C 
immediately.  
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Chemically-competent E. coli were transformed by defrosting an aliquot of competent cells on 
ice. Plasmid DNA (≤ 5 µl) was added to these cells, mixed briefly and gently using the pipette 
tip used to add the DNA, and the cells were incubated on ice for ≥ 30 min. Cells were then 
heat-shocked in a water bath at 42 ˚C for exactly 30 s, and then returned to ice for 5 min. LB 
broth pre-warmed to 37 ˚C was added to each tube of heat-shocked cells, and the mixture was 
transferred to a disposable 30 ml Sterilin tube to be incubated at 37 ˚C (1 hr, 220 rpm). From 
this culture, 150 µl was spread onto LB media containing appropriate antibiotics to select for 
transformants. An appropriate positive control (1 µl of a stock of either pUC19 or pACYC184) 
and negative control (5 µl of buffer EB) was included in every transformation experiment. 
Inoculated plates were incubated overnight and putative clones were sub-cultured for further 
analysis.  
 
2.2.12 – Molecular cloning of blaCARB-like  
 
To clone blaCARB-like, primers oMJD96 and oMJD97 were used to amplify blaCARB-like from 
gDNA extracted from NCTC 30. The primers were designed to incorporate restriction enzyme 
sites and STOP codons as outlined in Figure 4.22. PCR was carried out using Phusion® high-
fidelity DNA polymerase according to the manufacturer’s instructions, and a 10 mM dNTP 
mix (Thermo Scientific, #R0191). Twenty-nine PCR cycles were performed (annealing 
temperature: 65 ˚C; extension time: 90 s). Reaction intermediates were purified using the 
QIAquick PCR Purification kit (Qiagen, #28104) according to the manufacturer’s instructions. 
 
Approximately 1 µg of both this insert and pACYC184 were digested using 20 units each of 
BamHI and SalI (NEB, #R3136S and #R3138S respectively) in CutSmart buffer for 15 min at 
37 ˚C. One unit of rSAP (NEB, #M0371S) was added to the pACYC184 digest mixture in 
order to dephosphorylate the 5' ends of the digested vector. Both digestion reactions were 
continued for a further 30 min before digested DNA was purified as above.  
 
Digested insert and vector were mixed in a molar ratio of approximately 3:1, and ligated using 
T4 DNA ligase (NEB, #M0202S) at room temperature for 150 min. A ligase-minus reaction 
was included as a negative control. Ligase activity was inhibited by heating the mixtures to 65 
˚C for 10 min. These ligation mixtures (5 µl) were then used to transform competent E. coli.  
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E. coli that exhibited resistance to both ampicillin and chloramphenicol upon transformation, 
and were also subsequently confirmed to be tetracycline-sensitive, were cultured and stored as 
glycerol stocks. Plasmids were prepared from these transformants using the QIAprep Spin 
Miniprep kit (Qiagen, #27104) according to the manufacturer’s instructions. The presence of 
blaCARB-like in pMJD61 was checked by PCR using oMJD88 and oMJD89 (homologous to 
blaCARB-like), and confirmed by Sanger sequencing (GATC/Eurofins) with oMJD98 and 
oMJD99 (homologous to the sequences flanking tet on pACYC184). 
 
2.2.13 – Modified antimicrobial sensitivity assay 
 
A single colony of each strain to be assayed was used to grow a lawn of culture on an LB agar 
plate overnight (37 ˚C). Plasmid-harbouring strains were cultured on appropriate selective 
media. Sections of the lawn were suspended in 1.0 ml LB medium and the OD600 of this 
suspension was normalised to 0.5. This suspension was well-vortexed and cotton swabs were 
used to inoculate an LB agar plate with these standardised suspensions. Plates were allowed to 
air-dry for 15 min before an MICEvaluator Ampicillin test strip (Oxoid, #MA0110F) was 
applied to the plate surface. Plates were then incubated for 20 h at 37 ˚C. Break points were 
determined using the manufacturer’s instructions.  
 
2.2.14 – Extraction of plasmids from V. cholerae  
 
Plasmids were extracted from V. cholerae using the Qiagen Plasmid Midi kit (# 12143) with 
minimal modification to the manufacturer’s instructions. Briefly, 25 ml cultures of V. cholerae 
were grown overnight at 37 ˚C in baffled 250 ml Erylenmeyer flasks (180 rpm). Cells were 
collected by centrifugation (3,900 x g, 5 min, 4 ˚C) and the supernatant was discarded. The 
pellet was resuspended in 4 ml buffer P1 containing RNAse A. Buffers P2 and P3 were added 
according to the manufacturer’s instructions, and all samples were kept on ice for ≥15 min 
before centrifugation (3,900 x g, 45 min, 4 ˚C). Debris had not fully pelleted from the samples, 
and so the supernatant was transferred to a fresh 50 ml Falcon tube and re-centrifuged (3,900 
x g, 15 min, 4 ˚C). The resultant clarified supernatant was added to a pre-equilibrated Qiagen-
Tip 100 and was allowed to flow through the column. The column was then washed (2 x 10 ml 
Buffer QC) before impure plasmid DNA was eluted in 5 ml Buffer QF. DNA was precipitated 
using 3.5 ml room-temperature isopropanol and centrifuged (3,900 x g, 30 min, 4 ˚C). The 
supernatant was discarded and the pellet of DNA washed with 2 ml 70% v/v ethanol before 
 
   48 
being air-dried and rehydrated with 500 µl buffer TE. These samples were sterility-tested and 
removed from the CL3 facility.  
 
2.2.15 – Bacterial cultures for transcriptomic experiments 
 
Transcriptomic experiments were carried out using cultures derived from three independent 
colonies of a bacterial strain of interest. Each strain to be assayed was streaked for single 
colonies from -80 ˚C stocks onto an LB agar plate, which was incubated overnight at 37 ˚C. 
Three well-isolated colonies per strain were used to inoculate 3 ml overnight cultures in LB 
media in 30 ml Sterilin tubes, which were grown overnight (37 ˚C, 180 rpm). The OD600 of 
each overnight culture was then determined. 
 
Baffled 250 ml Erlenmeyer flasks were used as the culture vessels for transcriptomic 
experiments, and contained a pre-prepared culture medium appropriate for the experiment in 
question (LB media). All media used within an experiment were prepared as part of the same 
batch, and using the same base reagents, to minimise batch-effect variation amongst 
transcriptomic experiments. An appropriate volume of overnight culture was added to these 
flasks to a final OD600 of 0.01. The flasks were then loaded into a shaking incubator and grown 
for an appropriate period of time (either to a target OD600 or for a defined period of time post-
inoculation). Once the endpoint for the experiment had been reached, the contents of each flask 
was transferred to a 50 ml Falcon tube and cells were sedimented immediately (3,900 x g, 5 
min, room temperature). The supernatant was discarded and the resultant cell pellet was 
immediately frozen at -80 ˚C. All cell pellets pertinent to an experiment were batched together 
in order to ensure they were all processed on the same day, and under the same conditions, to 
minimise variability. 
 
2.2.16 – RNA isolation and purification 
 
The Masterpure Complete DNA and RNA Purification kit (Epicentre, #MC85200) was used 
to extract RNA from V. cholerae. Prior to processing samples, MSC surfaces, pipettes, 
plasticware etc., were decontaminated using RNaseZap to remove residual RNase 
contaminants. Cell pellets were thawed on ice, treated with 300 µl Tissue & Cell Lysis Solution 
containing Proteinase K, vortexed (10 s) and incubated at 65 ˚C for 20 min with intermittent 
vortexing. Pellets were cooled on ice. MPC Protein Precipitation Reagent (150 µl) was added 
 
   49 
to each sample, tubes were vortexed (10 s) and the contents centrifuged (13,200 x g, 10 min, 4 
˚C). If the resultant pellet was unstable, an additional 25 µl MPC reagent was added and the 
sample re-vortexed and re-centrifuged.  
 
Supernatants were transferred to clean 1.5 ml Eppendorf tubes and total nucleic acids were 
precipitated using 500 µl room-temperature isopropanol. Tubes were inverted 40 times and 
then centrifuged to collect precipitated nucleic acids (13,200 x g, 10 min, 4 ˚C). Supernatants 
were discarded and residual isopropanol was removed using a pipette. Each nucleic acid pellet 
was resuspended in 200 µl DNase buffer containing active DNase I, and incubated at 37 ˚C for 
30 min. After this incubation, 200 µl 2 X Tissue and Cell Lysis Solution (TCLS) was added to 
each sample, followed by 200 µl MPC reagent, to precipitate and inactivate DNase. Samples 
were vortexed (10 s) and centrifuged (13,200 x g, 10 min, 4 ˚C). Supernatants were transferred 
to clean 1.5 ml Eppendorf tubes and DNA-free RNA was precipitated using 500 µl room-
temperature isopropanol. Samples were mixed by inversion 40 times and then centrifuged 
(13,200 x g, 10 min, 4 ˚C). Precipitated RNA pellets were washed twice using 1 ml freshly-
prepared 70% v/v ethanol. The pellets were then dried and resuspended in 40 µl nuclease-free 
TE buffer. RiboGuard RNase inhibitor (1 µl) was added to each sample, which were then tested 
for sterility before being immediately stored at -80 ˚C.  
 
2.2.17 – RNA integrity assessment 
 
Once sterile RNA was removed from the CL3 facility, it was only defrosted once before being 
sent for sequencing, at which point its integrity was tested and it was aliquoted into a 96-well 
plate for submission for sequencing. To assess RNA integrity, an aliquot of each sample (5 µl) 
was electrophoresed on a 1% agarose gel, to check for the presence of discrete 23S and 16S 
rRNA bands. Select samples were also analysed using the Agilent Bioanalyser 2100 and the 
RNA 6000 Nano kit (Agilent, CA USA). 
 
2.2.18 – rRNA depletion and RNA sequencing 
 
rRNA was depleted and sequencing libraries prepared using the Ribo-Zero rRNA Removal Kit 
(Illumina) by the WSI Bespoke sequencing teams. RNA libraries were strand-specific and 
sequenced on a 150 PE Illumina 4000 run, multiplexed at 24 samples per lane (aiming to 
produce a minimum of ten million reads per sample).   
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Chapter 3 
 
Contrasting sources and behaviour of epidemic and endemic Vibrio 
cholerae in the Argentinian cholera epidemic, 1992-1998 
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3.1 – Overview 
 
An overall aim of this thesis is to compare the dynamics of pandemic V. cholerae to those non-
pandemic V. cholerae which incur a lesser burden of disease, with a particular interest in 
describing variation in these distinct V. cholerae across time and geography, and at both 
molecular and phenotypic levels. As previously discussed (Introduction), although there is a 
clear difference between V. cholerae lineages in their ability to cause epidemics and 
pandemics, studies of gene content variation and even of SNVs have not yet elucidated the 
specific genetic determinants responsible for “pandemicity”. However, these studies have been 
hampered by relying on relatively small numbers of laboratory strains, particularly of non-
pandemic V. cholerae, and by a limited understanding of the population structure of the species 
as a whole.  
 
One possible way to compare pandemic and non-pandemic V. cholerae is to examine 
differences in their evolutionary dynamics during an outbreak of pandemic cholera. Due to 
limited numbers of samples included in previous sequencing studies, we understand very little 
about how epidemic V. cholerae evolves once it is introduced into a population or a region, or 
how it contrasts to contemporaneous non-pandemic V. cholerae taken from the same region. 
The only study to date which has sequenced large numbers of closely geographically-related 
samples over a relatively short period of time has been performed in Bangladesh [235]. 
However, Bangladesh is hyper-endemic for cholera, and in that setting, multiple sub-lineages 
of 7PET were found to co-circulate with one another simultaneously. It is also known that there 
is background immunity to V. cholerae in this endemic setting [361]. It would be potentially 
misleading to infer from studies in such a setting rules that govern 7PET evolution and 
behaviour upon its introduction into a naïve population. Therefore, to study the evolutionary 
dynamics of a single 7PET sub-lineage, it was decided to re-visit the Latin American cholera 
epidemic of the 1990s.  
 
In 1991, cholera returned to Latin America after an absence of nearly 100 years [173, 362]. 
Crucially, those epidemics which had occurred prior to 1991 had been associated with 
pandemics 2 through 5, all of which are believed to be due to Classical V. cholerae 
(Introduction, section 1.3.1.1; [36, 97, 162]). Therefore, the introduction of 7PET into Latin 
America in 1991 is an excellent example of point-source introduction of a pandemic bacterial 
clone into what can be considered an immunologically naïve population. Latin America 
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presented a unique opportunity to understand the longitudinal evolution of pandemic V. 
cholerae upon its introduction into a naïve population. 
 
Epidemic cholera broke out in Peru in January 1991, and subsequently spread to Argentina, 
with the first cholera cases reported on the 5th of February 1992 in Salta province, close to the 
Bolivian border [174, 363, 364]. On 6th February 1992, a state of emergency was declared by 
Carlos Menem, then the Argentinian President, in response to outbreaks of cholera in towns in 
Salta province [365]. Thereafter, cholera cases were reported annually between 1992 and 1998 
in Argentina [186, 366–368], with a cumulative total of 4,281 cases reported to PAHO and 
WHO for this period [363, 369–372].  
 
The rapidity by which pandemic cholera can be transmitted is illustrated by an outbreak linked 
to Aerolineas Argentinas flight 386. On 14th February 1992, this flight departed Buenos Aires, 
Argentina, bound for Los Angeles. Following a stop-over in Lima, Peru [373], the flight landed 
in Los Angeles, carrying 336 passengers and 20 crew members [373, 374]. By 19th February 
1992, V. cholerae serogroup O1 had been isolated from five passengers suffering from 
diarrhoea, and by 21st February, one elderly passenger had died from cholera [374–376]. The 
Argentinian government insisted that contaminated food taken on board during the stop-over 
in Lima had been responsible for the outbreak; conversely, the Peruvian government claimed 
that a passenger beginning their journey in Buenos Aires had been the source of the outbreak 
[377]. Simultaneously, reports of cholera were received by the California Department of Health 
Services and the Los Angeles County Department of Health Services [373, 374]. Of the 336 
passengers on the flight, 100 were found to be carriers of V. cholerae, 75 reported diarrhoea of 
whom ten were hospitalised, one case of which was fatal [373]. Forty-eight V. cholerae isolates 
were obtained from these passengers, of which 34 were serotype Ogawa and 14 were serotype 
Inaba [373]. It is from this outbreak that the A1552 laboratory isolate, used for numerous 
functional studies of V. cholerae and the source of an important reference genome sequence 
used in this chapter, was obtained [378, 379].   
 
Argentina is an ideal and unique setting in which to study the evolution of 7PET during the 
1990s, because unlike some other countries in the region, the socioeconomic position of 
Argentina is thought to have enabled the monitoring and control of the epidemic [168, 380]. 
Argentina instituted mandatory notification of cholera cases nationwide during 1991 after 
cholera broke out in Peru [368], and developed public information campaigns which resulted 
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in a concomitant increase in the rate of diarrhoeal disease reporting [381]. During the epidemic 
period (1991-1998), all suspected cholera cases were tested in microbiology laboratories 
nationwide, and putative V. cholerae from clinical cases of suspected cholera, as defined by 
the Argentinian Ministry of Health, were isolated and sent to INEI-ANLIS “Dr. Carlos G. 
Malbrán” (INEI), the national reference laboratory of Argentina, for further confirmation. The 
INEI archives contain over 3,500 phenotypically-characterised V. cholerae isolates, which may 
represent over 82% of the WHO-reported cholera cases for the whole country from this 1990s 
epidemic (an epidemic which caused over 1.2 million disease cases of cholera across Latin 
America [168]).  
 
In order to study the similarities and differences in evolutionary dynamics between epidemic 
and endemic V. cholerae, an appropriate strain collection is required. Previous genomic work 
looking across Latin America and including five Argentinian isolates [189, 234] suggested that 
a single toxigenic V. cholerae clone belonging to the LAT-1 sub-lineage of 7PET was 
responsible for the Argentinian cholera epidemic, related to that which caused outbreaks in 
Peru [189]. Therefore, we hypothesised that the comprehensive strain collection at INEI, 
together with the metadata recorded for each isolate, would enable the study of the progression 
of an epidemic attributed to one discrete introduction of 7PET.  
 
Prior to the implementation of genomic analysis, observations made about cholera in Latin 
America have been difficult to resolve in the light of the cholera paradigm [29]. As discussed 
previously (Introduction, section 1.3.1.2), this paradigm suggested that epidemic cholera in 
Latin America was driven by environmental factors, which created an environment conducive 
to the expansion of local V. cholerae populations. These local V. cholerae were proposed to 
have been the aetiological agent of the 1990s epidemic [29, 382]. Although the role of the 
environment as a source of epidemic V. cholerae continues to be debated today [383, 384], the 
hypothesis that environmental sources gave rise to the Latin American cholera epidemics in 
1991 has been shown to be incompatible with genomic data [189]. The Haitian cholera 
epidemic which began in 2010 has also been shown not to be derived from an environmental 
source [26, 189]. In addition, genomic evidence has shown that even toxigenic V. cholerae O1 
that are local to Argentina [367], and to other Latin American countries, are distinct from the 
aetiological agent of the seventh pandemic cholera [189].  
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Previous V. cholerae sequencing projects have focused on studying isolates from clinical 
sources taken during outbreaks, and have therefore been enriched for serogroup O1 and 
toxigenic V. cholerae isolates. Indeed, it was only because of a combination of socioeconomic 
conditions and the materials preserved by certain laboratories that non-pandemic V. cholerae 
O1 lineages were sequenced in our previous study [189]. However, alongside the mandated 
collection of clinically-isolated V. cholerae O1, INEI also received and stored non-O1 V. 
cholerae of both clinical and environmental origin. Crucially, these non-O1 V. cholerae were 
isolated from the same times and places as the V. cholerae O1 during the epidemic. After the 
1990s epidemic ended in Argentina, environmental surveillance projects saw additional non-
O1 V. cholerae added to the INEI collection. Thus, it was reasoned that this collection of non-
O1 isolates may represent the V. cholerae diversity present in, and endemic to, Argentina 
during and after the period of the cholera epidemic.  
 
This thesis chapter describes an analysis of several hundred genomes of spatiotemporally 
diverse Argentinian 7PET isolates. These genomic data were then linked to related metadata 
and to historical literature, to describe in detail the dynamics and trajectory of the Argentinian 
cholera epidemic. Finally, a number of non-7PET V. cholerae, isolated during the time of the 
epidemic, were contrasted with the pandemic 7PET isolates, laying the foundation for more 
detailed analyses of non-7PET bacteria in subsequent chapters. 
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3.2 – Specific aims 
 
This chapter aimed to use the INEI collection of V. cholerae: 
 
a) To test the hypothesis of whether isolates belonging to the LAT-1 sub-lineage, which 
was introduced into South America in 1991, were the aetiological agents of epidemic 
cholera in Argentina between 1992 and 1998. 
b) Using sequencing data, to study how epidemic V. cholerae evolved genomically over 
the course of the epidemic (seven years). 
c) To characterise the genomes of non-O1 (and, presumably, non-epidemic) V. cholerae, 
and contrast the genomes of these isolates with those of contemporaneously-isolated 
pandemic V. cholerae. 
 
3.3 – Ethical statement 
 
The isolates described herein were acquired by the national reference laboratories at INEI-
ANLIS as part of the routine receipt of notifiable pathogens during this epidemic. No patient 
data, identifiable or otherwise, were made available for the analyses reported in this thesis. 
Accordingly, ethical approval was not required.   
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3.4 – Results 
 
3.4.1 – WHO/PAHO records 
 
In order to obtain an initial insight into the dynamics of the Argentinian cholera epidemic, the 
number of WHO and PAHO-reported cholera cases for the country were plotted (Figure 3.1). 
These data are cumulative, and report the number of cases of disease per annum.   
 
Figure 3.1 – Cholera cases reported to PAHO and WHO from Argentina, 1991-1999. Data were taken from 
[363, 369–372, 385, 386]. 
 
These data suggest that there were two ‘peaks’ of cholera incidence in Argentina between 1992 
and 1998, one in 1993 (2,080 cases) and one in 1996/1997 (474 and 637 cases respectively) 
(Figure 3.1). However, there are discrepancies between these apparent maxima and those 
presented in other governmental reports and research publications, which have suggested that 
there were ‘seven epidemics’ of cholera in Argentina between 1992 and 1997 [186, 366–368]. 
 
3.4.2 – The records of isolate receipt at INEI-ANLIS  
 
All V. cholerae received by INEI since 1992 have been recorded and documented, and these 
records were made available for this PhD thesis. Dates of isolate submission to INEI were 
available for each isolate, as was the location from which each V. cholerae was obtained, the 
serogroup, and for V. cholerae O1, the serotype. GPS co-ordinates were determined for each 
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province or city from which V. cholerae had been received at INEI, and these were used to 
produce maps of V. cholerae O1 and non-O1 receipt over time (Figure 3.2). These were 
therefore used as a proxy for identifying the location and magnitude of disease incidence across 
the country (Figure 3.2).  
 
 
Figure 3.2 – Origins of V. cholerae received by INEI, 1992-2002. The non-O1 isolates obtained from coastal 
regions south of Buenos Aires were obtained from environmental surveillance projects at Instituto Nacional de 
Investigación y Desarrollo Pesquero (INIDEP), Mar del Plata. The size of the circle scales with the number of 
isolates received from a particular region in the year indicated.  
 
V. cholerae were received from the North and Centre of Argentina. The geographic area 
covered by these isolates is approximately 1.2 million km2 (calculating the area of Argentina 
North of a latitude line from Buenos Aires). The nature of the national reporting scheme in 
Argentina at the time, enforced at the national level, made it mandatory that suspected cases of 
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cholera were tested for V. cholerae nationwide. This meant that the absence of isolates from 
the South represents a true absence of cholera reports and isolation from this region.  
 
The date associated with each bacterial isolate corresponded to the date on which the isolate 
was acquired by the reporting laboratories nationwide, rather than the date on which the isolate 
was received by INEI in Buenos Aires. The precise date of isolation was recorded for each 
isolate. Accordingly, it was reasoned that these data might describe the temporal variation in 
V. cholerae reported in Argentina in greater detail than the PAHO/WHO statistics (Figure 3.1). 
Dates of isolation were plotted across the period of the epidemic and beyond, to account for 
environmental sampling that continued beyond the end of the epidemic in 1998 (Figure 3.3).  
 
Of the isolates received, 2,189 were serogroup O1 (60.2 %), and 1,308 were non-O1 V. 
cholerae. Clinical isolates made up the majority (2,077, 94.8%) of V. cholerae O1; 112 isolates 
were either environmental isolates or their sources were not recorded. Of the non-O1 isolates, 
714 were of clinical origin (54.5%). There were 134 isolates for which there were no serogroup 
data recorded (n = 129), that were autoagglutinable (n = 4), or were recorded as being of 
serogroup O139 (n = 1). Of these 134 isolates, 106 were isolated in January 1993 and 
correspond to a reported outbreak of V. cholerae O1 (Josefina Campos, personal 
communication). Serotype data were not recorded for 25 of the V. cholerae O1 in these records 
(1.1%).  
 
At least six peaks of V. cholerae O1 receipt can be observed in Figure 3.3. A seventh peak may 
be visible in early 1998. These are consistent with reports of ‘seven epidemics’ of cholera in 
Argentina during the 1990s [186, 366–368]. Although there were periods during which no V. 
cholerae O1 were received by INEI (Figure 3.3), non-O1 V. cholerae were received more 
consistently during the 1990s, though their receipt rose coincidentally with peaks in V. cholerae 
O1 receipt. The apparent discordance between these data and the PAHO/WHO records likely 
reflects the fact that the PAHO/WHO data are only available as annual case/fatality statistics, 
and are not broken down by month.  
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Consistent with a previous report that V. cholerae Ogawa was predominant in Argentina during 
the 1990s epidemic [387], Ogawa isolates accounted for 82.0% of the V. cholerae O1 in these 
records (1,795 isolates), and 369 isolates were serotype Inaba (16.8%). This is despite the initial 
1991 Latin American cholera epidemic being ascribed to V. cholerae Inaba [369].   
 
3.4.3 – Selection of isolates to sequence for this study 
 
The isolates that were used for this project had been selected in order to represent as much of 
the country as possible (Figure 3.4) and to span the beginning and the end of the epidemic 
(Figure 3.5). A strong bias was applied towards sequencing V. cholerae O1, from 1992 and 
1996/7 and across Argentina, in order to allow questions to be asked about how epidemic V. 
cholerae evolved across space and time during the epidemic. Contemporaneous non-O1 V. 
cholerae from the same geographical regions were also sequenced, in order to compare and 
contrast the genomes of these non-O1 (and presumably, non-epidemic) bacteria with those of 
O1 isolates.  
 
 
Figure 3.4 – Locations from which the isolates analysed in this study were obtained. Of the 490 analysed 
isolates, 475 had region of origin recorded (96.9%). These data are not stratified by serogroup.   
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Figure 3.5 – Dates of isolation for the bacteria sequenced and analysed in this study. Dates of isolation were 
not recorded for four of the sequenced isolates (486/490 isolates represented in this figure; 99.1%). 
 
Genomic DNA was extracted from a total of 511 V. cholerae stored at INEI and sequenced on 
the Illumina X10 platform for the purpose of this PhD project. Twenty-one of the resultant 
sequences were excluded after failing to meet quality control criteria (see Methods). The 
distribution of assembly lengths before the application of a 5 Mbp threshold is presented in 
Figure 3.6 (the V. cholerae genome is approximately 4.1 Mbp in length [59]). Kraken reports 
were also used to identify and remove sequences which were likely to be heavily contaminated 
with non-V. cholerae DNA, or sequences corresponding to species other than V. cholerae, as 
were preliminary phylogenetic trees which were used to exclude isolates on extremely long 
branches (data not shown).  
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Figure 3.6 – Example of the application of an assembly length cut-off to SPAdes assemblies produced in 
this study. The dashed line corresponds to an assembly length of 5 Mbp – sequences of a longer assembly were 
assumed to be contaminated or of poor quality, and were excluded from further analysis. These 936 assemblies 
include previously-published sequences.  
 
Once low-quality sequences and contaminated samples were excluded, this left a total of 490 
genome sequences which were used for all subsequent analysis. A core-gene phylogeny was 
calculated using the 490 Argentinian sequences, together with a set of 7PET and non-7PET 
genomes (1,165 total genomes), in order to classify the Argentinian isolates as 7PET, or non-
7PET, based on their phylogenetic position (Figure 3.7). Based on these data, 425 of the 490 
sequenced V. cholerae were determined to be members of 7PET (86.7%) and 65 were classified 
as non-7PET (Figure 3.7). 
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Figure 3.7 – Maximum-likelihood core-gene phylogeny of 1,165 V. cholerae. Isolates sequenced in this study 
(n = 490) were determined to be 7PET, or not, on the basis of their phylogenetic position. The phylogeny was 
calculated using FastTree v2.1.10 [388] and used as an intermediate analysis step. 
 
3.4.4 – 7PET phylogeny  
 
The 425 7PET genomes were placed into phylogenetic context alongside 517 additional 
genomes [189], by mapping the reads for these sequences to the V. cholerae reference sequence 
(strain N16961 [59]) and calling non-recombinant SNVs using established analysis pipelines 
(see Methods). The sequences of both V. cholerae chromosomes in the N16961 reference were 
combined for this purpose. Within the resultant alignment of 942 sequences, Gubbins masked 
 
   64 
11.83% of the genome as being potentially recombined. When regions of recombination that 
were associated solely with pre-pandemic strain M66 were removed from consideration, 2.4% 
of the genome was predicted to be recombined (Figure 3.8). 
 
 
Figure 3.8 – N16961 chromosome regions predicted to be recombined from the 7PET alignment. Regions 
predicted by Gubbins to be recombined using the alignment of 942 V. cholerae sequences are indicated in red. 
The regions that are not solely associated with the pre-pandemic isolate M66 are indicated in blue (innermost 
ring). The two outermost rings indicate the presence of open reading frames on the forward and reverse strand, 
respectively. The sequences of both N16961 chromosomes were concatenated to produce this figure. 
 
A maximum-likelihood phylogenetic tree was then calculated from the non-recombinant SNVs 
in this alignment (Figure 3.9). Parsimony-informative SNVs were identified from the 
alignment and used to cluster the data with Fastbaps [334]. These clusters were used to guide 
the assignment of 7PET isolates to sub-lineages (Figure 3.9). Of the 425 7PET isolates from 
Argentina, 421 isolates were members of the LAT-1 sub-lineage, which had been introduced 
to Peru in 1991 and subsequently spread across Latin America [189]. Since none of the 
Argentinian genomes were members of any other 7PET sub-lineage, the hypothesis that 
epidemic cholera in Argentina was caused by the same strain introduced into Peru in 1991 is 
very strongly supported.  
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Figure 3.9 – A maximum-likelihood phylogeny of 7PET. Tree calculated using 7,556 non-recombinant SNVs, 
and rooted on the pre-pandemic isolate M66. Clustering was performed using Fastbaps and an alignment of 3,874 
parsimony-informative SNVs. Countries of origin for sequences from South and Central America are reported. 
LAT transmission events as described previously [189] are indicated; LAT-1 is indicated in red.   
 
The remaining four isolates were not members of LAT-1, but were phylogenetically closely 
related to F99/W (Figure 3.9). This is a isolate that had been reported previously [189, 389] 
and had been shown to be neither toxigenic nor a member of LAT-1 [189]. The genomes of 
the four isolates related to F99/W were investigated in more detail using comparative 
genomics, to determine the presence and absence of pathogenicity islands associated with 
7PET [54, 133] (Table 3.1). All but one were found to encode VPI-1, the genomic island which 
encodes TCP, the receptor for CTXφ [55]. None of these isolates were found to carry CTXφ 
or the ctxAB genes required to express CT, consistent with the original report of the F99/W 
genome sequence [189]. 
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Pathogenicity 
island 
F99/W isolate 
16853_4#67 
(F99/W) 
26268_1#261 
(CCBT0194) 
26268_1#259 
(CCBT0192) 
26268_1#257 
(CCBT0190) 
26268_1#254 
(CCBT0187) 
VPI-1 Yes No Yes Yes Yes 
VPI-2 Yes Yes Yes Yes Yes 
VSP-1 Yes Yes Yes Yes Yes 
VSP-2 Yes Yes No Yes Yes 
CTXφ No No No No No 
Table 3.1 – Presence of select pathogenicity islands in F99/W isolate genomes.  
 
ACT comparisons were used to confirm that these pathogenicity islands are present, and 
absent, in their totality from the canonical integration sites (based on the N16961 reference 
genome; Figures 3.10 to 3.12). The absence of CTXφ was also verified using pangenome gene 
presence/absence data in subsequent analyses, to exclude the possibility of the bacteriophage 
integrating into non-canonical loci. Similarly, in the case of CCBT0194, mapping data (against 
N16961) were visualised in order to verify the absence of VPI-1, by confirming that these 
regions in the reference genome were not covered by mapped reads from the relevant 
sequencing run (Figure 3.11).  
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Figure 3.10 – Confirming the presence and absence of VPI-1 and CTXφ in isolates phylogenetically-related 
to F99/W. (A): The sequence corresponding to VPI-1 is absent from CCBT0194 (26268_1#261) but present in 
all other sequences being compared, including the N16961 reference. (B): The CTXφ prophage is absent from the 
canonical integration locus on the larger chromosome in each of the isolates in the F99/W clade (Figure 3.9).   
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Figure 3.11 – Confirming the absence of CTXφ and VPI-1 from CCBT0194. The depth of reads mapped to 
the N16961 reference from isolate CCBT0194, the N16961 sequence, and the CCBT0194 assembly are presented. 
Panel (A) shows the section of the chromosome that harbours the CTXφ prophage and panel (B) shows the VPI-
1 integration locus. The drop in coverage to near-zero over these pathogenicity islands, together with the absence 
of these islands from the CCBT0194 assembly, supports the conclusion that this isolate lacks both CTXφ and 
VPI-1.  
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Figure 3.12 – Confirming the presence of VSP-1 in F99/W isolate genomes. VSP-1 is present in its canonical 
integration locus in all isolates in the F99/W clade (Figure 3.9).  
 
Since the F99/W clade of isolates harbour chromosomal pathogenicity islands that are 
associated with pandemic V. cholerae (Table 3.1), including VPI-1, it is interesting to speculate 
as to whether these have the potential to be infected by the CTXφ bacteriophage and to become 
toxigenic. However, live cultures of these isolates were not available with which to test this 
hypothesis.  
 
3.4.5 – LAT-1 phylogenetics 
 
Although all of the Argentinian LAT-1 genomes clustered together, there appeared to be 
additional topological structure within the LAT-1 phylogeny (Figure 3.9). Therefore, to study 
this in greater detail, we re-mapped the reads for the 531 sequences in the LAT-1 sub-lineage 
to the closed genome sequence of strain A1552 [326], and called SNVs against this reference. 
A1552 was obtained by the Schoolnik laboratory from the Californian Department of Health 
Services [379, 390]. It is an Inaba El Tor bacterium [326, 378], and was isolated from a traveller 
 
   70 
suffering from cholera in California in 1992 who arrived on Aerolineas Argentinas flight 386 
(section 3.1; [378, 379]).  
 
Based on this alignment of 532 sequences, just 0.03% of the A1552 genome was predicted to 
be recombined (Figure 3.13). A maximum-likelihood phylogeny was calculated using an 
alignment of 2,651 non-recombinant SNVs (Figure 3.14A). A mean of only 26.05 non-
recombinant SNVs across both chromosomes separated the sequence of each LAT-1 isolate 
from that of the A1552 reference genome (min 10, max 149, stdev 14.10; Figure 3.14B).  
 
 
Figure 3.13 – A1552 genome regions predicted to be recombined using the LAT-1 dataset. The sequences of 
both the larger and smaller chromosomes were concatenated to produce this figure (orange, brown respectively). 
The inner ring (red) indicates the sections of the genome sequence predicted to be recombined by Gubbins. tRNAs 
are indicated by green ticks. The two outermost rings indicate the presence of open reading frames on the forward 
and reverse strand, respectively.  
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Figure 3.14 – LAT-1 phylogeny and SNV distances from A1552. (A): A maximum-likelihood phylogeny 
calculated from an alignment of 2,651 non-recombinant SNVs relative to the A1552 reference (accession 
# CP025936, CP025937). The tree is rooted using the genome of an isolate from Burkina Faso taken in 1984, 
CNRVC980048. This isolate lacks the WASA-1 genomic marker of LAT-1 [158, 189, 234]. Metadata and the 
presence of the CTXφ prophage are indicated. An alignment of 725 parsimony-informative non-private SNVs 
was used to cluster the data using Fastbaps. (B): A density plot of non-recombinant SNVs separating each genome 
from A1552.  
 
From Figure 3.14 it is clear that LAT-1 sequences did not cluster by geography, either by 
province or region (Figure 3.14A). Isolates from different Northern provinces were 
interspersed amongst one another, as were isolates from countries bordering Northern 
Argentina such as Bolivia. However, limited clustering by date of isolation could be observed. 
Argentinian isolates from 1996 and 1997 clustered together, and cluster 1 was almost fully 
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made up of isolates from 1997. Cluster 2 contains Argentinian isolates from 1992 and 1993, 
and one isolate from 1997, from multiple provinces. Additionally, cluster 2 contained one 
Bolivian genome from 1992 and a Peruvian genome from 1991.  
 
Consideration was given to whether a dated phylogeny could be used to study transmission of 
LAT-1 within Argentina. However, a robust temporal signal was not detected in these data – 
plotting root-to-tip divergence of the LAT-1 phylogeny (Figure 3.14A) against time using 
TempEst v1.5.1 yielded a regression with a poor correlation coefficient and R2 value (Figure 
3.15). It was also noted that of the 2,651 SNVs in the LAT-1 alignment, 1,926 (72.6%) were 
private to single genomes in the dataset. This strongly suggested that each isolate may have 
evolved privately during storage. This may be a consequence of the way in which the isolates 
were stored; some isolates were stored for up to 27 years before being sequenced, and many 
had been preserved on stabs or at ambient temperature – as has been described previously, 
these are storage conditions that can select for hypermutator phenotypes, which would be 
consistent with accelerated private mutation [308, 391]. Therefore, to avoid drawing 
conclusions based on potentially spurious results, it was decided that it was inappropriate to 
calculate dated phylogenies using these data.  
 
 
Figure 3.15 – Root-to-tip distance versus time for the LAT-1 phylogeny. Argentinian sequences for which 
dates of isolation were not recorded (n = 4) were arbitrarily assigned to the year 1993. Figure produced using 
TempEst v1.5.1. 
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A pangenome was calculated using these 532 LAT-1 genomes. A total of 3,412 core genes 
were identified from a total of 6,860 genes in the pangenome (core: 97% <= strains <= 100%, 
see Methods). The gene presence/absence matrix was interrogated to determine the presence 
and absence of WASA-1, ctxAB, and CTXφ across the dataset, and to detect genes associated 
with IncA/C plasmids (Figure 3.16).  
 
 
Figure 3.16 – LAT-1 pangenome gene presence/absence matrix visualisation. Phylogeny is as presented in 
Figure 3.14A. The position of CTXφ bacteriophage genes and those genes present on IncA/C plasmids are 
highlighted. White horizontal lines in the core genome block correspond to a small number of poorly-assembled 
sequences, which have been included to contextualise these sequences with previously-published studies.  
 
In addition to the small accessory genome in these LAT-1 isolates, it was observed that the 
addition of new genomes to this analysis contributed negligible numbers of new genes to the 
pangenome overall – after the addition of 532 sequences, just ~1,800 unique genes had been 
added (Figure 3.17). This contrasts strongly with that observed in the non-LAT-1 genomes (see 
section 3.4.10).  
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Figure 3.17 – Gene discovery as LAT-1 genomes are added to the pangenome. The initial peak of new gene 
detection corresponds to the identification of the core genome.   
 
The presence of WASA-1 within LAT-1, a genomic island serving as a marker of the lineage 
[234], was confirmed by extracting the complete nucleotide sequence of WASA-1 from the 
A1552 genome sequence and using it to query each LAT-1 assembly with BLASTn. In order 
to confirm the presence of ctxAB and CTXφ, and to detect antimicrobial resistance genes and 
plasmid replicons, ARIBA was used together with the ResFinder and PlasmidFinder databases, 
and a custom database of V. cholerae virulence genes (Figure 3.18). ARIBA was also used to 
identify variation in the sequence of the wbeT gene, mutations in which are responsible for the 
switch from Ogawa to Inaba serotype [197, 198] (Introduction, section 1.3.1.3).  
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3.4.6 – Inaba and Ogawa serotype variation within LAT-1 
 
The serotype of V. cholerae O1 is of particular historical importance in Latin America. It is 
known that the initial 1991 cholera epidemics in Peru and elsewhere in Latin America were 
associated with serotype Inaba V. cholerae, which became dominated by serotype Ogawa 
bacteria in 1992 and thereafter [208, 369]. The Argentinian epidemic began in 1992 and was 
reportedly dominated by V. cholerae Ogawa [387], despite the initial cholera epidemic in Peru 
being ascribed to V. cholerae Inaba [369]. INEI records support this, and also suggest that the 
dominant serotype in Argentina varied between Inaba and Ogawa over time (Figure 3.3). This 
suggested subtleties to the dynamics of Ogawa and Inaba serotype V. cholerae O1 in Argentina 
during the epidemic, and begged the question of whether outbreaks due to Inaba bacteria in 
Argentina after initial Ogawa outbreaks was due to an Inaba strain being imported from 
elsewhere, or to seroconversion within the lineage already present in Argentina.  
 
As described in the Introduction (section 1.3.1.3), methylation of the terminal sugar on the O1 
lipopolysaccharide chain by the WbeT enzyme confers an Ogawa serotype on V. cholerae O1, 
and if the wbeT gene is disrupted, WbeT activity is abolished, and an Inaba phenotype results 
[197–199]. Therefore, to determine a genetic explanation for the apparent flux in serotype in 
Argentina over the course of the epidemic (Figure 3.3), the genotype of wbeT was determined 
for every isolate in LAT-1. Within the sub-lineage, nine distinct wbeT mutations were 
identified which were predicted to disrupt the WbeT protein (Figure 3.19). It was assumed that 
mutations that were predicted to frameshift or truncate translated wbeT would cause an Inaba 
phenotype (N62fs, N165fs, F244fs, Q274trunc), as would other mutations that either were 
found in Inaba isolates in this dataset (I206K) or were otherwise known to confer an Inaba 
phenotype (S158P [200]). Since all of the isolates harbouring the E36D wbeT mutation had an 
Ogawa phenotype, it was assumed that this mutation does not abolish WbeT function. Of the 
remaining eight mutations, the genomic predictions correlated well with the phenotypic 
serotype assigned to each isolate; the wbeT genotype matched the phenotypic serotype for all 
but two of the of the 398 serotyped LAT-1 isolates sequenced in this study (99.4% 
concordance; Figure 3.19).    
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Figure 3.19 – Variation in wbeT genotype across the LAT-1 phylogeny. The maximum-likelihood phylogeny 
presented in Figure 3.14A is re-drawn here with additional metadata and results of select ARIBA analysis results. 
Missing data are indicated by white space.  
 
Genome data show that the Peruvian Inaba isolates from 1991 harbour the N165fs mutation in 
wbeT (Figure 3.19). Since LAT-1 was introduced into Latin America from West Africa [189], 
we compared these data to West African Inaba isolates sharing a common ancestor with LAT-
1, but post-dating the Peruvian outbreak. These Angolan isolates were collected between 1992 
and 1995, just after LAT-1 had been introduced into Peru, and were found to harbour a different 
mutation, N62fs (Figure 3.19) [158, 189]. Sixty-eight LAT-1 isolates collected since 1991 
harbour the N165fs mutation, including isolates from Brazil, Mexico, Chile, Argentina and 
Colombia, as well as isolates from Peru, all of which were phenotypically serotype Inaba 
(Figure 3.19). Environmental isolates from Mexico collected between 2004 and 2010 also 
harbour this mutation, and are part of the same cluster of isolates (Figure 3.19). Hence, the 
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N62fs and N165fs mutations are likely to have arisen independently, prior to spreading within 
West Africa and Latin America, respectively. 
 
It has been hypothesised that cholera entered Argentina through the North of the country, which 
shares borders with Chile, Bolivia, Paraguay, and Brazil [174]. The LAT-1 phylogeny includes 
genomes from bacteria collected in 1991 and 1992 from Chile, Bolivia and Brazil [189, 234] 
(Figure 3.19). These were either serotype Ogawa (Bolivia, n = 7; Brazil, n = 1) or Inaba 
(N165fs; Brazil, n = 6; Chile, n = 1), and were interspersed amongst contemporaneous serotype 
Ogawa isolates which were collected in Northern provinces of Argentina (Figure 3.19). All 
were members of cluster 4, except for one Bolivian genome (1992) which was a member of 
cluster 2, as discussed previously (section 3.4.5; Figure 3.19). Cluster 4 also contains the 
A1552 reference sequence, which is of an Inaba genotype (N165fs; Figure 3.19). This 
observation further supports the hypothesis that the same V. cholerae sub-lineage circulated 
within, and between, countries at the Northern border of Argentina.  
 
Once the concordance between phenotypic serotype and genotypic inference had been 
established, these data were compared to the longitudinal data detailed in Figure 3.3. Following 
a relative lull in cholera cases in 1995, cases of cholera resurged in Argentina during 1996 
[369]. This was associated with serotype Inaba V. cholerae (Figure 3.3). Seventeen Argentinian 
Inaba V. cholerae isolates from 1996 formed a closely-related subclade within cluster 4 of the 
LAT-1 phylogeny (Figure 3.19). These isolates contain a unique mutation in wbeT, Q274trunc, 
and the subclade includes one 2010 Inaba isolate from Mexico (Figure 3.19). Additionally, this 
subclade shares a common ancestor with the clade of 48 isolates from 1997, which are serotype 
Ogawa and comprise cluster 1 (Figure 3.19). The 1996/1997 outbreak was not geographically-
restricted; this cluster contained isolates from multiple provinces (Figure 3.19). 
 
3.4.7 – Plasmids and antimicrobial resistance in LAT-1  
 
The identification of 3,368 core genes suggested that ~89% of the 3,776 annotated genes in the 
A1552 reference genome are core to LAT-1. This also implied that gene gain and loss within 
LAT-1 was also very rare (Figure 3.16; 3.17). However, some examples of gene gain/loss were 
identifiable; fifty-one of the genomes in the LAT-1 phylogeny were found to lack the CTXφ 
prophage in its entirety (Figure 3.16; Figure 3.19). It is possible that this loss was a result of 
long-term culture as has been noted previously [235, 392]. There was also evidence of sporadic 
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gene gains. For instance, four Argentinian LAT-1 V. cholerae were found to harbour genes 
encoding the extended-spectrum β-lactamases (ESBLs) blaCTX-M-3, blaOXA-8, and blaTEM 
(Figure 3.18). Manual interrogation of the assemblies for these isolates confirmed that these 
three ESBL genes were carried on contigs that also included IncA/C plasmid replicons (Figure 
3.20). 
 
IncA/C replicons were also detected in Angolan isolates from 1988 and the early 1990s, 
consistent with previous reports [158, 189] (Figure 3.18, 3.19). These isolates form part of 
cluster 3 in this dataset, which includes other African genomes pre-dating the transfer of LAT-
1 into Latin America in 1991 (Figure 3.18, 3.19). Although two of the Angolan genomes did 
harbour blaTEM (Figure 3.18), the complement of resistance determinants in these isolates does 
not match those found in Argentinian V. cholerae.  
 
 
Figure 3.20 – Comparison of a fully-assembled IncA/C2 plasmid from Argentinian isolate CCBT0329 to 
published V. cholerae multidrug resistance plasmids. The positions of the IncA/C replicon sequence present 
in the PlasmidFinder database and the three genes encoding β-lactamases in the CCBT0329 contig are indicated.  
The sequences and annotations for pVCR94ΔX and pVC211 were obtained from Genbank (accession # 
KY399978.1 and KF551948.1, respectively; [393, 394]). The CCBT0329 sequence was annotated with Prokka.  
 
Multidrug resistance plasmids encoding ESBLs have been previously reported in Argentinian 
V. cholerae [366, 387], where molecular characterisations of these large plasmids demonstrated 
that they can be mobilised and conjugated into E. coli [366]. Since IncA/C plasmids are 
conjugative [395], the plasmids identified in these sequencing data encoding blaCTX-M-3, 
blaOXA-8, and blaTEM are very likely to correspond to the MDR plasmids seen in V. cholerae 
O1 isolated during the 1990s epidemic from Argentina [366]. 
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3.4.8 – Phylogenetic contextualisation of Argentinian non-7PET isolates 
 
Having performed an in-depth characterisation of LAT-1, and found very limited genetic 
variation at the levels of SNVs, gene gain and loss, and homologous recombination, attention 
was turned to the 65 non-7PET Argentinian genomes, to compare the observable dynamics of 
these isolates to those of LAT-1. In order to contextualise the 65 non-7PET isolates sequenced 
in this study, these were combined with 318 published non-7PET genome sequences, including 
three Vibrio spp. A pangenome was calculated from these sequences, and 201,790 SNVs 
extracted from an alignment of 2,719 core gene sequences was used to calculate a maximum-
likelihood phylogeny for these isolates (Figure 3.21). The collection of genomes used for 
contextualisation included a set of recently-reported Chinese genomes [396]; these include 
isolates which were shown to be closely-related to lineages of V. cholerae O1 that had reported 
to be local to Latin America [189].  
 
Figure 3.21 – Non-7PET V. cholerae phylogeny. A maximum-likelihood phylogenetic tree calculated from 
201,790 SNVs identified from an alignment of 2,719 core genes (see Methods). Metadata are presented for the 
isolates sequenced in this study. The grey disc indicates a cluster of V. cholerae which are genetically distinct 
from pandemic lineages but are still members of the V. cholerae species, and will be discussed in greater detail in 
subsequent chapters. Included in this cluster is a non-toxigenic V. cholerae O139 isolate, described in Chapter 4. 
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In order to confirm the O1 serogroup status of these 65 isolates, the presence of the nucleotide 
sequence of the serogroup O1 operon extracted from N16961 was determined for each isolate 
using BLASTn. Four isolates were phenotypically and genotypically serogroup O1. Two of 
these were members of the previously-described Gulf Coast lineage of V. cholerae O1, 
including the single sequenced V. cholerae O1 from 1998 (Figure 3.21). Both Gulf Coast 
isolates harboured CTXφ and were toxigenic, and the two remaining V. cholerae O1 isolates 
were members of ELA-3 [189] (Figure 3.21). All four isolates were of clinical origin. The 
remaining 61 isolates lacked the genes required to produce cholera toxin, and were confirmed 
in silico not to harbour genes encoding the O1 antigen, though 45 of these were of clinical 
origin (Figure 3.21).  
 
Four new lineages of non-O1 non-7PET V. cholerae were identified amongst these isolates, 
defined as clades formed by three or more Argentinian non-7PET isolates in the phylogeny. 
These were labelled as A1-A4, where A stands for ‘Argentina’ (Figure 3.21). These lineages 
contained isolates that were of clinical origin alone (A1, A3) or clinical and environmental 
origin (A2, A4), were acquired in different years (A3, A4), and from different regions (A2, A3, 
A4), suggesting that these represent populations of non-7PET V. cholerae local to Argentina 
(Figure 3.21).  
 
3.4.9 – Type III secretion systems in Argentinian non-7PET isolates  
 
Of the 61 non-O1 non-7PET isolates, 21 harboured one of three distinct Type III secretion 
systems (Figures 3.21, 3.22). These virulence determinants have been associated with 
pathogenic non-O1 V. cholerae as well as with other pathogenic Vibrios [303]. The three 
T3SSs  detected in these isolates included the T3SS-2α described in V. cholerae AM_19226, 
an isolate commonly-used for functional and regulatory studies of T3SS [266, 397]. A less-
common system described by Carpenter et al., T3SS-2β, was also identified [397], as was a 
third putative T3SS element which most closely resembles a T3SS detected in two virulent 
Chilean Vibrio anguillarum isolate genomes [398] (Figure 3.22). This putative T3SS was found 
in lineage A2. The presence of T3SS-2β in lineage A3 was of particular interest – A3 is 
composed of clinical isolates, contains a previously-described Argentinian isolate, 
TUC_T2734 [189], and includes one isolate from Salta province collected in the year 2000. 
T3SS elements were mutually exclusive; no more than one T3SS was detected in a genome. It 
is also clear from these limited data that more T3SS-positive isolates were of clinical origin 
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than environmental (T3SS-2α: 10 clinical, 2 environmental; T3SS-2β: 5 clinical, 0 
environmental; V. anguillarum element; 1 clinical, 3 environmental). No T3SS were detected 
in 7PET.  
 
Figure 3.22 – Comparison of T3SS elements detected in Argentinian V. cholerae against T3SS taken from 
reference sequences. Co-ordinates for each region of the assemblies that have been aligned are reported (rev = 
reverse orientation). Annotations were obtained from Prokka-annotated assemblies used to calculate the 
pangenome, or from Genbank (PF4 and NCTC 30; accession # CP010081.1 and LS997867.1, respectively). The 
presence of T3SS-2β in NCTC 30 is discussed in Chapter 4 (section 4.3.10). The PF4 sequence was reflected 
manually to produce this figure (Adobe Illustrator). 
 
3.4.10 – Comparison of Argentinian LAT-1 and non-7PET pangenomes 
 
Having assigned all of the 490 Argentinian genomes to 7PET or non-7PET, maps of isolate 
origins stratified on lineage were produced (Figure 3.23). Although non-7PET isolates were 
fewer in number than 7PET, they were obtained from the same geographical regions and the 
same time periods as the 7PET isolates (Figure 3.23). This acted as reassurance that the O1 and 
non-O1 V. cholerae sequenced in this study had sampled the same times and regions as one 
another, albeit that V. cholerae O1 had been sequenced in larger numbers than non-O1 (Figure 
3.5). This also means that, in principle, both contemporaneous 7PET and non-7PET bacteria 
should have opportunity to access similar gene pools and to participate in HGT.  
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Figure 3.23 – Map showing geographic origin for isolates used in this analysis. Data from Figure 3.4 were 
stratified by lineage. The size of each circle scales with the number of isolates assigned to that year. Circles 
coloured by year.  
 
The non-7PET isolates had a considerably expanded accessory genome when compared to 
LAT-1 (23,458 cloud genes in the collection of 383 diverse genomes compared to 3,313 in the 
532 LAT-1 genomes) (Figure 3.24). Thus, the ratio of core genes to cloud genes in LAT-1 was 
approximately 1:1, whereas in the non-7PET pangenome, the core:cloud gene ratio was ~1:8.  
 
 
Figure 3.24 – Comparing the summary statistics for the LAT-1 and V. cholerae species pangenomes 
calculated in this study. Fractions of the total number of genes in the pangenome are presented. Definitions used: 
core: 97% <= strains <= 100%; soft core: 95% <= strains < 97%; shell: 15% <= strains < 95%; cloud: 0% <= 
strains < 15%.  
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The large non-core genome was also evident when the pangenome gene presence/absence 
matrix was visualised against the V. cholerae species phylogeny (Figure 3.25). This contrasted 
starkly with that of the LAT-1 dataset (Figure 3.16). 
 
 
Figure 3.25 – Visualisation of the V. cholerae pangenome gene presence/absence matrix. Phylogeny is as 
presented in Figure 3.21 and is similarly rooted on three Vibrio spp. genomes.  
 
The rate of gene discovery as sequences were added to the non-7PET pangenome (Figure 3.26) 
was much greater than was observed in the LAT-1 pangenome (Figure 3.17), despite there 
being 38% more sequences in the LAT-1 pangenome. Unlike the LAT-1 pangenome, in which 
the discovery of new genes was rare, the core of 2,719 genes in this dataset is dwarfed by the 
number of unique genes discovered as diverse genomes are added to the pangenome. Where 
the addition of 532 genomes to the LAT-1 pangenome saw ~1,800 unique genes being 
identified (Figure 3.17), after adding 383 non-7PET genomes to the V. cholerae pangenome, 
~13,000 unique genes were detected (Figure 3.26). 
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Figure 3.26 – Identification of new genes as genomes are added to the V. cholerae pangenome.  
 
The contrast between the clonality of LAT-1 and the diversity of the V. cholerae species dataset 
was also evident when other summary statistics were plotted for these pangenomes (Figure 
3.27). Of particular note are the differences in the numbers of total genes relative to conserved 
genes, the overall contribution to the number of pangenome genes made by adding each 
additional genome to both datasets, and the number of genes that have a diminishing BLASTp 
identity in the species pangenome compared to that of LAT-1 (Figure 3.27). 
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Figure 3.27 – Summary statistics for LAT-1 and non-7PET V. cholerae pangenomes.  
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As another measure of genetic distance, average nucleotide identity (ANI) values relative to 
the A1552 reference sequence were calculated for all genomes sequenced in this study. By this 
measure, the non-7PET isolates were also highly genetically diverse in comparison to the 7PET 
genomes, with a mean ANI relative to A1552 of 97.61 (min 95.90, max 99.65, stdev 0.960; 
Figure 3.28), in contrast to LAT-1 (mean ANI 99.99, min 99.96, max 99.998, stdev 0.0032; 
Figure 3.28). This finding is consistent with the phylogenetic analysis presented above (Figure 
3.21). It should be noted that an ANI value of 95% is commonly accepted to be threshold for 
separating species [340].  
 
 
Figure 3.28 – ANI values for genomes sequenced in this study relative to the A1552 reference sequence. 
Samples were stratified by phylogenetic assignments.  
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3.5 – Discussion 
 
A combination of factors mean that this study could only have been performed in Argentina. 
The limited introductions of 7PET sub-lineages into Latin America, the sole introduction of 
LAT-1 into Argentina, and the enhanced surveillance systems that were introduced in 
Argentina once cholera broke out in Peru all meant that the INEI culture collection was a 
comprehensive representation of the 1992-1998 Argentinian cholera epidemic in its entirety. 
Therefore, the number of isolates included in this project encompassed a very large proportion 
of the total cholera cases across the country and throughout the epidemic, presenting a unique 
opportunity to understand the dynamics of epidemic V. cholerae evolving over long periods, 
originating from point-source introductions. To the best of our knowledge, this is the largest 
genomic study to date that investigates a cholera epidemic in a single country. We also believe 
that it is the largest genomic analysis of any single bacterial pathogen in Argentina.  
 
There are a number of observations to be made using these data, chief among which is the fact 
that it is clear that a single clone of V. cholerae O1, now known to be one sub-lineage of 7PET 
[189], was responsible for pandemic cholera in Argentina, in spite of the seasonal fluctuations 
and serotype variation observed (Figure 3.3) [274, 367, 399, 400]. These data also show that 
LAT-1 circulated amongst the countries at the Northern borders of Argentina during the early 
1990s - for instance, cholera was first reported in Bolivia in August 1991 [401, 402], and 
Bolivian genomes from the early 1990s are mixed amongst the Argentinian genomes from the 
same period (Figures 3.14, 3.19). These genomic data also validate fundamental observations 
made by public health authorities during the cholera epidemics of the 1990s, such as that 
Argentinian cholera outbreaks were principally caused by V. cholerae O1 serotype Ogawa 
which had been shown by PFGE to be closely related to the Peruvian strain [208, 367, 403–
405].  
 
These data also explain historical observations on the variation of serotype during the 1990s 
epidemic across Latin America, and provide new insight into the microevolution of LAT-1 
during the Argentinian cholera epidemic. V. cholerae Ogawa from Argentina in 1992 were 
shown to be closely related to Inaba isolates from Peru (Figure 3.19), and the shift in dominant 
serotype from Inaba to Ogawa that was observed in Peru and elsewhere in Latin America [208] 
represented variation within LAT-1, rather than a separate introduction of another strain 
(Figure 3.14A). Similarly, the outbreak of Inaba V. cholerae in Argentina in 1996 was also a 
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result of variation within LAT-1; the outbreak was caused by LAT-1 isolates in which wbeT 
had mutated from wild-type Ogawa genotype to an Inaba genotype (Q274trunc). This mutation 
is likely to have occurred in Argentina. The Q274trunc mutation is distinct from others 
identified within LAT-1, particularly the mutation associated with the Inaba phenotype in 
contemporaneous Mexican isolates (N165fs). These results strongly indicate that Argentinian 
cholera in 1996 was not caused by an introduction of a new Inaba (sub)lineage from elsewhere 
in Latin America; rather, LAT-1 V. cholerae that had already been introduced into Northern 
Argentina, or neighbouring countries, acquired a new Inaba genotype. In turn, the Argentinian 
cholera outbreak in 1997 was caused by a sub-clade of LAT-1 that was closely related to the 
1996 Inaba clone. However, the topology of our phylogeny suggests that this was not a result 
of ‘reversion’ from the Inaba Q274trunc genotype to an Ogawa genotype (Figure 3.19). These 
data underline that Ogawa/Inaba phenotypic variation is not phylogenetically informative, and 
may be both misleading and inappropriate to use as an epidemiological marker. 
 
Furthermore, the inclusion of non-7PET V. cholerae in our study has highlighted that a highly 
diverse population of the V. cholerae species existed in Argentina concurrently with the 
extremely invariant LAT-1 pandemic sub-lineage during the 1990s. It is suggested that these 
non-7PET bacteria, including serogroup O1 and non-O1 isolates, represent those V. cholerae 
that are truly endemic to Argentina, which are evolving locally, but lack the propensity or 
ability to cause global epidemics and to spread in the same way as 7PET. Therefore, it can be 
concluded that the reason that Latin America was cholera-free for 97 years was due solely to 
the absence of pandemic V. cholerae lineages from the continent. In the absence of 
comprehensive clinical data associated with these non-7PET isolates, it cannot be determined 
whether they are aetiological agents of cholera, or of a cholera-like illness. However, it is very 
clear that non-7PET V. cholerae were present in Argentina, and associated with disease at a 
low level, throughout the 1992-1998 cholera epidemic and thereafter (Figure 3.3).  
 
In spite of the sustained circulation and dissemination of LAT-1 across Northern Argentina, an 
area of approximately 1.2 million km2 (Figure 3.4), these data suggest that very little genetic 
change, in terms of SNVs, recombination, and gene gain/loss, occurred in this sub-lineage over 
a period of nearly six years. The invariance of LAT-1 is juxtaposed with the diversity observed 
in non-O1 V. cholerae in Argentina (Figures 3.14A, 3.16, 3.21, 3.24-3.28). As discussed in the 
Introduction to this chapter, although V. cholerae research has focused on studying epidemics 
and outbreaks, by definition, this tends to describe epidemic lineages. Non-7PET V. cholerae 
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are highly variable – within this dataset, as well as examples of local lineages of non-7PET V. 
cholerae, isolates were also identified which were confirmed microbiologically to be Vibrio 
cholerae, but were diverse phylogenetically (Figure 3.21) and as measured by ANI values 
(Figure 3.28). The pathology of the disease associated with these isolates – and whether 
virulence determinants such as T3SS contribute to this disease – is beyond the scope of this 
thesis but is the focus of future work, though evidence does suggests that T3SS do contribute 
to diarrhoea and disease caused by non-7PET bacteria [305]. With the caveat of a small sample 
size, it can also be observed that the clinical non-7PET isolates were enriched for the presence 
of T3SS (16/21 isolates).  
 
It is particularly vital to understand the diversity of local, endemic V. cholerae that co-exist 
alongside 7PET during a cholera epidemic, because non-epidemic V. cholerae present in a 
country may contribute to disease that is symptomatic of cholera, but does not pose the same 
relative risk to public health as 7PET [189]. Similar observations have recently been made in 
China [396]. The relative risk of V. cholerae lineages should be accounted for in the magnitude 
of epidemic preparedness responses to such outbreaks. This is particularly relevant in the wake 
of the GTFCC commitment to reducing deaths from cholera by 90% before the year 2030 [9]. 
This campaign focuses on the control of cholera, the disease, rather than on controlling 7PET, 
the aetiological agent of pandemic cholera. As cholera control is implemented, countries 
experiencing a high incidence of cholera attributable to 7PET will see a decline in the number 
of cholera cases. Therefore, it is anticipated that as pandemic cholera reduces in magnitude, 
disease caused by non-7PET V. cholerae will become more visible, as was observed in 
Argentina and Latin America. By using genomics to differentiate pandemic and non-pandemic 
lineages for public health epidemic preparedness responses, concerted control efforts including 
epidemiologists, public health authorities and microbiology laboratories targeting 7PET 
specifically, and accounting for background levels of endemic non-7PET disease, could see 
epidemic cholera eliminated in Latin America. 
 
To summarise, as well as describing the genomic history of cholera in Argentina during the 
1990s, this chapter describes the stark contrasts can be observed during a country-wide cholera 
epidemic between the clonality of 7PET and the diversity of contemporaneously-isolated non-
7PET V. cholerae. This suggests that to understand more about the disease, particularly the 
disease that can be caused by non-epidemic and non-pandemic V. cholerae, our efforts must 
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begin to turn from the exclusive study of pandemic V. cholerae towards a more holistic and 
concurrent analysis of pandemic and non-pandemic isolates.  
 
This chapter has focused on analysing LAT-1 in detail, and has made high-level comparisons 
between the LAT-1 and species datasets. Clearly, although non-7PET V. cholerae continue to 
be associated with clinical cases of disease, they remain understudied. In Chapter 4, a detailed 
study of a small number of historically- and medically-important non-7PET non-O1 V. 
cholerae will be described, using both in silico and in vitro approaches. This will focus on 
characterising specific aspects of their genomes. Once these isolates have been described in 
fine-detail, subsequent chapters will be of broader scope, return to studying larger collections 
of genomes in silico with the aim of extrapolating the results of these analyses into the context 
of larger collections of diverse genomes. The non-7PET genomes described in this chapter will 
also be re-examined in subsequent chapters, to consider aspects such as antimicrobial 
resistance, virulence gene distribution, and plasmid replicons, in the context of additional 
diverse genomes and the data presented in Chapter 4.  
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Chapter 4 
 
Long-read sequencing of modern and historical V. cholerae  
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4.1 – Overview 
 
In Chapter 3, I used a collection of V. cholerae genomes from Argentina to perform a detailed 
analysis of the evolution of a sub-lineage of highly clonal and genomically-invariant pandemic 
V. cholerae O1. As has been mentioned previously (section 3.5), if research efforts are focused 
on 7PET alone, the diversity of the species will be neglected. To that end, Chapter 3 included 
a high-level characterisation of genomic differences between pandemic and non-pandemic V. 
cholerae. For instance, amongst just 61 non-O1 Argentinian V. cholerae, examples could be 
seen of isolates with ANI values suggesting that they were on the boundary of being classifiable 
as a new species (section 3.4.10; Figure 3.28). 
 
The fact that the diversity of the V. cholerae species is juxtaposed to the clonality of 7PET 
indicates that to understand this species further, the sequencing and characterisation of non-
pandemic V. cholerae is required. However, although thousands of V. cholerae have been 
sequenced to date, there are still very few high-quality and accurate genome assemblies for this 
species, particularly for non-pandemic non-O1 V. cholerae isolates. High-quality genome 
sequences are needed to perform robust comparative genomic studies, some of which have 
been discussed previously (Introduction, section 1.4.1). Such comparative studies are required 
to address one of the most fundamental questions in V. cholerae research – the need to describe 
what discriminates pandemic and non-pandemic V. cholerae.  
 
Since exploring the differences between pandemic and non-pandemic V. cholerae was a major 
aim of this PhD (section 1.5), it was decided to use long-read sequencing to generate accurate 
assemblies for five important V. cholerae isolates. These comprise four recently-isolated V. 
cholerae of serogroup O139, and a fifth historical strain isolated in 1916. Long-read 
technologies were used in order to resolve problems that are specific to the sequencing of V. 
cholerae, such as the presence of repeats in the integron on chromosome 2 [49, 406], and the 
potential for multiple copies of the CTXφ prophage to be integrated into one or both 
chromosomes [54, 162]. Having access to long- and short-read data for the same sample also 
enable hybrid assembly approaches, which use both long- and short-reads obtained from the 
same gDNA preparation, and allow the benefits of both PacBio RSII and Illumina technologies 
to be combined to produce high-quality genome assemblies [316, 319, 407], to a minimum of 
‘improved high-quality draft’ status [407].   
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An overview of the history of V. cholerae O139 has been presented in the Introduction (section 
1.3.2.1). It is known that epidemic V. cholerae O139 form a sub-lineage of the 7PET pandemic 
lineage [158, 234]. Although a serogroup O139 isolate obtained from a patient in India during 
1992, dubbed MO10 [241], has been sequenced and used for comparative genomics in the past 
[54, 133], a closed genome for this clinically- and epidemiologically-important 7PET sub-
lineage had not been reported prior to this PhD work. In this project, PacBio sequences for 
three toxigenic and one non-toxigenic V. cholerae O139 were assembled and analysed [244]. 
All four isolates were of clinical origin [244]. 
 
V. cholerae is a pathogen controlled under Schedule 5 of the Anti-Terrorism, Crime and 
Security Act (ATCSA) in the United Kingdom [408]. This means this bacterium must be 
worked on in a laboratory that meets specific security requirements. The only facilities at WSI 
that meet these requirements are a subset of our Containment Level 3 (CL3) laboratories. 
Therefore, as part of establishing a CL3 laboratory at WSI for conducting research into V. 
cholerae, a reliable protocol for the efficient extraction of high molecular weight gDNA from 
this species was required (Methods, section 2.2.5). Large fragments of gDNA that have not 
been mechanically sheared are required for long-read sequencing. The first V. cholerae isolate 
chosen to be cultured for PacBio sequencing using this methodology was NCTC 30, the oldest 
V. cholerae accessioned by NCTC, and to our knowledge, the oldest live isolate of this species 
that is publicly available for research. NCTC 30 is a unique scientific curiosity, as well as an 
important historical V. cholerae isolate. 
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4.2 – Specific aims  
 
The work described in this chapter aimed to 
 
1) Assemble, annotate, and characterise V. cholerae O139 genomes sequenced with long-
read technologies, to generate reference assemblies for this medically-important sub-
lineage of 7PET, 
2) Sequence to completion the genome of NCTC 30, an historical curiosity and an 
important example of a non-O1/O139 V. cholerae which caused ‘choleraic diarrhoea’, 
and 
3) Capitalise on having access to a live culture of NCTC 30 to validate genomic 
observations experimentally, and to optimise experimental protocols for use at CL3.  
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4.3 – Results 
 
4.3.1 – Closed genome assemblies for toxigenic and non-toxigenic V. cholerae O139 
 
Four previously-reported V. cholerae of serogroup O139 [244] had been re-sequenced using 
PacBio RSII technology prior to the beginning of this project, in order to generate reference-
grade assemblies for genomic analyses. Illumina short-reads were also available for these 
isolates [244]. De novo assemblies of these PacBio reads were generated and annotated as 
described in Chapter 2.  
 
Using the long-reads for each of these genomes, single contig assemblies were produced for 
each of the two chromosomes in each isolate, which were then corrected and circularised 
(Methods, section 2.1.2.2). The short-read data for each isolate were used to correct the 
assemblies, but this correction step did not make any improvements to the PacBio-only 
assemblies. Accordingly, it was decided to proceed with using these long-read assemblies for 
subsequent analyses in this chapter. Coverage percentages and other summary statistics for 
these assemblies are listed in Table 4.1.  
 
Internal 
sequence ID Sample name 
CTXφ 
present? 
Genome 
size (bp) 
Coverage of 
de novo 
assembly 
with long 
reads (%) 
Coverage of 
N16961 (%) 
SNVs 
relative to 
N16961 
48853_F01 MP_070116 No 4123525 165.76 58.5 122865 
48853_G01 P_0684000 Yes 4092641 170.56 97 271 
48853_H01 ICVB_2236_02 Yes 4092645 147.29 97 270 
48853_A02 SMIC_67_01 Yes 4092644 165.65 97 274 
 
Table 4.1 - Summary statistics for four closed V. cholerae O139 assemblies. Potentially recombined SNVs 
were not excluded from this analysis because 48853_F01 was extremely genetically distant from N16961. 
Modified from [409]. The HGAP assembler assembled the reads from sample 48853_G01 into three contigs. Re-
assembling this sample with Canu v1.1 [410] produced a two-contig assembly, which was used for subsequent 
analysis. 
 
4.3.2 – Phylogenetic position of toxigenic V. cholerae O139 
 
The phylogenetic position of the three toxigenic sequences was confirmed by placing these 
isolates into context with additional V. cholerae O139 sequences [242, 244] and other 7PET 
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genomes [234]. A maximum-likelihood phylogeny was calculated from an alignment of 1,630 
non-recombinant SNVs, which had been identified by mapping short-read data to the N16961 
reference sequence (Figure 4.1). Since the three toxigenic isolates varied in length by four 
bases at most (Table 4.1), and were phylogenetically identical to one another, just one of the 
assemblies (48853_H01) was chosen to be used as an exemplar sequence for all subsequent 
comparative analyses.  
 
Figure 4.1 – Maximum-likelihood phylogenetic tree of 7PET. Phylogeny rooted on the M66 outgroup 
sequence. Scale bar denotes the number of substitutions per variable site. This phylogeny was computed under 
the GTR+Gamma model using RAxML v8.2.8 with 500 bootstrap replicates [411]. Modified from [409].  
 
4.3.3 –CTXφ prophage sequences in toxigenic V. cholerae O139 
 
Previous work had reported that multiple types and arrangements of CTXφ prophage had been 
detectable in V. cholerae O139 chromosomes, depending on the year and location from which 
an isolate was isolated [230]. In particular, isolates obtained from Calcultta in 1996 had been 
reported to harbour two types of prophage, CTXφcal and CTXφEl Tor in the configuration 
CTXφEl Tor - CTXφcal - CTXφcal [412–414]. However, the assembly for MO10, used by many 
as an O139 reference isolate [241] was insufficiently well-assembled to be confident of the 
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context of CTXφ in this laboratory strain; this assembly is currently available in 84 contigs 
(accession # GCA_000152425.1). Similarly, the short-read data from the three more recently 
sequenced V. cholerae O139 isolates could not be assembled across the CTXφ region into a 
single contig, and in those assemblies, only one of the two ctxB genes was identifiable (the 
Illumina assemblies for 48853_G01 and 48853_H01 contained only a ctxB4 allele in a small 
contig, and 48853_A02 contained ctxB5 in a larger contig).  
 
Using the long-read assemblies generated here, it was evident that 48853_H01 contains three 
CTXφ prophages arranged in tandem, at the same integration site on the larger chromosome of 
N16961, between the VC_1450 and VC_1467 loci (Figure 4.2). This was the case in all three 
toxigenic V. cholerae O139 sequenced here (data not shown). In order to verify the presence 
of multiple copies of CTXφ in these genomes, the Illumina reads previously reported for this 
isolate were mapped to the N16961 reference and the coverage of these mapping data over the 
CTXφ region were visualised (Figure 4.3). The CTXφ region was covered 2-3 times as highly 
as the surrounding chromosome, supporting further the existence of multiple CTXφ copies in 
these V. cholerae O139 genomes.  
 
 
Figure 4.2 – Comparison of the CTXφ region in assembly 48853_H01 and N16961. Region annotated as per 
[99]. Reproduced from [409]. 
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Figure 4.3 – Validating the presence of multiple CTXφ copies by mapping. Figure depicts the depth of short-
reads for V. cholerae O139 isolate 48853_H01 mapped to the N16961 reference sequence. Mapping coverage 
was plotted using Bamview and Artemis [339, 356]. Annotation as described in Figure 4.2. Reproduced from 
[409]. 
 
Two of these repeats harboured distinct ctxB alleles, ctxB4 and ctxB5. The ctxB gene closest to 
rtxA in these assemblies was a ctxB5 allele, and the second ctxB was a ctxB4 allele. Both ctxB 
alleles have been found in V. cholerae O139 strains previously [415, 416]. The third CTXφ 
repeat was partial, and lacked the ctxAB operon while comprising the genes between and 
including zot and rstA, and an rstR open reading frame corresponding to rstRCalc [417] (Figure 
4.2). A complete attL sequence was identified adjacent to the VC_1465 locus in 48853_H01 
[96]. The phage sequence in the attR site adjacent to rtxA is not identical to that reported by 
Huber and Waldor [96], although the attR element does contain the central recombination motif 
and the residual bacterial attB sequence (see section 1.2.3 for an overview of CTXφ integration 
mechanisms). Although it has been reported that V. cholerae O139 can harbour more than one 
type of CTXφ phage simultaneously [230, 413, 414, 417], we were unaware of previous reports 
of multiple ctxB alleles co-existing in the same V. cholerae genome. 
 
The ctxB4 and ctxB5 alleles differ from one another at two nucleotide positions; 83 and 115 
(Figure 4.4A). These produce corresponding non-synonymous substitutions at amino acids 28 
and 39 (Figure 4.4B). Additional confirmation that these alleles co-exist in the V. cholerae 
O139 genomes was obtained by inspecting manually the sequences of reads mapped to this 
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locus (Figure 4.5), and from the fact that the assemblies for all three toxigenic V. cholerae 
O139 harboured both ctxB alleles, in CTXφ that were in the same chromosomal arrangement 
in all three genomes (Figure 4.2). It was also confirmed by manual inspection of the assemblies 
that no CTXφ prophage were present in the smaller chromosome in these isolates.  
 
 
Figure 4.4 – Alignment of ctxB and CtxB variants. Highlighted ctxB allelic variations (A) give rise to non-
synonymous variations in encoded CtxB proteins (B). The ctxB1 allele is associated with Classical V. cholerae, 
and ctxB3 with wave 1 7PET V. cholerae such as N16961 [59, 97, 234]. None of these mutations are located in 
the region of ctxB which encodes the N-terminal signal sequence (annotation taken from [77]).  
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Figure 4.5 – Reads corresponding to both ctxB4 and ctxB5 from toxigenic V. cholerae O139 map to N16961. 
In this example, the base at position 83 in ctxB has been highlighted (see Figure 4.4). These reads are mapped to 
the opposite strand to the annotated ctxB.   
 
Since multiple CTXφ configurations have been reported in V. cholerae O139, and in order to 
broaden our observations, a set of 50 V. cholerae O139 genomes that were obtained during a 
study of intra-household cholera transmission in Dhaka, Bangladesh were re-examined [235]. 
These formed two sub-lineages within 7PET (dubbed B3 and B4) and were isolated in 2002 
and 2003, pre-dating the isolates sequenced in this study. Forty-one of these isolates harboured 
both ctxB4 and ctxB5 alleles simultaneously, all of which were in lineage B4. The short-read 
data for the genomes sequenced in this chapter had been included in the Dhaka household 
transmission study, and were closely related to B4 [235]. The remaining 9 only harboured one 
ctxB allele, ctxB4. All of these were in lineage B3. This suggests that there is genomic 
complexity and population structure within the O139 sub-lineage of 7PET that has been 
previously-hidden due to the lack of an accurate reference sequence for the sub-lineage.  
 
4.3.4 – Genomic island complements of V. cholerae O139 isolates 
 
Having seen variation in CTXφ, the complement of other genomic islands contained in the 
three toxigenic and one non-toxigenic V. cholerae O139 isolates’ genomes was determined. 
Examined were the canonical pathogenicity islands, prophages, the SXT ICEVchInd4 element, 
and other genomic islands that have been reported previously in V. cholerae [54, 55, 133, 134, 
141]. VPI-1 and VSP-2 were present in all three toxigenic V. cholerae O139 isolates (Table 
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4.2; Figure 4.6). Moreover, VPI-2 was severely truncated to the point of absence in these three 
isolates. This truncation has been described previously in  MO10 and is a hallmark of toxigenic 
V. cholerae O139 [54, 418] (Table 4.2; Figure 4.6). VPI-1 was partially present in the genome 
of the non-toxigenic isolate (Table 4.2). 
 
Sample 
Name 
VSP-1 
(VC_0174-
VC_0186) 
VSP-2 
(VC_0489-
VC_0517) 
VPI-1 (VC_0809-
VC_0848) 
VPI-2 
(VC_1757-
VC_1810) 
CTXφ 
(VC_1451-
VC_1465) 
SXT 
(VC_0659 
insertion) 
48853_F01 Absent Absent 
Partially present 
(deletion of 
VC_0817-VC_0848) Absent Absent 
64% match to 
ICEVchInd4 
48853_G01 
Present, and 
duplication 
on chr2 Present Present 
Deletion of 
VC_1761-
1787 
Present, in 
more than 
one copy 
100% match 
to 
ICEVchInd4 
48853_H01 
Present, and 
duplication 
on chr2 Present Present 
Deletion of 
VC_1761-
1787 
Present, in 
more than 
one copy 
100% match 
to 
ICEVchInd4 
48853_A02 
Present, and 
duplication 
on chr2 Present Present 
Deletion of 
VC_1761-
1787 
Present, in 
more than 
one copy 
100% match 
to 
ICEVchInd4 
 
Table 4.2 – Presence and absence of select genomic islands in V. cholerae O139 genome assemblies. 
Similarity percentages were obtained by comparing SXT element sequences to that of ICEVchInd4 using 
BLASTn. chr2 = chromosome 2. Modified from [409]. 
 
A genomic island integrated into the VC_0659 locus (encoding peptide chain release factor 3) 
was detected in each of the three toxigenic V. cholerae O139 assemblies. This island was 
identical to SXT (also known as ICEVchInd4 [156]) and was integrated into the same locus as 
is SXT in MO10 [156]. An insertion into VC_0659 was also identified in the non-toxigenic 
O139 genome assembly, which was 64% identical to ICEVchInd4 (Table 4.2). These 
observations are fully consistent with previous data on genomic island distribution in the MO10 
genome [54].  
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Figure 4.6 – BLAST atlas illustrating the location, presence, and absence of key genomic islands in V. 
cholerae O139 assemblies relative to the N16961 reference sequence. The sequences of both N16961 
chromosomes were concatenated to produce this figure. Reproduced from [409]. 
 
VSP-1 was integrated on the larger chromosome between genes VC_0173 and VC_0187 in the 
three toxigenic V. cholerae O139 isolates, as it is in N16961 [54] (Figure 4.6; Table 4.2). 
However, a 14.3 kb sequence of DNA was also detected on the smaller chromosome of each 
of the toxigenic isolates, integrated between VC_A0695 and VC_A0696, that was 99% identical 
at the nucleotide level to VSP-1 (VC_0175 to VC_0186; Figure 4.7A). This strongly suggested 
that a second copy of the VSP-1 element was present on the second chromosome in each of 
these genomes. In order to verify this, the short-reads for each isolate were mapped to the 
N16961 reference genome the read depth was plotted for VSP-1 relative to the surrounding 
genome (Figure 4.7B). 
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Figure 4.7 – Presence of VSP-1 on both chromosomes of V. cholerae O139. DNA that was homologous to 
VSP-1 was detected on both chromosomes of 48853_H01 (A). Mapping short-reads from 48853_H01 to N16961 
confirmed that there were approximately double the number of sequencing reads for VSP-1 relative to the 
surrounding chromosome (B). Modified from [409]. 
 
This VSP-1 duplication was detected in each of the three toxigenic V. cholerae O139 genome 
assemblies (Table 4.2). It is known that VSP-1 is capable of excising from the larger V. 
cholerae chromosome [141], and it has been previously reported that the V. cholerae O1 isolate 
MJ-1236 (the Matlab variant) harbours a second copy of VSP-1 integrated between VC_A0695 
and VC_A0696 [419]. Separately, Grim et al. identified a single clinical isolate of V. cholerae 
O139 from Bangladesh that appeared to harbour an insertion between VC_A0695 and 
VC_A0696 that resembled VSP-1, but this isolate was not described further [419]. This is likely 
to be the same phenomenon observed and confirmed to be present in these three V. cholerae 
O139 genomes.  
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4.3.5 – Antimicrobial resistance and accessory virulence determinants 
 
Since the ambition of this project was to use these assemblies as reference sequences for future 
studies of V. cholerae O139, having made comparisons to N16961, these assemblies were then 
compared to the MO10 sequence. This allows for consistency amongst these data and 
comparisons with previous publications (Figure 4.8). MO10 harbours the VSK prophage GI-
16 [54], which N16961 lacks. GI-16 is also absent from the four sequences in this study (Figure 
4.8). Likewise, MO10 harbours a kappa prophage (genomic island GI-11 [54]), which is neither 
present in N16961 nor in the O139 sequences characterised here (Figure 4.8). Importantly, 
MO10 does not appear to harbour the second VSP-1 copy on chromosome 2 identified in these 
three isolates, which were isolated more recently than MO10.  
 
Figure 4.8 – BLAST atlas comparing V. cholerae O139 assemblies to MO10. The absence of O139-specific 
LPS and capsule genes from N16961 is evident, as is the absence of pathogenicity islands and CTXφ from the 
non-toxigenic isolate. All MO10 contigs were concatenated to produce this figure. Reproduced from [409]. 
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MO10 harbours an SXT element [156] which is expanded relative to that found in these 
genomes (Figure 4.8). The MO10-specific SXT expansion includes genes conferring resistance 
to the antimicrobials streptomycin (strAB), sulfamethoxazole (sul2), trimethoprim (dfr18), and 
chloramphenicol (floR). Accordingly, the assemblies for all four V. cholerae O139 genomes 
were scanned for antimicrobial resistance genes. No antimicrobial resistance genes were 
detected in the non-toxigenic 48853_F01 genome. The three toxigenic isolate genomes also do 
not contain antimicrobial resistance genes with the exception of one catB9 gene that is common 
to almost all 7PET V. cholerae [158] (Chapter 3, Figure 3.18), and is known not to render 
isolates resistant to phenicols [420]. These results agree with the original antimicrobial 
sensitivity testing of these isolates, which found that they were resistant only to nalidixic acid 
[244]. Examination of the gyrA and parC genes in these sequences confirmed that these four 
isolates harbour mutations predicted to result in an S83I mutation in GyrA. The non-toxigenic 
isolate 48853_F01 contains an additional mutation in gyrA (predicted to cause substitution 
A171S) and a S85L mutation in parC (predicted to cause an S85L substitution in ParC). All of 
these mutations are associated with nalidixic acid resistance in V. cholerae [155].  
 
The four genome assemblies were also scanned for the presence of V. cholerae accessory 
virulence genes, with the specific objective of determining whether candidate virulence genes 
were present in the genome of the otherwise non-toxigenic V. cholerae O139 isolate, given that 
this isolate was obtained from a patient suffering from severe diarrhoea [244]. However, no 
known virulence determinants were detected in the 48853_F01 genome assembly other than 
those typically found across the V. cholerae species [1] (Table 4.3). 
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Accessory virulence 
gene 
Present in 
48853_F01 
Present in 
48853_G01 
Present in 
48853_H01 
Present in 
48853_A02 
ToxR (VC_0984) Yes Yes Yes Yes 
Zona occludens toxin, 
Zot (VC_1458) No Yes Yes Yes 
Accessory cholera 
enterotoxin, Ace 
(VC_1459) No Yes Yes Yes 
Haemolysin, hlyA 
(VC_A0219) Yes Yes Yes Yes 
Mannose-sensitive 
haemagglutinin, MSHA 
(VC_0398..VC_0414) Yes Yes Yes Yes 
MARTX toxin, rtxA 
(VC_1451) Yes Yes Yes Yes 
MARTX toxin accessory 
gene, rtxC (VC_1450) Yes Yes Yes Yes 
HA/protease, hapA 
(VC_A0865) Yes Yes Yes Yes 
Heat-stable enterotoxin 
NAG-ST (Accession # 
M85198.1) No No No No 
Type III secretion system 
from V. cholerae 
AM_19226 (typically 
present in lieu of VPI-2; 
accession # 
AATY01000000) No No No No 
Table 4.3 – Accessory virulence genes in V. cholerae O139. Locus IDs from the N16961 reference, or accession 
numbers for sequences absent from N16961, are provided. Reproduced from [409]. 
 
4.3.6 – Phylogenetic position of non-toxigenic V. cholerae O139 
 
It had been reported previously that isolate 48853_F01 was phylogenetically distantly related 
to the three toxigenic isolates [244]. In order to contextualise this isolate, the genomes of 61 
additional V. cholerae, and those of three non-cholera Vibrios, were used to calculate an 
alignment of 2,103 core genes. From this sequence alignment, 168,476 SNVs were identified, 
which were used to calculate a core-gene phylogeny for these isolates (Figure 4.9).    
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Figure 4.9 – A phylogeny of non-7PET V. cholerae. Rooted on three Vibrio spp. genomes. Hatch marks denote 
branches which have been manually shortened for illustrative purposes. This phylogeny was computed under the 
GTR+Gamma model using RAxML v8.2.8 with 500 bootstrap replicates [411]. Modified from [409].  
 
The phylogenetic analysis showed that 48853_F01 forms a cluster with three isolates that are 
distantly related to the three toxigenic V. cholerae O139, falling outside of the 7PET lineage 
to which they belong (Figures 4.1, 4.9; grey disc). This cluster includes two Haitian non-O1 V. 
cholerae isolates from 2010 and a Mexican isolate from 1991 – unfortunately, serotype data 
were not recorded for these isolates (Figure 4.9). Moreover, several Argentinian V. cholerae 
sequenced in Chapter 3 were found to cluster with these sequences (shown in Figure 3.21).  
 
Given the phylogenetic position of this non-toxigenic isolate, the capsule and 
lipopolysaccharide (LPS) biosynthesis loci in this genome were compared to the MO10 
sequence and to those V. cholerae O139 that belonged to the 7PET lineage. Using closed 
genome assemblies generated here, it was confirmed that the three toxigenic strains contain 
O139 LPS operons that strongly resemble that found in MO10 (Figure 4.10). The equivalent 
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region in the non-toxigenic isolate 48853_F01 is less similar, although this strain exhibits a 
strong O139-positive phenotype using the rapid dipstick assay and slide agglutination tests 
[244]. It was also noted that the three non-O1 Haitian and Mexican V. cholerae which cluster 
with the non-toxigenic O139 isolate share capsule biosynthesis genes with 48853_F01, but 
they do not harbour the same LPS operon (Figures 4.9, 4.10). These isolates therefore are 
unlikely to be V. cholerae of serogroup O139.  
 
Figure 4.10 – O-antigen chromosomal loci in select V. cholerae. The loci known to encode the O1 and O139 
antigens, as well as capsule biosynthesis genes, are indicated. HE_09 is phylogenetically related to the non-
toxigenic V. cholerae O139 (Figure 4.9) but lacks the O139 biosynthesis operon. Reproduced from [409]. 
 
Serendipitously, the phylogenetic position of the non-toxigenic isolate 48853_F01 was made 
even more intriguing in the context of work on NCTC 30, the genomic and experimental 
characterisation of which is now presented. 
 
 
 
 
   110 
4.3.7 – NCTC 30 genome sequencing and assembly 
 
NCTC 30 was isolated in 1916 and was accessioned into NCTC in 1920 (Figure 4.11). This V. 
cholerae was originally named “Martin 1”, and was isolated from a British soldier convalescent 
in Egypt against the background of World War 1 (WW1). This was a period in history during 
which cholera’s epidemic potential was both recognised and feared [421, 422]. In spite of this, 
the British Expeditionary Forces remained largely free of cholera throughout this period. It has 
been estimated that the British Expeditionary Forces incurred 11,096,338 casualties during 
WW1, but reportedly experienced just 1,918 cholera cases in 1916, 209 cases in 1917, and 450 
cases in 1918 [423]. Of these cholera patients, 49 died in 1917, and 106 died in 1918 [423].   
 
NCTC 30 has been described as being ‘probably’ serogroup O2, and its biochemical profile 
has been described as part of its maintenance as the thirtieth strain to be accessioned into the 
NCTC culture collection (Figure 4.11). NCTC 30 stocks have been maintained since the strain 
was accessioned into the collection (Figure 4.12).  
 
 
Figure 4.11 – The NCTC 30 check card. The card details the provenance of the isolate as well as aspects of its 
original biochemical and microbiological characterisation. Reproduced from supplementary material of [424].  
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For this PhD, a freeze-dried culture of NCTC 30 was revived and sequenced to completion 
using both long- and short-read technologies. NCTC has produced four lyophilised batches of 
NCTC 30 to date (Figure 4.11, 4.12), and the culture sequenced in this study was a derived 
from the earliest batch of lyophilised bacteria available for research (batch 3, lyophilised in 
1962; Figures 4.11; 4.12). This was to minimise the risk of sequencing a culture that had 
acquired mutations as a consequence of long-term passage or maintenance. Molecular and 
genetic experiments were then carried out, to characterise further the biology of this historical 
isolate, and to validate genomic results.  
 
 
Figure 4.12 – A timeline of events in the history of NCTC 30. Figure based on data contained in Figure 4.11 
and reproduced from [425]. Publications on NCTC 30 that are discussed throughout this chapter have been listed 
(not exhaustive).   
 
gDNA extracted from one clone of minimally-passaged NCTC 30 (MJD382) was sequenced 
using both short- and long-read technologies (Illumina HiSeq X10 and PacBio RSII). The long-
read assembly strategy used for these data (see Methods) produced two circular contigs, and 
the long reads covered the finished assembly to a depth of 148.01 X. The NCTC 30 genome 
assembly consisted of two circularised contigs, one corresponding to the larger chromosome 
of 2,922,904 bases, and one to the smaller chromosome of 1,029,451 bases (Figure 4.13). To 
guard against genetic rearrangements or contamination introduced through long term storage, 
a technical replicate extraction of gDNA from MJD382, as well as a biological replicate 
(gDNA from MJD439, a second colony of NCTC 30 obtained from the first passage of NCTC 
30 after rehydration) were also sequenced using both long- and short-read sequencing 
technologies.  
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Figure 4.13 – Illustration of the NCTC 30 chromosome sequences. Modified from [424].  
 
A comparison between the NCTC 30 assembly and that of the N16961 reference strain revealed 
a large inversion in NCTC 30 chromosome 1 of ~ 1,040,746 bases, between genes VC_1056 
and VC_2013 (Figure 4.14). The short-reads from the same NCTC 30 gDNA preparation used 
for the assembled long-read sequencing were mapped back to both the PacBio assembly and 
to N16961, and to guard against this inversion being an artefact of genome assembly using 
long-reads only, paired reads were identified that mapped to either side of the inversion 
junction, and individual reads were identified which spanned the junction itself (Figure 4.15). 
This was confirmed further using sequencing data from a second gDNA isolation from 
MJD382, as well as from MJD439, a culture grown from a colony of NCTC 30 that had been 
separated from MJD382 at passage 1 (Methods, section 2.2.4; data not shown). 
 
Figure 4.14 – A comparison between chromosome 1 of NCTC 30 and N16961. The chromosomal location of 
genomic islands and virulence determinants, discussed in subsequent sections, are indicated. The position of the 
inversion is indicted by the green/red inverted regions of synteny, in an ‘hourglass’ shape. Modified from [424]. 
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Figure 4.15 – Mapping reads across the inversion junctions. NCTC 30 short-reads were mapped to the N16961 
(A) and NCTC 30 (B) genome sequences. The regions delineating the genomic inversion shown in Figure 4.14 
are presented. In N16961, no reads map to the inversion region adjacent to VC_1057, and none of the reads that 
map to one of adjacent sequences have a paired read on the other side of the inversion site (A). The inversion site 
at VC_2013 is similar. However, when NCTC 30 reads are mapped to the NCTC 30 long-read assembly, reads 
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map which span the inversion junction, and reads map to each side of the inversion which are paired to reads on 
the other side of the inversion site (B). The gene VC_2012 is poorly conserved between NCTC 30 and N16961; 
hence, few NCTC 30 reads map to this gene. Hatch marks denote a truncation of the genome sequence view.  
 
4.3.8 – NCTC 30 motility and flagellation defects 
 
When NCTC 30 was being revived and cultured, it grew noticeably more slowly than other V. 
cholerae on both solid and liquid media, where it showed erratic growth kinetics (Figure 4.16). 
The inversion on chromosome 1 was confirmed not to encompass the crtS locus, and therefore 
should not interfere with the rate and timing of chromosome 2 replication, or with the growth 
rate of NCTC 30 [58] (section 1.2.1). 
 
 
 
Figure 4.16 – Growth kinetics of NCTC 30 and NCTC 5395. In this assay, NCTC 30 demonstrated a growth 
defect at 37 ˚C relative to NCTC 5395. Under these conditions, V. cholerae does not grow to an OD600 exceeding 
1.0 – accordingly, a non-logarithmic Y-axis scale has been deliberately used. Representative data from single 
biological experiments are reported.  
 
This observation prompted the microscopic examination of NCTC 30, using transmission 
electron microscopy (TEM). Representative TEM images for NCTC 30 and a control strain of 
classical biotype V. cholerae, NCTC 10732, were captured and are presented in Figure 4.17. 
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Figure 4.17 – V. cholerae transmission electron micrographs. NCTC 30 is compared to a control strain of 
flagellated V. cholerae, NCTC 10732. Modified from [424].  
 
It was noted immediately that NCTC 30 cells did not appear to express the monotrichous 
flagellum characteristic of V. cholerae [1] (Figure 4.17). This was particularly intriguing 
because previous studies of NCTC 30 had recorded this bacterium as being flagellated [39]. 
Based on these microscopy data, it was hypothesised that NCTC 30 would be non-motile. 
Accordingly, NCTC 30 and two control strains of V. cholerae were cultured on motility media. 
No motility was observed in NCTC 30 under these conditions (Figure 4.18).  
 
 
Figure 4.18 – NCTC 30 is non-motile when grown in soft agar. A lateral zone of growth corresponds to motile 
bacteria ‘swimming’ within and across the agar; such lateral growth was not observed in NCTC 30. Control strains 
NCTC 5395 and NCTC 10732 were used for comparisons elsewhere in this chapter. Soft agar plates were 
incubated for 18 hours before imaging. Reproduced from [424].  
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Since the flagellar regulatory and biosynthesis hierarchy has been well-studied in V. cholerae 
[426–428] (Figure 4.19), it was decided to attempt to explain this phenotype using the NCTC 
30 genome sequence. Each of the genes listed in Figure 4.19 were inspected manually in the 
NCTC 30 genome assembly, and a putative frameshift was identified in the flrC gene (Figure 
4.20).  
 
 
Figure 4.19 – Illustration of flagellar biosynthesis and regulatory hierarchy for V. cholerae. The FlrA protein 
activates transcription of Class II genes, including the flrBC operon. FlrB and FlrC then activate multiple Class 
III flagellar genes. Figure derived from [428]. 
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Figure 4.20 – Schematic of the predicted truncation of FlrC caused by the frameshift in flrC. (A): The 
frameshift in flrC is predicted to truncate FlrC, removing the DNA binding domain from this protein, thereby 
eliminating its ability to regulate its target genes. (B): This frameshift is predicted to disrupt the reading frame 
such that a premature STOP codon is introduced at amino acid position 436. Modified from [424].  
 
The FlrC protein is a response regulator that governs the expression of Class III flagellar genes 
in V. cholerae [426] (Figure 4.19). Class III genes encode components of flagellin, as well as 
proteins that form part of motor and chemotaxis machinery in V. cholerae [427] (Figure 4.19). 
The mutation detected in flrC was predicted to introduce a frameshift, truncating FlrC by 
removing the last 48 amino acids from the protein (Figure 4.20). This region of FlrC is 
predicted to encode the DNA-binding domain, and its removal should prevent the transcription 
of FlrC-regulated Class III genes required for the production of V. cholerae flagella.  
 
Although the hypothesis that the flrC frameshift was responsible for the absence of flagella 
was compelling, two additional sequencing technologies were used to ensure that this 
frameshift was not an artefact of long-read assembly. High-accuracy short-read Illumina data 
were mapped to the NCTC 30 assembly, and the region was also amplified and sequenced 
using commercial Sanger sequencing. All three sequencing technologies confirmed the 
existence of this frameshift in this gene (Figure 4.21).  
 
Additionally, since Davis and Park’s previous report was submitted for publication in April 
1962 [39], prior to the preparation of batch 3 of NCTC 30 (Figure 4.11), it was necessary to 
consider the possibility that the flrC mutation may have arisen during the preparation of batch 
3, during long-term storage [429], or during passage in our laboratory. Since the mutation was 
confirmed to be present in sequences of MJD382 and MJD439, two independently-sequenced 
clones separated from each other immediately upon rehydration of our vial of batch 3 NCTC 
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30, this suggested either that this mutation predated the introduction of the strain into our 
laboratory, or had arisen immediately upon rehydration of our lyophilised stock.  
 
In order to test whether the flrC mutation was unique to our laboratory stocks, gDNA was 
prepared from batch 4 of NCTC 30 in laboratories at PHE, separate to our laboratory. Batch 4 
was lyophilised in 1985 from a culture of batch 3 bacteria (Figure 4.11, 4.12). flrC was 
amplified from batch 4 gDNA by PCR, and Sanger sequencing was used to confirm that the 
flrC frameshift mutation was also present in batch 4 of NCTC 30 (Figure 4.21). This indicates 
strongly that the mutation arose either during or prior to the preparation of batch 3 of this 
lyophilised culture, and that this mutation ought to be present in NCTC 30 cultures which are 
purchased from NCTC in the future. 
 
 
Figure 4.21 – Confirmation of flrC frameshift using Sanger sequencing. The mutation that causes the predicted 
frameshift in flrC in NCTC 30 batch 3 (nine G-C base pairs) are also present in the batch 4 DNA preparation. 
Sequencing traces were visualised using 4Peaks 14.  
                                               
14 https://nucleobytes.com/4peaks/index.html 
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Unfortunately, it proved impossible to culture NCTC 30 efficiently enough to attempt to 
transform it with plasmid vectors, either to repair the flrC mutation by homologous 
recombination, or to supply an episomal copy of flrC in trans to complement the defect. 
However, it was noted that the microscopic images of NCTC 30 were consistent with that of 
an flrB targeted mutant [426]. FlrB and FlrC form a two-component system in which FlrB 
phosphorylates FlrC, which then acts as a response regulator and trans-activates Class III genes 
in a σ54-dependent manner [426, 430] (Figure 4.19). Given that flrC is the only flagellum-
biosynthesis gene in NCTC 30 that is disrupted, it is reasonable to infer that this flrC mutation 
is responsible for this phenotype.  
 
4.3.9 – Antimicrobial resistance in NCTC 30  
 
A previous taxonomic study of Vibrio bacteria suggested that NCTC 30 was insensitive to a 
concentration of penicillin to which a control V. cholerae strain, NCTC 5395, was partially 
sensitive [39]. The NCTC 30 genome assembly was scanned for antimicrobial resistance genes 
in silico and one putative resistance gene, encoding a β-lactamase, was identified. The gene 
was located within the integron on the smaller chromosome, which had been fully-assembled 
by virtue of the long-reads. The translated sequence of this gene was used to query the NCBI 
nr database. The most similar sequences (99% amino acid similarity) were those of the V. 
cholerae β-lactamases CARB-7 and CARB-9. CARB-7 was first described in an 
environmental V. cholerae isolated in Argentina that resisted ampicillin to an MIC of 256 
µg/ml, and was also encoded by a gene within the integron of chromosome 2 [152]. CARB-9 
is also an integron-encoded β-lactamase first identified in environmental non-O1/O139 V. 
cholerae from Argentina which resisted ampicillin to an MIC of 64 µg/ml [151]. 
 
The presence of a gene predicted to encode an antimicrobial resistance determinant neither 
guarantees that the gene is responsible for a resistance phenotype, nor that it is actually 
expressed. In order to validate whether this gene was at all functional or responsible for the 
penicillin insensitivity reported previously [39], within the constraints of working at CL3 and 
with a difficult-to-culture NCTC 30 (section 4.3.8), it was decided to clone the gene into 
pACYC184, a low-copy vector encoding resistance to chloramphenicol and tetracycline [359]. 
The blaCARB-like gene was amplified from NCTC 30 template DNA. The amplicon was digested 
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and ligated into pACYC184, disrupting the native tet gene on the plasmid (Figure 4.22; 
Methods, section 2.2.12).  
 
 
Figure 4.22 – Strategy to clone blaCARB-like from NCTC 30 gDNA. blaCARB-like was amplified from the NCTC 30 
genome using primers oMJD96 and oMJD97, incorporating BamHI and SalI restriction sites. This was digested 
and ligated into the tet gene on pACYC184, introducing a premature in-frame STOP codon into tet. BPROM 15 
predicted E. coli σ70 -35 and -10 elements within the insert (indicated). Although this software predicts promoters 
from E. coli, not V. cholerae, it should be noted that this might provide a native promoter from which blaCARB-like 
expression may be driven in E. coli. Figures are not to scale. Reproduced from [424]. 
 
The plasmid harbouring blaCARB-like, pMJD61, was transformed into a cloning strain of E. coli 
and MICEvaluator strips were used to compare the relative sensitivities of V. cholerae and 
transformed E. coli (see section 2.2.13 for assay details). This assay was not used to determine 
quantitative MICs. Cells harbouring pUC19 which confers resistance to β-lactams, and 
pACYC184, an empty vector, were used as positive and negative controls respectively. NCTC 
30 was found to be sensitive to ampicillin to a lesser extent than NCTC 5395, the same strain 
used in Davis and Park’s original work [39] (Figure 4.23). The faint growth of NCTC 30 close 
to the test strip above the 16 µg/ml position resembles satellite colonies that emerge due to β-
lactam degradation by enzyme secreted by adjacent bacterial culture (Figure 4.23).  
                                               
15 http://softberry.com 
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Figure 4.23 – Ampicillin sensitivity phenotypes of V. cholerae and plasmid-harbouring E. coli. Arrows 
indicate the break points as interpreted using the MICEvaluator manufacturer’s instructions. pMJD61, the plasmid 
containing blaCARB-like (Figure 4.22), confers an equivalent ampicillin resistance to that conferred by the pUC19 
ampicillin-resistance plasmid in E. coli 5-alpha. Modified from [424]. 
 
4.3.10 – Virulence determinants in NCTC 30 
 
Earlier comparisons (Figure 4.14) had demonstrated the absence of the canonical pathogenicity 
islands VPI-1, VPI-2, VSP-1 and VSP-2, as well as the CTXφ prophage from the NCTC 30 
genome. Therefore, the sequence was interrogated to attempt to identify genetic determinants 
that may explain the clinical symptoms giving rise to its isolation (section 4.3.7). The presence 
of accessory virulence genes in the assembly, including zot, ace, hlyA, rtxA, rtxC, hapA, MSHA 
and heat-stable enterotoxin, was determined (Table 4.4).  
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Accessory virulence gene 
Locus ID in N16961 reference 
genome 
Present in NCTC 30 
(Percentage identity of 
translated protein) 
Zona occludens toxin (Zot) VC_1458 No (CTXφ) 
Accessory cholera enterotoxin 
(Ace) VC_1459 No (CTXφ) 
Haemolysin (hlyA) VC_A0219 Yes (98%) 
Mannose-sensitive 
haemagglutinin (MSHA) VC_0398..VC_0414 Yes, see Figure 4.24D 
MARTX toxin (rtxA) VC_1451 Yes (93%) 
MARTX toxin accessory gene 
(rtxC) VC_1450 Yes (100%) 
HA/protease (hapA) VC_A0865 Yes (98%) 
Integrative conjugative element 
SXT/R391 
Absent (if present, integrates into 
VC_0659) No, VC_0659 homologue is intact 
Heat-stable enterotoxin NAG-ST 
(Genbank accession M85198.1) Absent No 
Table 4.4 – Accessory virulence genes present in NCTC 30. Identity percentages were calculated by alignment 
of protein sequences from NCTC 30 and N16961 using BLASTp. The translated NAG-ST nucleotide sequence 
(accession M85198.1) was used as a tBLASTx query to scan NCTC 30 for the gene encoding this enterotoxin. 
Modified from [424]. 
 
Although it appeared that NCTC 30 was devoid of canonical V. cholerae virulence genes 
(Table 4.4; Figures 4.14; 4.24), it remained the case that this bacterium was of clinical origin 
– it had been isolated from a convalescent soldier (Figure 4.11), and it had been reported that 
the source of NCTC 30 was ‘choleraic diarrhoea’ [41]. Accordingly, the NCTC 30 genome 
was scanned for other putative virulence determinants seen in other Vibrio.   
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Figure 4.24 – Presence and absence of genomic islands and virulence genes in the NCTC 30 genome 
assembly. Comparisons are relative to the N16961 reference sequence and compare nucleotide identity. CTXφ 
(A), VPI-1 (B) and VSP-1 (C) are absent from NCTC 30. The genes that encode the MSHA accessory virulence 
determinant are present in NCTC 30 (D), although the NCTC 30 mshQ gene is dissimilar to that of N16961 (Table 
4.4). Reproduced from [424]. 
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A type III secretion system (T3SS) was detected on the larger chromosome of NCTC 30 
(Figures 4.14; 4.25). This island is integrated between VC_1757 and VC_1810, the same 
integration site as used by VPI-2 in N16961 (Figure 4.14, 4.25). This T3SS is more similar to 
the T3SS found in the genome of V. parahaemolyticus strain 10329 [52] than the T3SS found 
in V. cholerae AM_19226, the strain used to characterise T3SS activity in V. cholerae [45,46] 
(Figure 4.25). It is notable that a handwritten note on the NCTC’s internal quality check card 
for NCTC 30 refers to “intermediate V. cholerae / V. parahaemolyticus” (Figure 4.11). No 
further information is available to explain why this note was made.  
 
 
Figure 4.25 – Comparison of T3SS from NCTC 30 and other Vibrios. The T3SS harboured by NCTC 30 is 
most similar to one found in V. parahaemolyticus strain 10329, and is dissimilar to that encoded by V. cholerae 
AM_19226 [266]. The integration locus for T3SS in both NCTC 30 and AM_19226 is the same, and is the same 
as the VPI-2 integration locus in N16961. However, the genes flanking the T3SS in V. parahaemolyticus are not 
similar to those of V. cholerae.  Modified from [424].  
 
4.3.11 – Phylogenetic position of NCTC 30 and distribution of T3SS-2β 
 
The T3SS detected in NCTC 30 and V. parahaemolyticus 10329 corresponds to the T3SS-2β 
described in limited numbers of previously-published V. cholerae [397] and also found in a 
number of the Argentinian non-O1 V. cholerae described in Chapter 3 (Figure 3.21). Building 
on the data from Chapter 3, a pangenome was constructed using 197 other V. cholerae genome 
sequences, and those of three Vibrio spp. that are closely related to V. cholerae. These context 
genomes are the same as those used to contextualise Argentinian non-7PET V. cholerae in 
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Chapter 3. A maximum-likelihood phylogeny was then calculated using a core-gene alignment 
of 2,622 genes from this pangenome. NCTC 30 was found to be more closely related to Vibrio 
cholerae than to other members of the Vibrio genus, though it was part of a clade separated 
from many of the V. cholerae in this collection (Figure 4.26). This observation is logical when 
considered together with a taxonomic study of V. cholerae performed in 1970, which 
questioned whether NCTC 30 is a true member of the Vibrio cholerae species [38]. The 
phylogenetic separation which we observed is likely to reflect the phenotypic and molecular 
differences that questioned the classification of NCTC 30 [38]. Intriguingly, this cluster of 
isolates is the same cluster of which 48853_F01, the non-toxigenic V. cholerae O139 isolate, 
was a member (Figure 4.9), and to which several of the Argentinian non-7PET V. cholerae 
belonged (Figure 3.21).  
 
 
Figure 4.26 – A maximum-likelihood V. cholerae phylogeny including NCTC 30. An unrooted phylogeny 
shows that NCTC 30 clusters together with six isolates that have been previously reported to be V. cholerae (grey 
disc), including 48853_F01, the non-toxigenic V. cholerae O139 described in this chapter. The position of 7PET 
and Classical pandemic lineages [189] are noted. Scale bar denotes the number of mutations per variable site. 
Modified from [424].  
 
Genomes in the pangenome which harboured either T3SS-2β and blaCARB-like were then 
identified (BLASTp similarity cut-offs of 95%), to map the distribution of these elements 
across the phylogeny. Ten genomes harbouring blaCARB-like homologues were identified both in 
strains closely related to NCTC 30 as well as in all members of the MX-3 lineage of V. cholerae 
O1, which was isolated in Mexico during 2000 [189] (Figure 4.27). Three V. cholerae genomes 
in the dataset lack CTXφ but contained genes similar to those of the NCTC 30 T3SS-2β [53]. 
(Figure 4.27).  
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Figure 4.27 – The distribution of T3SS-2β and blaCARB-like within the V. cholerae phylogeny. The tree presented 
in Figure 4.26 is reproduced here, rooted on the three Vibrio spp. genomes. Lineages defined previously [189] are 
indicated, as is the phylogenetic position of the NCTC 5395 control strain used for molecular analyses in this 
chapter [213]. Modified from [424].  
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4.4 – Discussion  
 
Piecing together the history of current and previous cholera pandemics requires not only an 
understanding of pandemic V. cholerae lineages, but also a view of the more diverse non-
pandemic V. cholerae that co-exist contemporaneously with the pandemics. This theme has 
also been discussed throughout Chapter 3. NCTC 30 was isolated in 1916, at a time when the 
sixth cholera pandemic was waning [36, 163, 431], but is not a member of the Classical 
pandemic lineage (Figure 4.26). Very few V. cholerae isolates and genome sequences are 
available from this time period, making NCTC 30 a valuable isolate for future evolutionary 
studies of the V. cholerae species. Similarly, the non-toxigenic V. cholerae O139 was isolated 
during the seventh cholera pandemic, but was not related to the O139 sub-lineage of the 7PET 
pandemic lineage.  
 
The manual and focused fine-scale analysis of single genomes presented in this chapter is 
highly complementary to the larger-scale analyses described in Chapter 3. The observations 
made from the study of these genomes can be extrapolated to larger datasets easily – for 
example, examining the distribution of T3SS and β-lactamases across larger collections of V. 
cholerae (Figure 4.27). Similarly, although it was by virtue of manual inspection that the 
coincidence of more than one ctxB allele in one closed V. cholerae O139 genome assembly 
was observed, once it was clear that this needed to be looked for, it was feasible to examine 
larger collections of V. cholerae O139 genomes for the coincidence of ctxB4 and ctxB5, 
including those V. cholerae O139 from Domman et al [235]. This approach – the extrapolation 
of knowledge gleaned from the study of single genomes and laboratory strains into the context 
of larger populations – is a theme that will be re-visited in Chapter 5.  
 
In vitro data strongly support the hypothesis that 7PET V. cholerae participated in homologous 
recombination, mediated by natural competence, to convert from serogroup O1 to O139 [144]. 
V. cholerae O139 have only caused cholera epidemics in South East Asia [244]. It is interesting 
to speculate that a bacterium similar to the non-toxigenic V. cholerae O139 sequenced in this 
study might have been the source of the O139 operon which was acquired by 7PET in this 
event. Likewise, the O139 V. cholerae that are distantly related to 7PET are likely to have 
originated from non-O1 progenitors, as suggested previously [230]. It is also evident that non-
7PET V. cholerae O139 may harbour pathogenicity islands – among the non-7PET serogroup 
O139 isolates studied by Siriphap et al were four non-toxigenic isolates obtained in 2011, all 
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of which were shown to harbour VPI-2 [242]. The closed toxigenic and non-toxigenic genome 
sequences reported in this chapter will therefore serve as useful reference sequences for the 
future genomic analysis of both pandemic and non-pandemic V. cholerae O139.  
 
A recurring theme from Chapters 3 and 4 is the presence of T3SS in non-O1 V. cholerae of 
clinical origin (Figure 3.21; Figure 4.27). It may be that the T3SS encoded by NCTC 30 was 
responsible for clinical symptoms that led to the isolation of these bacteria, not least because it 
was the most compelling virulence determinant identified in the genome of this bacterium. 
Although a detailed characterisation of this element was beyond the scope of this PhD project, 
this is the focus of future study. The possibility cannot also be excluded that the patient was 
co-infected with another pathogen in addition to NCTC 30, perhaps an O1 V. cholerae or 
another bacterium such as enterotoxigenic E. coli [54,55], which might also have caused 
“choleraic diarrhoea”. Although co-infection may explain the isolation of a non-toxigenic V. 
cholerae O139 from a patient suffering from diarrhoea, it is known that even the non-toxigenic 
vaccine strains of V. cholerae O1 can elicit a diarrhoeal response in vaccine recipients [432]. 
Thus, the contribution of co-infections and non-toxigenic V. cholerae to enteric disease should 
be the focus of further research.  
 
The study of blaCARB-like in NCTC 30 was valuable because it provided confirmation that this 
gene can confer ampicillin resistance, and provides genomic explanations for previous 
phenotypic studies of this isolate [39]. This confirmation was necessary because NCTC 30 
predates the introduction of penicillin as an antibiotic, the antimicrobial activity of which was 
first reported by Fleming in 1929 [433]. Consequently, NCTC 30 is unlikely to have acquired 
its drug resistance phenotype in response to selective pressures imposed by the therapeutic use 
of antibiotics. It is reasonable to speculate that NCTC 30 may possess blaCARB-like in order to 
resist antibiotics found in its environment – i.e., to defend itself against antibiotic-producing 
micro-organisms with which it might co-exist in the environment. This might also explain why 
NCTC 30 appears not to resist the antibiotic completely (Figure 4.23); it may be that blaCARB-
like is expressed at levels sufficient to protect NCTC 30 from diffuse, low-concentration 
antibiotics present in an environment. It is also notable that β-lactams are not recommended 
for the treatment of cholera [11, 434], and that although a β-lactamase gene homologous to 
blaCARB-like (blaCARB-2) was identified in the MX-3 lineage of V. cholerae O1, antimicrobial 
susceptibility testing (AST) performed on an isolate from this lineage did not lead to this isolate 
being classified as resistant to β-lactams [189].  This may reflect variety in β-lactam resistance 
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phenotypes in V. cholerae; blaCARB-2 might elevate β-lactam resistance in MX-3, but not to a 
level sufficient to classify a strain as “resistant” to an antimicrobial. 
 
One of the most striking observations in this chapter is that both 48853_F01 and NCTC 30 
occupy the same clade of the V. cholerae phylogeny, one which is very distinct from the section 
of the tree which containing pandemic clones and other V. cholerae O1 isolates (Figures 4.9, 
4.26, 4.27). The phylogenetic separation which was observed is likely to reflect the phenotypic 
and molecular differences that led to the taxonomic classification of NCTC 30 being 
questioned [38], though these collective data do strongly indicate that isolates in this clade are 
indeed V. cholerae rather than another species per se. The structure and gene content of this 
clade will be explored in more detail in Chapter 5.  
 
In Chapter 5, I will collate the genomes discussed in this chapter and the non-7PET Argentinian 
genomes from Chapter 3, together with an additional set of genome sequences from historical 
and contemporary diverse V. cholerae, to produce a collection of ~600 genome sequences. 
Using these data, I will explore the distribution of key virulence determinants across the 
diversity of V. cholerae, with particular focus on the phylogenetic clade to which 48853_F01 
and NCTC 30 belong, on T3SS and accessory virulence determinants, and on the genes and 
SNVs which determine the El Tor biotype.  
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Chapter 5 
 
The accessory genome - concordance and conflict between V. 
cholerae genomics and phenotypic dogma 
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Nick Thomson supervised the work described in this chapter. NCTC cultures were supplied by 
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I performed all experiments and analyses, and produced all figures.  
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Cambridge and the Sanger Institute by the COVID-19 pandemic. This affected planned 
experiments to validate in vitro the genomic observations described in this chapter.  
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5.1 – Overview 
 
Chapters 3 and 4 have both highlighted the striking differences in diversity between pandemic 
and non-pandemic V. cholerae. Chapter 3 described a focused study of a clonal sub-lineage of 
pandemic V. cholerae, and presented an initial characterisation of 65 non-pandemic V. cholerae 
from Argentina. In Chapter 4, an effort was made to explore the diversity of V. cholerae beyond 
the pandemic lineage by focusing specifically on the forensic analysis of a small number of 
closed genome sequences, taken from specific V. cholerae that were of biological and historical 
interest. 
 
Much of our understanding of the differences between pandemic and non-pandemic V. 
cholerae, particularly at the level of gene expression and regulation, come from detailed 
molecular studies of a handful of reference strains of bacteria. These include 7PET isolates 
such as N16961, the strain used for the initial V. cholerae sequencing study, and C6706 and 
A1552, both from Latin America [54, 59, 378]. Classical isolates such as O395 [97] and 569B 
[219, 435] have been well-characterised, as have a handful of serogroup O139 isolates [436] 
and non-O1 isolates such as V52 and AM_19226 [256, 266]. However, the insights gleaned 
from these laboratory strains are rarely extrapolated into a wider genomic context, to 
understand how key regulators of gene expression or phenotypic determinants are distributed 
and vary across a diverse population of bacteria. 
 
Expanding horizons to consider larger and more diverse collections of genome sequences 
increases the context into which our understanding can be placed. For example, by studying a 
single representative isolate of classical biotype V. cholerae (O395), it was initially 
hypothesised that all classical biotype (and thus, Classical lineage) isolates possessed a 
mutation in hapR, preventing HapR-dependent regulation of gene expression in response to 
cell density [437]. However, considering additional genomes caused this generalisation to be 
disproven – although O395 does indeed have an inactivating mutation in hapR, this is not the 
case in all Classical isolates, such as CA401[438].  
 
Having access to as many diverse genomes as possible is therefore essential to allow for a 
maximally-unbiased study of the V. cholerae species. For instance, it has been stated previously 
that in V. cholerae, plasmids are rare, and drug resistance is usually encoded by conjugative 
transposons in the bacterial chromosome [230]. In order to make accurate determinations about 
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the frequency of plasmid types or antimicrobial resistance determinants across a species, it is 
essential not to focus exclusively on 7PET – as has been demonstrated in earlier chapters in 
this thesis, the dynamics of 7PET and non-7PET V. cholerae are extremely different.  
 
In this chapter, I present an analysis of a collection of diverse, non-pandemic V. cholerae. 
These were collated from several sources, and include a set of historically-important isolates 
from the NCTC collections, a set of recent isolates from travellers returning to the United 
Kingdom [439], and non-O1 isolates of both clinical and environmental origin from Mexico. 
These were added to the diverse phylogeny of isolates presented in previous chapters, to 
expand as much as possible the sequenced diversity of V. cholerae. 
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5.2 – Specific aims 
 
In this chapter, I aim to:  
 
1) Determine the population structure of a large collection of genomically-diverse V. 
cholerae isolates,  
2) Characterise the distribution of key virulence, antimicrobial resistance genes across the 
dataset, 
3) Characterise the genomes of a number of historically-significant isolates, and use these 
to understand phenotypic observations made about these isolates in the past, and 
4) Explore the molecular basis of biotypes across the V. cholerae species.  
 
The isolates described in this chapter were particularly valuable because information on their 
history and provenance was available for analysis. The dataset consisted of a wide variety of 
V. cholerae collected as part of several different projects. In this chapter, a targeted approach 
was taken to characterise the distribution across the species of genetic determinants that are 
specifically associated with important phenotypes.  
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5.3 – Results 
 
5.3.1 – Expansion of the V. cholerae species phylogeny 
 
Two hundred and sixty-eight additional genomes were added to the 383 genomes used to 
compute the non-7PET phylogenies presented in Chapters 3 and 4. A deliberate effort was 
made to include non-O1 V. cholerae when compiling these genomes, to attempt to maximise 
the genetic diversity within the dataset. After excluding contaminated and poorly-assembled 
sequences, a pangenome was calculated using the final collection of 651 sequences (11 isolates 
were sequenced twice, meaning that 640 independent sequences are represented in this dataset). 
Using 187,675 variable sites in a core-gene alignment of 2,721 genes, a maximum-likelihood 
phylogeny for these isolates was calculated. Statistical support for this phylogeny was 
determined using 5,000 ultrafast bootstrap approximations (Figure 5.1).  
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Figure 5.1 – A maximum-likelihood phylogeny of 646 V. cholerae and 5 Vibrio spp. Triangles on nodes 
indicate a node that has >95% UFBootstrap support (5,000 replicates). The outer ring denotes the strain collection 
from which each sequence was obtained. Coloured circles on leaves indicate that a live culture of the sequenced 
isolate was available at WSI for subsequent experimental analyses. Lineages were coloured and named for 
consistency amongst thesis chapters. Height of red bars indicates ANI percentage relative to the A1552 reference 
sequence as described in Chapter 3. Plasmid replicons were identified using ABRicate and the PlasmidFinder 
database (see below). The tree is rooted on the Vibrio spp. outgroup. Scale bar denotes substitutions per variable 
site. The clade of isolates to which NCTC 30, 48853_F01 and multiple Argentinian non-O1/O139 V. cholerae 
belong is highlighted in each case (grey disc). 
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5.3.2 – Initial characterisation of diverse V. cholerae 
 
It was apparent that two of the Mexican isolates sequenced in this study clustered adjacent to 
the Vibrio spp. outgroup (Figure 5.1). Inspection of the Kraken QC report for these two isolates 
confirmed their identity to be Vibrio metoecus. These two sequences were retained as part of 
the outgroup for subsequent analysis. A clade of divergent V. cholerae, to which NCTC 30 and 
the non-toxigenic V. cholerae O139 (48853_F01) belong, was also substantially expanded as 
a result of adding these diverse genomes (Figure 5.1).  
 
Comparing the topology of V. cholerae species phylogenies from Chapters 3 and 4 to the 
phylogeny discussed in this chapter provided an intuitive overview of the diversity being 
discovered as non-O1 isolates were added to the sequence collection (Figure 5.2).  
 
 
Figure 5.2 – Illustrating the iterative expansion of the V. cholerae phylogeny during this thesis research. A: 
The phylogeny from Figure 4.26, consisting of previously-published isolates and NCTC 30. B: The phylogeny 
from Figure 3.21, which consists of the dataset used in (A), Argentinian V. cholerae, and published Chinese 
genomes. C: Adding 217 genomes for this chapter to the phylogeny in (B). This phylogeny is presented in detail 
in Figure 5.1. Lineages are coloured as in Figures 3.21, 4.26 and 5.1. Scale bars denote substitutions per variable 
site. All phylogenies rooted on Vibrio spp. 
 
In addition to phylogenetic analysis, average nucleotide identity (ANI) calculations relative to 
the A1552 reference were performed for each genome assembly, to provide an overview of the 
relative differences in nucleotide diversity across the phylogenetic tree. These data show that 
sequences in this divergent clade have a mean ANI of 96.15% relative to A1552 (min 95.85, 
max 96.42), which is significantly different both to the remaining V. cholerae (mean 98.65, 
min 97.54, max 100) and Vibrio spp (mean 88.6, min 88.0985, max 89.3209) (Figure 5.3). 
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Figure 5.3 – Comparing ANI values for V. cholerae, Vibrio spp., and the group of diverse sequences 
highlighted in Figures 5.1 and 5.2. A Wilcoxon rank-sum test was used for statistical testing, to avoid assuming 
that ANI data were normal in nature. ***: p < 0.001, ****: p < 0.0001. The highlighted cluster corresponds to 
isolates contained within the grey disc in Figure 5.1. 
 
The genomic heterogeneity of this divergent clade relative to the remainder of V. cholerae in 
the dataset was also illustrated by the gene presence/absence matrix for this pangenome (Figure 
5.4). In this visualisation, clusters of genes absent from this cluster but present in the remainder 
of sequenced V. cholerae are evident.   
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5.3.3 – Virulence gene distribution across the V. cholerae phylogeny 
 
To begin to explore the diversity of these genomes, the distribution of orthologues of known 
virulence determinants across the dataset was determined. Many of the non-pandemic isolates 
for which genomes were available were obtained from clinical sources – i.e., they caused an 
illness in a human patient. Although the clinical metadata for these isolates are sparse, 
determining the possible mechanisms by which these isolates might have caused illness from 
their genome sequences was performed. To do this, the presence of genes included in the VFDB 
database was determined across the pangenome. In addition, the analysis of Argentinian non-
7PET genomes in Chapter 3 had identified genes corresponding to three distinct T3SS. These 
were used to determine whether such systems were present in this expanded dataset using the 
pangenome gene presence/absence matrix. These results are presented in Figure 5.5.  
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Figure 5.5 legend: The presence of T3SS elements was determined by identifying genomes containing 
orthologues of the T3SS genes characterised in Chapter 3. The genome for isolate SRR221551 was the only 
sequence to contain a large set of P. aeruginosa virulence genes. Manual inspection of this assembly and 
verification of its Kraken report demonstrated that this sequence was contaminated with Pseudomonas sequence. 
Hatch marks denote branches which have been manually shortened for illustrative purposes. Figure has been split 
into two sub-figures for legibility purposes. 
 
Clusters of T3SS genes appear to be distributed amongst the diverse V. cholerae in the dataset, 
though they are absent from the epidemic lineages and the lineages related to these (Figure 
5.5). It also appears that T3SS are rare amongst the clade of highly-diverse isolates, though 
T3SS-2β was detected in NCTC 30 and related isolates (Figure 5.5). The presence of V. 
parahaemolyticus T3SS genes, as identified by ABRicate using VFDB, appears to indicate the 
presence of T3SS-2α (ABRicate did not identify complete T3SS in genomes harbouring either 
the T3SS-2β or the V. anguillarum T3SS described in Chapters 3 and 4). However, two of the 
T3SS-2α genes included in VFDB were detected in isolates harbouring V. anguillarum T3SS, 
suggesting that these genes are conserved amongst or common to the two systems. Genes 
encoded by VPI-1 were found throughout pandemic lineages, related genomes, and in diverse 
isolates within the dataset. No isolate harboured ctxAB in the absence of VPI-1, consistent with 
our understanding that VPI-1 encodes the TCP receptor to which CTXφ binds, notwithstanding 
transduction of CTXφ amongst TCP- V. cholerae [93]. T3SS elements were not mutually 
exclusive with either CTXφ or VPI-1. This is not the same as the observations made in Chapter 
3, and underlines the fact that as more diverse V. cholerae are sequenced, our understanding of 
gene distribution within the species will be refined.  
 
One clade of isolates was identified which harboured the T3SS most similar to a system from 
V. anguillarum, described in Chapter 3 (Figure 5.5). This cluster of isolates was polyphyletic, 
consisting of one clade of the three Argentinian genomes described in Chapter 3 and a second 
clade comprising an additional 11 non-O1 isolates from Mexico and Guatemala (eight of 
clinical origin, three of unknown origin). None of these genomes appear to contain any other 
known V. cholerae virulence determinants. This observation underlines further the fact that 
there is a great need to understand the contributions made by T3SS to disease caused by V. 
cholerae in humans – throughout this thesis research, several examples have been identified of 
clinically-isolated V. cholerae that lack putative virulence determinants other than T3SS, 
justifying further research into the roles that such systems may play in causing acute watery 
diarrhoea or symptoms of cholera. 
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5.3.4 – Serogroup assignment of isolates in silico 
 
Complete metadata were unavailable for the sequenced isolates contained in this analysis. 
Therefore, the serogroup (O1 or non-O1) of each isolate was confirmed in silico. To do this, 
the presence and absence of each of the genes in the O1 biosynthesis gene loci was determined 
for each isolate in the dataset (Figure 5.6A). These loci have been delineated previously in V. 
cholerae (discussed in Chapter 4 in the context of V. cholerae O139). Isolates that are known 
not to be serogroup O1 – including serogroup O139 and O37 isolates – were confirmed to lack 
genes present in serogroup O1 isolates (Figure 5.6B). Based on these results, all of the isolates 
in the dataset were determined to be O1 or non-O1 V. cholerae.   
 
 
Figure 5.6 – The distribution of O1 antigen biosynthesis genes in the V. cholerae pangenome. (A): Schematic 
of the genomic organisation of the O1 biosynthetic locus in the N16961 reference sequence annotated with Prokka 
for uniformity within the pangenome dataset. The genes involved in producing the core lipopolysaccharide as 
well as the O1-specific LPS antigen are denoted. (B): The presence and absence of the 60 genes labelled in (A) 
across the pangenome of 651 isolates presented in Figure 5.1. Isolates which harbour all of the genes in (A) were 
determined in silico to be serogroup O1. Where required, this was also validated using BLASTn to search the 
assembly for the presence of the O1 biosynthesis locus in its entirety, as carried out in Chapter 3. This approach 
allows for the easy recognition of non-O1 V. cholerae; the O37 and epidemic O139 clusters (7PET sub-lineage) 
are indicated as examples.   
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5.3.5 – Distribution of key pathogenicity islands amongst V. cholerae 
 
It has been stated repeatedly in the literature that the four major V. cholerae pathogenicity 
islands, VPI-1 and VPI-2, VSP-1 and VSP-2, are markers for epidemic and pandemic lineages 
of V. cholerae O1 [133, 142]. Having determined whether or not each isolate in the phylogeny 
was serogroup O1, and knowing from Chapter 4 that these elements may be present in more 
than one copy, the presence/absence and copy number of the genes encoded by these 
pathogenicity islands across the phylogeny was determined. This was done by testing for the 
presence of each of the genes that comprise these islands in the pangenome data, in order to 
obtain a sense of the variability within these elements across the phylogeny. These results are 
summarised in Figure 5.7.  
 
Some previously-described phenomena were evident amongst these results, such as the VPI-2 
deletion in V. cholerae O139 [134, 409], and the deletion in VSP-2 reported in recent 7PET 
isolates [309]. As previously observed, a number of non-7PET V. cholerae O1 from China 
were found to harbour VSP-1 in its entirety [396], as does a non-7PET V. cholerae O1 isolate 
from Thailand [440]. These results are of particular importance because they challenge the 
hypothesis that VSP-1 and VSP-2 are specific to 7PET [133]. It also appeared that genes 
orthologous to those encoded by VSP-2 were identifiable in multiple V. cholerae that were 
distantly related to 7PET (Figure 5.7). It was also evident that a number of non-O1 isolates in 
this dataset harboured VPI-1 (genes on which encode TCP), suggesting at least in principle that 
these non-O1 isolates could be lysogenised by CTXφ. However, no non-O1 isolates harbouring 
VPI-1 and CTXφ were detected amongst these data (Figure 5.7). 
 
This analysis underscored the importance of using closed genome assemblies for such analyses. 
To compute this phylogeny, a short-read assembly for the toxigenic V. cholerae O139 
described in Chapter 4 was used, rather than the corresponding long-read assembly. 
Consequently, the duplication of VSP-1 was not detected in this isolate, although its 
duplication had been demonstrated repeatedly in Chapter 4. However, VSP-1 was found to be 
duplicated in the closed genome of MJ-1236, consistent with a previous report of this isolate 
[98]. 
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Figure 5.7 legend: The locus IDs from the N16961 reference genome for each pathogenicity island are indicated. 
Genes flanking these pathogenicity islands were also included, and are evident as genes at the beginning or end 
of each island which are present in nearly every isolate in the dataset. Serogroup assignment was taken from 
Figure 5.6. Since this plot reports the presence and absence of elements found in N16961, tcpAEl Tor appears to be 
absent from genomes which harbour the tcpAClassical allele, though the remainder of VPI-1 genes are present in 
such genomes 
 
5.3.6 – Plasmid and antimicrobial resistance gene distribution amongst V. cholerae 
 
Continuing the exploration of these diverse genomes, all genome assemblies were scanned for 
the presence of antimicrobial resistance determinants and plasmid replicon sequences (see 
Methods). The results of this analysis are summarised in Figure 5.8. It was evident that isolates 
within the diverse clade (Figure 5.8, grey disc) harbour sequences homologous to the beta-
lactamases blaCARB-7 and blaCARB-9. These two genes have been discussed in Chapter 4; briefly, 
both are chromosomally-encoded within the integron on chromosome 2 [151, 152]. This is 
consistent with the lack of plasmid replicon sequences amongst these genomes (Figure 5.1, 
5.8). In this analysis, NCTC 30 was determined to harbour blaCARB-7, which corresponds to the 
functionally-validated blaCARB-like gene (section 4.3.9). Other observations that were consistent 
with previous reports include the presence of a catB9 gene within 7PET [158], and the detection 
of qnrVC quinolone resistance genes amongst Chinese non-7PET genomes [396] (Figure 5.8).  
 
It is important to note that the tet(34) sequence, predicted to be present in 650 of 651 isolates 
in this dataset, is homologous to a xanthine-guanine phosphoribosyltransferase (XPRT) gene 
present on the V. cholerae chromosome [59, 441]. This sequence was not detected in analyses 
for previous chapters, which made use of ARIBA to scan short-read data for resistance 
determinants (Chapter 3), and the Resfinder web interface, which scans assemblies using 
BLASTn (Chapter 4). Moreover, tetracycline resistance was not reported in the vast majority 
of phenotyped V. cholerae included in this dataset (Chapters 3, 4). Since this was the first time 
that ABRicate had been used to detect resistance genes in assemblies, it is possible that 
detection of tet(34) is an artefact of the chosen analysis method. Additional validation would 
be required before further inferences can be drawn from this observation.  
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From these data, it was evident that the majority of sequenced V. cholerae possessed very few 
antimicrobial resistance genes; 550 of the 651 genomes harboured two or fewer AMR 
determinants (Figure 5.9). The presence of a plasmid replicon is statistically significantly 
associated with a V. cholerae isolate harbouring three or more AMR genes (χ2 (d.f. = 1, n = 
650) = 75.84; p < 0.00001; Table 5.1). This suggests that the majority of AMR genes amongst 
this dataset are present on plasmids, of which there are very few types amongst these 
genetically heterogenous isolates.   
 
 
Figure 5.9 – The vast majority of V. cholerae isolates harbour two or fewer AMR genes. The potentially-
dubious detection of tet(34) gene means that those isolates predicted to harbour one resistance gene are likely to 
be pan-susceptible.  
 
 Plasmid Replicon  
AMR genes No Yes Σ(rows) 
≤ 2 542 8 550 
≥ 3 79 21 100 
Σ(columns) 621 29 650 
 
Table 5.1 – χ2 contingency table. Testing for association between the presence of a plasmid replicon (IncQ1, 
IncA/C1, IncA/C2, ColRNAI) and increased numbers of AMR genes.  
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It was evident that within this dataset were a number of serogroup O1 V. cholerae, many of 
which were part of a collection of V. cholerae supplied by NCTC. Many of these were the 
lineages local to Latin America that were previously-described [189], or were from a recent 
study of Chinese non-7PET V. cholerae O1 [396]. However, a number of non-7PET V. 
cholerae O1 were evident which were part of the NCTC collection of historical V. cholerae 
isolates. This prompted a closer investigation of the history and genomes of the NCTC V. 
cholerae, discussed below. 
 
5.3.7 – Phylogenetic positions of historically-important NCTC isolates 
 
As part of this thesis research, I spent time at PHE Colindale examining historical records for 
V. cholerae contained within the NCTC collection, and collating these data with the assistance 
of Jake Turnbull. Names and basic metadata for the 35 isolates included in this chapter are 
listed in Table 5.2. Following the detailed characterisation of the PacBio-assembly of NCTC 
30 (Chapter 4), the phylogenetic position of all other V. cholerae that were in-stock and 
available from the NCTC collection was determined (Figure 5.1). All of these isolates were 
available as live cultures for experimentation under CL3 conditions, and were sequenced using 
both PacBio and Illumina technologies with gDNA prepared using the methodology optimised 
using NCTC 30 (Methods, section 2.2.5). All live isolates are denoted on Figure 5.1.
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NCTC 
No. 
Other strain references 
and names 
Year of 
isolation 
Internal 
isolate 
ID 
Serogroup/Serotype 
from records 
Phylogenetic 
lineage 
(Figure 5.1) 
In silico 
serogroup 
30 ATCC14735; MARTIN 1 1916 MJD382 Non-O1/O139 (O2) - Non-O1 
3661 
CN 5870; DOORENBOS 
80 1931 MJD383 O1 El Tor near-ELA5 O1 
4693 JAPANESE ORIGINAL pre-1936 MJD384 O1 Inaba Classical O1 
4711 
ATCC 14730; 
NANKING 32/123 
Pre-
1936 MJD385 O2 - 
Non-
O1/O139 
4714 EL TOR 34-D 19 1934 MJD386 Non-O1/O139 - 
Non-
O1/O139 
4715 
ATCC 14731; CN 3426; 
ELTOR 34-D 23 1934 MJD387 O3 - 
Non-
O1/O139 
4716 
ATCC 14732; KASAULI 
73 1932 MJD388 O4 - 
Non-
O1/O139 
5395 ATCC 14734; IRAQ 1938 MJD389 O1 El Tor Ogawa pre-7PET O1 
5596 SHANGHAI 10 pre-1939 MJD390 O1 Ogawa Classical O1 
6585 SUBAMMA pre-1944 MJD391 No data Classical O1 
7258 EGYPT 109 pre-1948 MJD392 No data Classical O1 
7260 EGYPT 117 pre-1948 MJD393 No data Classical O1 
7270 HIKOJIMA pre-1948 MJD394 O1 Inaba Classical O1 
8021 ATCC 14035; RH 1094 pre-1950 MJD395 O1 Classical Ogawa Classical O1 
8039 CAIRO 1A pre-1950 MJD396 O1 Classical Inaba Classical O1 
8040 726/575 A pre-1950 MJD397 O1 Classical Inaba Classical O1 
8041 
757 
AUTOAGGLUTINABLE pre-1950 MJD398 O Rough Classical O1 
8042 
ATCC 14733; WDCM 
00203 pre-1950 MJD399 Non-O1/O139 - 
Non-
O1/O139 
8050 CALCUTTA pre-1950 MJD400 No data - O1 
8367 4 Z pre-1952 MJD401 O1 Classical Ogawa Classical O1 
8457 
ATCC14033; CN5774; 
DO1930; RH1092 1930 MJD402 O1 El Tor near-ELA5 O1 
9420 CN 5789; TOR A pre-1955 MJD403 El Tor pre-7PET O1 
9421 CN 5790; TOR 1 pre-1955 MJD404 O1 El Tor Ogawa pre-7PET O1 
9422 CN 5871; TOR 8 pre-1955 MJD405 O1 Inaba near-ELA5 O1 
9423 TOR 31 pre-1955 MJD406 No data pre-7PET O1 
10255 CN 5745; 20109 1961 MJD365 O1 El Tor Ogawa 7PET O1 
10256 CN 5748; 20111 1961 MJD366 O1 El Tor Ogawa 7PET O1 
10732 CN 3534; 384/52 1952 MJD367 O1 Classical Inaba Classical O1 
10733 
AJ 1592; CN 3539; I-5; 
586/52 1952 MJD368 O1 Classical Ogawa Classical O1 
10954 1330 1973 MJD369 El Tor 7PET O1 
11090 NCIB 9341; 1077 pre-1950 MJD370 No data - O1 
11348 
VL3029; WDCM00136, 
CCUG67718, 
DSM101014 pre-1981 MJD372 O24 - 
Non-
O1/O139 
11500 VL 7050 pre-1983 MJD373 No data - 
Non-
O1/O139 
11643 VL 4944 pre-1985 MJD380 No data - 
Non-
O1/O139 
12946 ATCC 51395; MO3 1993 MJD381 O139 7PET (O139) O139 
Table 5.2 – NCTC V. cholerae sequenced for this thesis research. Excluded from this list is one sequenced 
isolate which was found to be a member of the Aeromonas genus upon analysis of the genome assembly.  
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5.3.7.1 – Pandemic NCTC isolates 
 
Of the 35 NCTC isolates that were included in this analysis, four were found to be members of 
7PET (Figure 5.10). One of these was NCTC 12946, also known as MO3, a serogroup O139 
strain isolated at the beginning of the V. cholerae O139 epidemic in 1993 [436]. Genomic 
analysis confirmed that this isolate possessed serogroup O139 LPS genes, was toxigenic, and 
was phylogenetically positioned amongst previously-sequenced toxigenic V. cholerae O139 
within 7PET (Figure 5.10). NCTC 10255 and 10256 were isolated from patients during an 
outbreak of “paracholera” in Hong Kong during 1961 [358]. Vella demonstrated that these El 
Tor Vibrios were highly virulent in a mouse model, and that these isolates showed some ability 
to immunise mice against re-infection [358]. NCTC 10954 has been used historically as a 
positive control strain for haemagglutination in V. cholerae biotyping [40].  
 
Thirteen isolates were members of the Classical lineage (Figure 5.10). Vella compared NCTC 
10255 and 10256 to a “true cholera” vibrio, NCTC 7260, the most virulent isolate available at 
the time [358] (Table 5.1; Figure 5.10). The finding that this is a Classical isolate is logical, 
given that Vella had referred to this as a “true cholera” Vibrio when compared to El Tor isolates 
[358]. Other isolates of interest that were members of the Classical lineage include NCTC 8367 
(strain 4Z), which has been used as a source of neuraminidase (“receptor destroying enzyme”) 
[135, 442]. Neuraminidase is encoded by nanH, part of VPI-2 [134] (section 1.2.5), a 
pathogenicity island found in Classical V. cholerae [54, 133, 134] and in this isolate (Figure 
5.7). Characterising the phylogenetic position of NCTC 8021 is particularly important because 
this isolate is the Vibrio cholerae type strain and the neotype of the V. cholerae species [443]. 
In 1965, Hugh compared the biochemical phenotypes of 258 V. cholerae isolates to that of 
NCTC 8021 [444], and requested an opinion from the Judicial Commission of the International 
Committee on Bacteriological Nomenclature that this strain be considered the V. cholerae 
neotype [209]. V. cholerae appeared on the Approved List of Bacterial Names in 1980 [35], 
and Hugh’s work was cited as the description of the V. cholerae species [35, 444]. NCTC 8021 
has been used as a reference standard for the negative haemagglutination phenotype used to 
biotype Classical V. cholerae [40]. It is reassuring that this type strain is a member of the 
Classical lineage, given that NCTC 8021 was designated a type strain during the 1960s, at a 
time when Classical V. cholerae was still considered to be the sole aetiological agent of cholera 
[1, 36]. Thus, the type strain chosen was indeed biochemically, microbiologically, and 
genomically, a representative of the aetiological agent of Asiatic cholera.  
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Figure 5.10 – A V. cholerae phylogenetic tree annotated with the names and IDs of NCTC isolates. The 
phylogeny presented in Figure 5.1 is re-drawn and the position of NCTC isolates indicated. Where necessary for 
illustrative clarity, sub-trees were extracted from the original phylogeny and visualised separately (Figtree v1.4.3). 
The names of NCTC isolates and key reference sequences have been retained. Hatch marks indicate branches that 
were manually shortened for illustrative purposes. 
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5.3.7.2 – Non-pandemic NCTC V. cholerae O1 
 
Of interest was a set of three V. cholerae O1 which were not part of either the 7PET or Classical 
lineages. NCTC 3661, 8457, and 9422 were all recorded as being serogroup O1 in NCTC 
records (Table 5.2). NCTC 3661 and 8457 were also recorded as being biotype El Tor (Table 
5.2). Genomic analysis confirmed that these three isolates harboured the genes necessary to 
make these serogroup O1, but lacked VPI and VSP pathogenicity islands and CTXφ, though 
they were predicted to harbour T3SS-2α (Figure 5.6, 5.7, 5.8). In the absence of any further 
clinical metadata, it is impossible to know whether the T3SS-2α predicted to be present in these 
isolates is either functional or contributed to causing disease in a patient. 
 
These three isolates were particularly interesting because of their history. NCTC 3661, 
Doorenbos 80, was isolated in 1931 from a healthy Mecca pilgrim [41]. Gardner and 
Ventakraman described this as having ‘typical’ biochemical characteristics, being of O-
subrgoup I, and to be capable of haemolysing goat erythrocytes [41]. In subsequent studies, 
NCTC 3661 was also shown to be haemolytic on sheep blood agar, produced a positive Voges-
Proskauer test result, and was positive in a Grieg test for haemolysis [445]. However, this strain 
has been shown to be sensitive to group IV cholera bacteriophage, a phage to which El Tor 
isolates tend to be resistant [446].  
 
NCTC received a batch deposition of four V. cholerae from A.H. Wahba, which were received 
simultaneously from Cairo in 1953 (NCTC records). At the time, these isolates were named 
Tor A, Tor 1, Tor 8 and Tor 31 (Table 5.2), and were simply described as “El Tor strains” 
(NCTC records). These were accessioned into the NCTC collection as NCTC 9420-9423. A 
recent study reported genome sequences for NCTC 9420 and NCTC 5395, and found that both 
of these sequences were basal to the 7PET lineage [213], dubbed “pre-7PET” here. These 
sequences are included in the phylogeny presented in Figure 5.10. It has been stated that the 
properties of NCTC 9420, as well as NCTC 8457 and 5395, are likely to resemble those of the 
original El Tor biotype V. cholerae described by Gotschlich, which tended to be isolated from 
asymptomatic patients [211, 213]. For this PhD project, NCTC 9420, 9421 and 9422 were 
sequenced. Although NCTC 9420 and 9421 are basal to 7PET, isolate NCTC 9422 sits adjacent 
to NCTC 3661 (Figure 5.10). This strongly suggests that the El Tor phenotypes, which led 
NCTC 9420-9423 to be isolated and deposited with NCTC, are consistent between the pre-
7PET isolates and the phylogenetically-unrelated NCTC 9422. 
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A closer inspection of the NCTC 3661 and NCTC 9422 genome sequences demonstrated that 
both isolates were predicted to harbour IncA/C2 plasmids (Figures 5.1, 5.8). This was 
surprising, because when the assemblies for both of these isolates were scanned for 
antimicrobial resistance determinants, no putative resistance genes were detected (Figure 5.8). 
To address this, a combination of PacBio RSII long-reads and Illumina short-reads were used 
to produce hybrid assemblies for these genomes. Unicycler, with ‘conservative’ settings, was 
used to minimise the likelihood that contigs would be merged spuriously (see Methods). A 
~130 kb circularised contig was identified in the hybrid assemblies of both genomes. 
Visualisation of the De Brujin graph from the corrected, circularised assembly confirmed that 
this element was independent of the two V. cholerae chromosomes (see Figure 5.11 for 
representative result from NCTC 3661), and this contig contained the IncA/C2 replicon. No 
antimicrobial resistance genes were detected on this contig.  
 
Figure 5.11 – Visualisation of the De Brujin graph for the polished, rotated hybrid assembly for NCTC 
3661. The integron on chromosome 2 was not completely assembled; this is a consequence of running Unicycler 
on ‘conservative’ settings. An identical plasmid of 131,185 bp was assembled from NCTC 9422.  
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Comparative genomics demonstrated the similarity between this putative IncA/C2 plasmid 
(pNCTC3661) and previously-published V. cholerae plasmids from the same family, including 
the rare MDR IncA/C2 plasmid detected in Argentinian LAT-1 V. cholerae described in 
Chapter 3 (Figure 5.12). It also highlighted that the variable regions of the plasmid backbone, 
which can harbour antimicrobial resistance genes, are much shorter in this drug-sensitive 
plasmid compared to plasmids encoding resistance determinants (Figure 5.12).  
 
5.3.7.1 – NCTC 8457 
 
The first report of NCTC 8457 was made by Doorenbos and Kop, in 1951, in which paper the 
isolate is recorded as having been isolated 20 years prior to the publication [447]. This strain 
is serogroup O1, biotype El Tor, and non-toxigenic [213]. On this basis, Hugh argued that 
NCTC 8457 should be the neotype of Vibrio eltor Pribram (i.e., El Tor V. cholerae), since this 
isolate displayed all of the characteristics of an El Tor vibrio [210]. A genome sequence for 
NCTC 8457 was reported in 2009 [54] but was first sequenced in 2006 at TIGR (accession # 
NZ_AAWD00000000.1). This sequence has subsequently been used as an exemplar of the 
“pre-seventh pandemic” group of V. cholerae [54, 213]. In particular, this strain was used 
alongside other historical isolates to make inferences about the evolution of the lineage now 
dubbed 7PET [213]. 
 
Unlike our sequence data for NCTC 9420 and 5395, the phylogenetic position of our sequenced 
isolate of NCTC 8457 was not consistent with that of the previously-reported genome (Figure 
5.10). Rather than co-clustering with the previously-sequenced NCTC 8457 isolate as did our 
re-sequenced NCTC 5395 and 9420 (Figure 5.10D), our stock of NCTC 8457 clustered with 
the two serogroup O1 biotype El Tor isolates NCTC 9422 and 3661 (Figure 5.10B). This was 
a surprising result, but was replicated when gDNA from an independent batch of NCTC 8457 
(DNA supplied by M.A. Fazal at NCTC) was sequenced and similarly analysed. This suggested 
that there may be discrepancies between the previously-sequenced culture of NCTC 8457 and 
the stocks which were sequenced for this PhD project.  
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In light of this apparent discrepancy, a number of confirmatory analyses were performed to 
validate our genomic observations, and to provide support for the phylogenetic position of this 
sequence. Firstly, it was confirmed in silico that NCTC 8457 was likely to be of serogroup O1 
(Figure 5.6). This is fully-consistent with previous reports [54]. Similarly, a manual inspection 
of the genome confirmed that CTXφ and the genes encoding cholera toxin could not be 
detected in this genome (Figure 5.7); again, consistent with previous characterisations of the 
isolate.  
 
Interestingly, a conservatively-generated hybrid assembly for NCTC 8457 suggested the 
presence of a small circular element in this assembly, which was independent of the two 
chromosomes (Figure 5.13). No plasmids were detected in the hybrid assembly using the 
Plasmidfinder website or in the earlier analysis of the short-read assembly (Figure 5.8).  
 
Figure 5.13 – Visualisation of the De Brujin graph for the NCTC 8457 hybrid assembly. Figure produced 
using Bandage and the polished assembly graph generated by Unicycler.  
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The six contigs that comprised this 6.9 kb element were extracted from the hybrid assembly, 
and their concatenated sequence was used to query the nr database using BLASTn. The most 
similar sequence to this element was a 3.8 kb plasmid called pVC (accession # AY423429), 
the sequence of which covered the query from NCTC 8457 by 69%, with 98.99% nucleotide 
identity. pVC is a cryptic plasmid which was isolated from an environmentally-derived non-
O1/O139 V. cholerae isolate dubbed MP-1 [448]. This manuscript reported that four CDSs of 
unknown function were identifiable on pVC, that attempts to cure pVC from MP-1 were 
unsuccessful, and that pVC was likely to replicate via theta replication [448, 449]. The 
replication origin of pVC was identified in this work [448], and this sequence is shared between 
pVC and the putative plasmid from NCTC 8457. 
 
In order to confirm further whether the 6.9 kb element in NCTC 8457 might be an 
extrachromosomal plasmid, plasmid extractions were performed using stationary-phase 
cultures of this strain and others (alkaline lysis using Qiagen Midiprep kits; Methods, section 
2.2.14). A small DNA element was successfully extracted from cultures of NCTC 8457 (stock 
ID MJD402; Figure 5.14), further suggesting that this isolate harbours a small plasmid that 
replicates extrachromosomally. Additional support for these observations was obtained while 
reviewing the literature surrounding NCTC 8457 - a previous publication had reported that 
NCTC 8457 harboured a small cryptic plasmid [450]. In future work, excising this DNA 
element and using a combination of Sanger sequencing and primer walking may allow for the 
identity and sequence of this element to be confirmed. 
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Figure 5.14 – Gel of plasmid preps from V. cholerae and E. coli. The plasmid preparations presented here were 
made from different organisms (E. coli and V. cholerae). Plasmids of known size from E. coli (lanes 1-8) were 
extracted from 2 ml stationary-phase overnight cultures using a Qiagen miniprep kit (Methods). Plasmids were 
extracted from 25 ml cultures of V. cholerae (lanes 9-12) using a Qiagen midiprep kit (Methods). Plasmids were 
not linearised before electrophoresis and host organisms were not consistent; hence, sizes are approximate. 
Ladder: Hyperladder 1 kb. 
 
5.3.8 – Biotype determinants 
 
The collection of historically-important isolates described above led us to investigate the basis 
of biotyping across this phylogeny. We chose to do this because (a) a number of Classical 
genomes had been added to the collection, and (b) three O1 El Tor isolates had been 
characterised which were distantly related to 7PET. Understanding the distribution of biotype-
determining mutations across the species is an important step towards understanding what the 
“default” biotype would be for a newly-emerging O1 lineage, though it is accepted that 
biotyping reactions are uninformative when used on non-O1 V. cholerae [206]. The three 
principal phenotypes used to biotype V. cholerae O1 are sensitivity to polymyxin B, the Voges-
Proskauer test, and haemolysis [40, 206]. The molecular and genetic bases of each of these 
phenotypes have been characterised, and were investigated across the phylogeny.  
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5.3.8.1 – Voges-Proskauer test and acetoin biosynthesis in V. cholerae 
 
The Voges-Proskauer test detects acetoin in bacterial cultures [451]. Acetoin is produced as an 
intermediate molecule by V. cholerae during the fermentation of glucose to 2,3-butanediol 
[452]. El Tor V. cholerae produce acetoin and test positive when subjected to the Voges-
Proskauer test, and classical V. cholerae do not produce acetoin, producing negative Voges-
Proskauer test results [206]. The inability of classical V. cholerae to ferment glucose (via 
acetoin) means that classical biotype strains exhibit a severe growth defect when cultured on 
minimal media containing glucose as a sole carbon source, acidifying their growth media [452].  
 
It has been shown that the AphA transcription factor negatively regulates acetoin production 
in V. cholerae [453]. This occurs because AphA directly repressed the alsD gene and the gene 
encoding the AlsR transcriptional regulator [453]. Additionally, the ability to produce 
(p)ppGpp has been shown to regulate acetoin production; this is independent of AphA [454]. 
It has also been shown that HapR, the master regulator of V. cholerae quorum-sensing 
responses, represses aphA when cultures reach a high cell density [455]. Thus, at high cell 
density, HapR represses aphA, thereby de-repressing the genes whose products are required to 
ferment acetoin (Figure 5.15) [453]. It has been shown that a single GàT mutation at position 
-77 in the aphA promoter ablates the ability of HapR to bind to, and repress, transcription of 
aphA [455]. It has been demonstrated that the -77T mutation in PaphA is present in the Classical 
V. cholerae reference strain, O395, and that the -77G allele is present in 7PET isolate C6706 
[455]. 
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Figure 5.15 – Overview of the effects of PaphA alleles on the expression of acetoin metabolism genes. At high 
cell density, HapR levels accumulate, and repress transcription of aphA if HapR binds to PaphA (only if -77G allele 
is present). Diminished rates of aphA transcription and AphA translation leads to a concomitant de-repression of 
the als genes required to ferment acetoin.  
 
In order to determine the PaphA variants present in each isolate included in this dataset, in silico 
PCR was used to extract the aphA promoter sequence from each genome assembly (parameters 
listed in Methods, section 2.1.17). PaphA was successfully extracted from 632 of the 651 
sequences in the dataset. These sequences were aligned and compared to identify the variable 
sites in the promoter (Figure 5.16). 
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Figure 5.16 – PaphA motif generated from a Clustal Omega alignment of 632 PaphA sequences extracted using 
in silico PCR. The 50 bp region of interest was extracted from the “amplified” sequence using trimal. The MEME 
web server was used to produce the motif figure.  
 
Two variable sites were visible in the PaphA sequence that had been previously characterised – 
these were position -85, known not to influence HapR binding [455], and position -77, mutation 
of which from G to T abolishes HapR binding to PaphA [455]. 
 
5.3.8.2 – Cholera toxin expression: an additional contrasting phenotype between 
classical and El Tor biotype isolates 
 
The original study of aphA regulation by HapR was carried out in order to understand how 
HapR contributed to virulence gene expression in V. cholerae through AphA, and how this 
varied in a biotype-specific manner [455]. Canonically, classical biotype V. cholerae express 
the toxR virulence regulon in vitro at much higher levels than do El Tor isolates, which need 
to be cultured under stringent conditions to induce expression of virulence genes and CT in 
vitro [456, 457]. At low cell density, AphA and AphB co-ordinately activate the tcpPH 
promoter, and the binding of AphA to PtcpPH enhances the binding of AphB to PtcpPH [458, 459]. 
Resultant increases in TcpP and TcpH levels lead to an upregulation of toxT and the activation 
of virulence gene expression [458]. In classical isolates, the -77T mutation in PaphA prevents 
aphA from being repressed by HapR; therefore, in classical isolates, the virulence regulon is 
not repressed at high cell density. In El Tor isolates, PaphA is sensitive to HapR repression; 
therefore, at high cell density, AphA-mediated activation of PtcpPH is reduced [458]. 
 
The differential activation of PtcpPH by AphB is known to be necessary and sufficient to drive 
the classical and El Tor differences in virulence gene expression [460]. This has been shown 
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to be due to a single mutation in PtcpPH ; the binding affinity of AphB for this promoter is tenfold 
higher if an A is present at position -65 [459]. In the O395 classical isolate, an A is present at 
-65, and in C6706, a G is present at the equivalent position (-66). Mutagenesis of both genetic 
backgrounds has shown that these alleles are sufficient to confer an El Tor or a classical 
virulence gene expression phenotype on V. cholerae [459]. This is summarised in Figure 5.17.  
 
 
Figure 5.17 – Overview of the effects of PtcpPH alleles on virulence gene expression. AphB (using AphA as a 
binding partner) has greatly enhanced affinity for PtcpPH if an A is present at position -65/66. AphA/AphB binding 
to PtcpPH activates expression of tcpPH and elevates intracellular levels of TcpP and TcpH. These, together with 
ToxRS, activate expression of toxT, thereby directly activating the expression of virulence genes. Conversely, in 
an “El Tor” background (PtcpPH -66G), AphA and AphB have a lower affinity for PtcpPH; therefore, virulence gene 
expression is lower.  
 
It is important to consider mutations in both PtcpPH and PaphA at once, because together they 
couple the expression of virulence genes to quorum-sensing (Figure 5.18). In a Classical 
genetic background such as that of O395, aphA is rendered insensitive to repression by HapR. 
Therefore, regardless of cell density, aphA will be transcribed and AphA will be translated. 
Combined with the increased affinity for PtcpPH experienced by AphA and AphB in this 
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background, this will lead to maximal expression of the toxR/toxT virulence regulon (Figure 
5.18). 
 
 
 
Figure 5.18 – Coordinate effects of Classical PtcpPH and PaphA alleles on virulence gene expression. The 
presence of both promoter alleles is predicted to lead to very high expression of the ToxT regulon.  
 
In a similar manner to the study of PaphA, the PtcpPH sequence was extracted from all genomes 
in the dataset that harboured VPI-1 (258 isolates total), and compared to identify the variable 
sites in this promoter. This is illustrated in Figure 5.19.  
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Figure 5.19 – PtcpPH motif generated from a Clustal Omega alignment of 258 PtcpPH sequences extracted 
using in silico PCR. The 50 bp region of interest was extracted from the “amplified” sequence using trimal. The 
MEME web server was used to produce the motif figure.  
 
The genotype of PaphA and PtcpPH was determined for each genome in the dataset and mapped 
against the phylogeny, to determine the distribution of these variants (Figure 5.20). It was 
immediately apparent that both PaphA -77T and PtcpPH -65A were exclusively detected in 
Classical lineage V. cholerae, whereas the PaphA -85 position was variable across the phylogeny.  
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Figure 5.20 – Distribution of PaphA and PtcpPH allelic variants across the V. cholerae phylogeny. Isolates that 
were phenotypically serogroup O1 (for which those data were available) are indicated, as are those determined 
computationally to be serogroup O1. Lineages of V. cholerae O1 are indicated. Since tcpPH genes are harboured 
on VPI-1, PtcpPH could only be detected in genomes containing VPI-1.  
 
These data strongly indicate that genetic determinants which confer classical phenotypes 
(acetoin production and virulence gene expression) are almost exclusively in isolates that 
belong to the Classical lineage. Additional biotyping determinants were similarly studied, to 
determine whether this applies just to these promoters, or represents a more general 
observation.  
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5.3.8.3 – Polymyxin B sensitivity and haemolysis 
 
El Tor biotype V. cholerae are classified as being resistant to polymyxin B – specifically, for 
an El Tor strain, a zone of inhibition will not be visible around a disc containing 50 units of 
polymyxin B [206]. In contrast, classical V. cholerae are sensitive to this concentration of 
polymyxin B and a zone of inhibition will be visible around the disc (the size of the zone of 
inhibition is not important in this specific assay) [206]. Briefly, the almEFG operon encodes 
three proteins which are responsible for catalysing the transfer of glycine residues to lipid A in 
El Tor V. cholerae, rendering them resistant to polymyxin B [461]. In a Classical isolate 
(O395), it was observed that the almF gene was disrupted, and that this mutation was 
responsible for the inability of this strain to resist polymyxin B – expression of an intact 
almEFG operon in trans dramatically elevated polymyxin B resistance in O395 [461].  
 
Haemolysis in V. cholerae is mediated by the secreted haemolysin HlyA, which is processed 
into an active form by proteolysis [462, 463]. As mentioned in the Introduction (section 
1.3.1.4), El Tor V. cholerae are characteristically haemolytic, and classical isolates are not [40, 
206]. Classical isolates have been shown to be non-haemolytic as a consequence of a frameshift 
mutation in hlyA [464]. The hybrid strains of El Tor V. cholerae have been reported to be non-
haemolytic, or haemolytic with a range of phenotypes [222]. Recent work suggests that 
multiple independent mutations in hlyA can be detected amongst hybrid V. cholerae [221]. It 
should also be noted that haemolysis is recognised to be an unreliable phenotype by which to 
characterise V. cholerae [206].  
 
The state of almEFG and hlyA were determined across the phylogeny (Figure 5.21). Again, it 
was immediately evident that the mutations that confer a canonical classical biotyping 
phenotype – non-haemolysis due to an hlyA frameshift and sensitivity to polymyxin B due to 
an almF disruption – are both exclusive to the Classical lineage of V. cholerae (Figure 5.21). 
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Figure 5.21 – Presence of intact and disrupted polymyxin B resistance genes and hlyA across the V. cholerae 
phylogeny. The absence of almF was determined from the pangenome matrix, as was the presence of the classical 
hlyA frameshift.   
 
Collectively, these data show that genetic determinants which confer V. cholerae biotypes are, 
in fact, describing the Classical lineage rather than 7PET.  
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5.4 – Discussion 
 
The results presented in this chapter describe some important aspects of V. cholerae biology, 
and challenge a number of dogmatic views in V. cholerae research. Firstly, it is not true to say 
that the VSP and VPI pathogenicity islands are found exclusively in epidemic or pandemic 
lineages of V. cholerae. Figures 5.5 and 5.7 show that these elements can be found in other V. 
cholerae of serogroup O1 as well as in non-O1 bacteria, consistent with previous reports (e.g., 
[55, 396, 440]) and summarised below in Figure 5.22. Moreover, the presence of VPI-1 in non-
O1 isolates underlines the fact that V. cholerae other than the members of pandemic lineages 
have the capacity to become lysogenised with CTXφ and to gain the capacity to express CT.  
 
 
Figure 5.22 – Model of genetic determinants contributing to cholera. (A): Canonically, V. cholerae O1 
harbouring a combination of genetic determinants can produce CT in a human host, causing cholera. However, 
the data presented in this chapter, as well as other work cited throughout, has shown that these genetic 
determinants can be found in multiple lineages of V. cholerae O1, not just those that cause pandemic cholera (B).  
 
Our results suggest that the stocks of NCTC 8457 held by NCTC may not be the same as the 
strain that was sequenced in 2007 (Figure 5.10). The additional data available to us, including 
the fact that our sequenced stock is genomically of serogroup O1 and is phylogenetically 
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related to other non-7PET V. cholerae O1, and that this sequence appears to harbour a small 
extrachromosomal plasmid (Figures 5.13, 5.14), indicate that in order to resolve this 
satisfactorily, it will be necessary to obtain and re-sequence a culture of the originally-
sequenced NCTC 8457 stock. Since this original sequence was generated by TIGR in the USA, 
it is possible that the stocks of NCTC 8457 held by ATCC (under accession # ATCC 14033; 
Table 5.2) and by NCTC are not identical.  
 
To our knowledge, the data in this chapter represent the first report of a sequenced IncA/C2 
plasmid which lacks any resistance determinants. Moreover, since NCTC 3661 was isolated in 
1931, this suggests that pNCTC3661 is one of the oldest sequenced IncA/C2 plasmids and may 
be an example of an ancestral IncA/C2 plasmid backbone into which antimicrobial resistance 
determinants were imported as the use of antibiotics as therapeutics became more frequent. 
This sequence may be of considerable utility for the construction of plasmid phylogenies, or 
otherwise for understanding how IncA/C2 plasmids evolved to acquire AMR determinants 
over time. Since this plasmid type seems to be one of very few types that establish themselves 
in V. cholerae (Figures 5.1, 5.8; [158]), studying this plasmid type both within  and outside the 
context of Vibrio spp. may be of considerable evolutionary interest.  
 
This cluster of historical non-7PET serogroup O1 V. cholerae from NCTC underline the fact 
that using biotyping to identify V. cholerae of clinical importance is of very limited utility. 
These data show that all of the principal phenotypes upon which the biotyping scheme was 
devised describe the Classical lineage, rather than an El Tor lineage. This is exemplified by 
NCTC 9422 and the fact that this was co-deposited alongside other El Tor bacteria to which it 
was distantly related. It is apparent that the El Tor phenotype is much more broadly distributed 
across V. cholerae than just 7PET and local O1 lineages, whereas the specific mutations 
causing the Classical biotype appear to be coincident only in the Classical lineage. This 
genomic evidence is complementary to a conclusion from Chapter 3, in which the reliance on 
Inaba/Ogawa serotyping for epidemiological purposes was shown to be of very limited utility. 
Taken together, the work in this thesis so far strongly suggests that, in the light of genomic 
evidence, many of the bacteriological and biochemical assays used to study epidemic V. 
cholerae are misleading.  
 
It has been observed that recent 7PET isolates, such as those which caused cholera outbreaks 
in Yemen, were sensitive to polymyxin B in spite of being part of an “El Tor” lineage [309]. It 
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was postulated that a non-synonymous mutation in vprA (causing a D89N mutation in VprA) 
was responsible for this phenotype, because functional VprA is required for the expression of 
the almEFG operon [309, 465]. This indicates that the acquisition of polymyxin B sensitivity 
in these recent 7PET isolates is not due to the acquisition of a Classical almF genotype – 
indeed, almF is intact in these recent 7PET isolates, a representative of which was included in 
the phylogeny discussed in this chapter (Figure 5.21). This indicates that although recent hybrid 
7PET isolates appear to be acquiring “classical-like” phenotypes, this is not due to the 
acquisition of the same genetic mutations found in Classical isolates [221, 222, 309]. 
Understanding whether acquiring classical phenotypes alter the fitness of 7PET is an area of 
active research [466].  
 
It appears that as diverse bacteria continue to be sequenced, the V. cholerae phylogeny 
continues to expand. Of particular interest for future study is the population of diverse genomes 
in the phylogeny, with a lower ANI to 7PET than the rest of the species (Figures 5.1, 5.3). It is 
possible that this clade corresponds to the ‘novel species’ or ‘basal lineage’ described by [467], 
though such a taxonomic determination would require considerable additional computational 
and microbiological study, and was outside the scope of this thesis research. As part of this 
PhD, the number of genomes available in this clade has been substantially expanded, and 
includes two closed genomes (NCTC 30, 48853_F01; Chapter 4). Thus, this is a promising 
area of future research into the diversity of the V. cholerae species.  
 
In the final results chapter of this thesis, I consolidate the lines of enquiry that I have followed 
thus far, exploring the differences between pandemic and non-pandemic V. cholerae. To do 
this, I select eight key isolates from the phylogeny presented in this chapter, and design 
experiments by which to characterise the differences in the transcriptomes of these isolates 
when cultured under the same growth conditions. This is to explore whether gene expression 
patterns are more similar within or between lineages, and whether differences in regulation can 
be detected within lineages. 
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Chapter 6 
 
Variation in gene expression in phylogenetically-selected V. cholerae 
 
Contribution statement 
 
Nick Thomson supervised the work described in this chapter. George Salmond, Gordon 
Dougan, and Julian Parkhill made substantive intellectual contributions to experimental design. 
rRNA depletion, library construction, and cDNA sequencing was performed by the WSI 
Bespoke RNA team. The live isolates used in this project were supplied by IVI, NCTC, and 
PHE, and have been described in Chapter 5. 
 
I performed RNA-seq experiments, analysed the data and produced all figures.  
 
COVID-19 statement 
 
The work described in this chapter was severely affected by the shutdown imposed on the 
University of Cambridge and the Sanger Institute by the COVID-19 pandemic. This affected 
both the generation and analysis of RNA-seq data, as well as in vitro validation of the results 
from transcriptomic analysis. Aspects of the analysis herein may therefore be incomplete, but 
are the subject of current and future research.  
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6.1 – Overview 
 
Throughout the preceding chapters, it has been demonstrated and discussed that the O1 
serogroup and El Tor biotype do not exclusively describe the lineage of V. cholerae causing 
current pandemic cholera. It is also clear that pathogenicity islands and virulence determinants 
once thought to be found solely in pandemic V. cholerae are not exclusively found in pandemic 
lineages of V. cholerae (Chapter 5). In spite of this, the pandemic 7PET lineage continues to 
present a considerably elevated public health threat relative to that of local or endemic V. 
cholerae, as has been shown previously [189] and is exemplified by the Argentinian case study 
presented in Chapter 3. The biological basis of this phenomenon remains unclear. 
 
Although V. cholerae can be compared and contrasted in terms of their gene complements (as 
has been done throughout this thesis), it is also necessary to consider functional differences 
between these bacteria. One approach that can be applied to understanding the biological 
differences between related bacteria is that of comparative transcriptomics, whereby bacteria 
are cultured under similar conditions and the expression profile of the genes they harbour is 
determined. Such experiments provide a snapshot of gene expression under appropriately-
controlled in vitro (or in vivo) growth conditions.  
 
Comparative transcriptomic experiments have been carried out in V. cholerae since the 
development of microarrays using the sequence of the N16961 reference genome [59]. 
Microarray-based experiments rely on the hybridisation of fluorescently-labelled cDNA, 
generated from total RNA extracted from V. cholerae grown under specific conditions, to spots 
of complementary ssDNA corresponding to genes on glass microarray slides. Experiments 
using microarrays have been used to characterise V. cholerae gene expression in vitro [468] 
and during infection [128], in the hyperinfectious state post-shedding [469], and to define 
regulons by comparing isogenic knock-outs in master regulators to a wild-type background 
[129]. This approach has also been used to characterise differences in gene expression between 
classical and El Tor biotype isolates (O395 and A1552, respectively) [470].  
 
Over time, transcriptomic experiments shifted from microarray-based experiments to those 
employing RNA-seq, the use of next-generation sequencing to sequence quantitatively cDNA 
produced from V. cholerae. These experiments have included exploring bacterial gene 
expression during infection [471] and defining gene regulation networks [472, 473]. Recent 
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work has sought to collate previously-published V. cholerae gene expression studies for the 
purposes of meta-analyses [474]. By sequencing transcripts from the bacterium, RNA-seq also 
has the advantage of being able to monitor changes in expression of small RNAs (sRNAs) 
(e.g., [475]),  and other elements that microarray experiments cannot capture. It is important to 
note that the majority of transcriptomic experiments in V. cholerae have made use of a small 
number of laboratory strains. These include the 7PET strains N16961 and A1552, and the 
Classical strain O395.  
 
In this chapter, I describe pilot experiments designed to optimise RNA-seq analysis and 
experiments for use under CL3 conditions. As mentioned in section 4.1, V. cholerae is 
classified as a bioterrorism agent under ATCSA Schedule 5. The Schedule 5-compliant 
laboratories at WSI operate at CL3, which imposes considerable constraint on the scale and 
scope of experimental work on V. cholerae. Therefore, preliminary experiments were 
important to optimise RNA isolation protocols under these containment conditions. As part of 
establishing these methodologies, I performed a transcriptomic experiment designed to explore 
the variation in gene expression of eight V. cholerae across multiple growth conditions, chosen 
to represent multiple lineages and genotypes of V. cholerae. I present the rationale for choosing 
these isolates, which was principally to determine whether pandemic and non-pandemic V. 
cholerae O1 exhibit different patterns of gene expression. I highlight a number of these results 
which are amenable to future study, and discuss how these follow-up experiments might be 
performed and what they might tell us about V. cholerae biology.  
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6.2 – Specific aims 
 
In this final chapter, I aimed to: 
 
1. Optimise experimental methods for CL3 operations by comparing the transcriptomes 
of Classical and 7PET V. cholerae grown under identical conditions, and compare the 
lists of differentially-expressed genes to those identified in previous studies, 
2. Select rationally a total of eight live V. cholerae isolates suitable for transcriptomic 
comparisons, and 
3. Execute a large pilot experiment to compare gene expression across eight V. cholerae, 
and to carry out an initial analysis of the resulting data.  
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6.3 – Results 
 
6.3.1 – Methods optimisation and initial transcriptomic studies 
 
Initial experiments were carried out in order to optimise transcriptomic methodologies for use 
in our CL3 laboratory. These experiments were also carried out in order to assess (i) the quality 
of RNA produced by our extraction protocol, (ii) the reproducibility within an experiment 
carried out under CL3 conditions, and (iii) the degree to which transcriptomic data generated 
using the live isolates at our disposal were concordant with previously-published datasets. In 
preliminary experiments, biological triplicate 25 ml cultures of V. cholerae were grown to an 
OD600 of 0.55 in LB liquid media at a defined temperature (either 30 or 37 ˚C) in baffled flasks 
with aeration (180 rpm). The OD600 of each culture was measured hourly. Once the target OD600 
was reached, bacteria were collected from the culture by centrifugation, and the cell pellet 
frozen immediately at -80 ˚C. Total RNA was then extracted from cell pellets (details set out 
in Methods, section 2.2.16). This methodology is also outlined in Figure 6.1. 
 
 
Figure 6.1 – Overview of RNA-seq experimental methodology for pilot experiment. All manipulations with 
the exception of culture incubation were performed inside a Class II MSC.  
 
As well as assessing whether intact and sequence-able RNA could be isolated in the CL3 
laboratory, this experiment aimed to determine whether differences in gene expression could 
be detected between a 7PET and a Classical culture grown to the same density. Cultures of 
bacteria were grown at both 37 ˚C and 30 ˚C, to assess the influence of temperature on gene 
expression in a strain, and whether these differences were similar or different across strains.  
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6.3.2 - RNA integrity and sequencing 
 
Prior to submitting extracted RNA for rRNA depletion, library preparation and sequencing, the 
integrity of extracted RNA was assessed both by gel electrophoresis and by analysis on an 
Agilent Bioanalyser 2100 (Methods, section 2.2.17; data not shown). Only intact RNA samples 
were used for library construction; any which appeared to be degraded were discarded. 
Following the depletion of rRNA, strand-specific library preparation was performed and 
libraries were sequenced on one Illumina HiSeq 4000 lane. All of the samples for this 
experiment were batched together and sequenced on the same HiSeq lane, aiming to produce 
at least 10 million reads per sample. Details of total numbers of reads per sample, and the 
number of reads mapped to the N16961 genome sequence, are listed in Table 6.1 (see section 
2.1.18 for computational details). Briefly, sequencing reads were mapped to the sequences of 
chromosomes 1 and 2 separately, gene expression was quantified, and differential gene 
expression analysis was performed using the Rockhopper package.  
 
Sample ID Strain Condition 
Number of 
reads 
Reads mapped 
Chr1 
Reads mapped 
Chr2 
25900_7#1 7PET 37 ˚C, rep 1 14,092,482 12,200,919 (87%) 353,889 (3%) 
25900_7#2 7PET 37 ˚C, rep 2 16,353,593 14,384,549 (88%) 283,329 (2%) 
25900_7#3 7PET 37 ˚C, rep 3 22,897,140 19,977,810 (87%) 239,410 (1%) 
25900_7#4 Classical 37 ˚C, rep 1 13,233,279 11,288,322 (85%) 334,318 (3%) 
25900_7#5 Classical 37 ˚C, rep 2 18,441,714 15,733,617 (85%) 516,216 (3%) 
25900_7#6 Classical 37 ˚C, rep 3 17,065,558 14,213,502 (83%) 730,105 (4%) 
25900_7#19 7PET 30 ˚C, rep 1 16,724,553 12,862,968 (77%) 2,058,588 (12%) 
25900_7#20 7PET 30 ˚C, rep 2 25,965,794 20,038,037 (77%) 3,092,668 (12%) 
25900_7#21 7PET 30 ˚C, rep 3 26,594,182 21,059,504 (79%) 2,645,698 (10%) 
25900_7#22 Classical 30 ˚C, rep 1 27,133,194 21,954,557 (81%) 1,552,086 (6%) 
25900_7#23 Classical 30 ˚C, rep 2 20,970,321 16,216,919 (77%) 1,659,157 (8%) 
25900_7#24 Classical 30 ˚C, rep 3 22,291,274 18,175,615 (82%) 1,026,833 (5%) 
Table 6.1 – Lane IDs and summary statistics for RNA sequenced in pilot experiment. All reads mapped to 
the N16961 reference genome, accession # GCA_000006745.1. Strains chosen were MJD1402 (7PET) and 
MJD1404 (Classical); details presented in Table 6.6.  
 
6.3.3 – Identification of differentially-expressed genes in pilot data 
 
Previous studies of inter-biotype differential gene expression had been performed using 
microarray technologies, and had quantified differential gene expression for V. cholerae 
cultured in M9 + NRES minimal media at 30 ˚C to an OD600 of 0.65 [470]. Supplementation 
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of minimal media with asparagine, arginine, glutamate and serine (NRES) is required to induce 
expression of TCP and CT in minimal media [476]. This previous work had compared gene 
expression in the O395 strain of Classical lineage V. cholerae to that of A1552, a 7PET LAT-
1 isolate from 1992 (detailed in section 3.4.5). Although the target OD600 and growth 
temperature in our pilot experiment was similar to those used by Beyhan et al., the growth 
media were not identical.  
 
Therefore, the first analysis carried out using these data aimed to identify genes which were 
differentially-expressed at 30 ̊ C between 7PET and Classical V. cholerae. The fact that Beyhan 
and colleagues had performed a similar experiment using non-identical reference strains 
provided an important benchmark for our experiment, allowing for any expression differences 
that might be expected from the literature to be identified. Genes were determined to be 
differentially expressed if the log2 fold-change of expression between conditions was greater 
than or equal to 2, or less than or equal to -2, and that the q-value for that calculation was less 
than 0.01 (to account for multiple testing). Genes which met these criteria are listed in Tables 
6.2 and 6.3 - triplicate data have been normalised to produce average expression values.  
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Gene ID Product 
Expression
.7PET 
Expressi
on.Cl pValue qValue 
log2Ra
tio 
Chromosome 1 
VC_0107 hypothetical protein 1323 209 9.07E-33 1.79E-31 
2.6622
3821 
VC_0163 conserved hypothetical protein 237 39 5.23E-15 7.21E-14 
2.6033
4103 
VC_0181 conserved hypothetical protein 339 1 0 0 
8.4051
4146 
VC_0205 hypothetical protein 141 0 0 0 Inf 
VC_0285 
4-hydroxy-2-oxoglutarate aldolase/2-deydro-3-
deoxyphosphogluconate aldolase 146 8 2.09E-122 6.04E-121 
4.1898
2456 
VC_0471 SprT protein, putative 91 9 6.80E-27 1.26E-25 
3.3378
6964 
VC_0502 type IV pilin, putative 707 1 0 0 
9.4655
664 
VC_0512 methyl-accepting chemotaxis protein 331 0 0 0 Inf 
VC_0707 hypothetical protein 1298 45 0 0 
4.8502
2157 
VC_0732 transcriptional regulator, LysR family 90 14 7.19E-19 1.12E-17 
2.6844
9817 
VC_0771 vibriobactin-specific isochorismatase 224 31 1.09E-43 2.45E-42 
2.8531
5861 
VC_0775 vibriobactin synthesis protein, putative 4864 460 1.18E-239 4.13E-238 
3.4024
3746 
VC_0867 hypothetical protein 132 23 4.96E-08 4.92E-07 
2.5208
3216 
VC_0990 transcriptional activator RfaH, putative 814 69 1.29E-154 4.01E-153 
3.5603
6053 
VC_1008 sodium-type flagellar protein MotY 980 94 9.33E-201 3.10E-199 
3.3820
4909 
VC_1292 hypothetical protein 4296 714 2.68E-53 6.41E-52 
2.5889
9801 
VC_1455 transcriptional repressor RstR 96 0 0 0 Inf 
VC_1464 transcriptional repressor RstR 96 0 0 0 Inf 
VC_1616 glutaredoxin, putative 290 15 2.93E-114 8.38E-113 
4.2730
1849 
VC_1654 hypothetical protein 160 13 2.48E-38 5.32E-37 
3.6214
8838 
VC_1788 hypothetical protein 135 16 2.57E-34 5.16E-33 
3.0768
156 
VC_1822 PTS system, fructose-specific IIABC component 268 32 7.56E-104 2.13E-102 
3.0660
8919 
VC_1824 
PTS system, nitrogen regulatory IIA component, 
putative 900 140 5.47E-72 1.39E-70 
2.6844
9817 
VC_1828 conserved hypothetical protein 1246 77 0 0 
4.0163
0181 
VC_1829 hypothetical protein 455 62 7.41E-20 1.19E-18 
2.8755
2642 
VC_1970 benzoate transport protein 1354 92 0 0 
3.8794
5007 
VC_2147 hypothetical protein 173 28 1.23E-15 1.74E-14 
2.6272
7331 
VC_2324 transcriptional regulator, LysR family 96 4 5.67E-172 1.83E-170 
4.5849
625 
VC_2327 hypothetical protein 4128 205 0 0 
4.3317
4716 
VC_2328 hypothetical protein 260 25 7.67E-27 1.42E-25 
3.3785
1162 
VC_2329 
2,3,4,5-tetrahydropyridine-2-carboxylate N-
succinyltransferase 95 15 1.63E-21 2.75E-20 
2.6629
6501 
VC_2365 hypothetical protein 1352 190 1.52E-85 4.11E-84 
2.8310
2383 
VC_2509 hypothetical protein 93 8 2.01E-20 3.30E-19 
3.5391
5881 
VC_2534 magnesium transporter 216 27 4.18E-67 1.04E-65 3 
VC_2544 fructose-1,6-bisphosphatase 106 7 4.93E-110 1.40E-108 
3.9205
6553 
VC_2545 inorganic pyrophosphatase 566 27 0 0 
4.3897
7074 
VC_2563 hypothetical protein 73 12 2.25E-12 2.83E-11 
2.6048
6206 
VC_2608 ABC transporter, ATP-binding protein 176 20 1.56E-85 4.19E-84 
3.1375
0352 
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VC_2613 phosphoribulokinase 73 3 8.29E-207 2.78E-205 
4.6048
6206 
VC_2707 hypothetical protein 126 21 7.79E-09 8.09E-08 
2.5849
625 
VC_2759 fatty oxidation complex, beta subunit 143 20 1.30E-39 2.81E-38 
2.8379
4324 
VC_t038 tRNA-Met 186 15 5.27E-35 1.07E-33 
3.6322
6822 
VC_t068 tRNA-Leu 95 14 4.27E-09 4.57E-08 
2.7625
0069 
VC_0107 hypothetical protein 1323 209 9.07E-33 1.79E-31 
2.6622
3821 
VC_0163 conserved hypothetical protein 237 39 5.23E-15 7.21E-14 
2.6033
4103 
VC_0181 conserved hypothetical protein 339 1 0 0 
8.4051
4146 
VC_0205 hypothetical protein 141 0 0 0 Inf 
VC_0285 
4-hydroxy-2-oxoglutarate aldolase/2-deydro-3-
deoxyphosphogluconate aldolase 146 8 2.09E-122 6.04E-121 
4.1898
2456 
VC_0471 SprT protein, putative 91 9 6.80E-27 1.26E-25 
3.3378
6964 
VC_0502 type IV pilin, putative 707 1 0 0 
9.4655
664 
VC_0512 methyl-accepting chemotaxis protein 331 0 0 0 Inf 
VC_0707 hypothetical protein 1298 45 0 0 
4.8502
2157 
VC_0732 transcriptional regulator, LysR family 90 14 7.19E-19 1.12E-17 
2.6844
9817 
VC_0771 vibriobactin-specific isochorismatase 224 31 1.09E-43 2.45E-42 
2.8531
5861 
VC_0775 vibriobactin synthesis protein, putative 4864 460 1.18E-239 4.13E-238 
3.4024
3746 
VC_0867 hypothetical protein 132 23 4.96E-08 4.92E-07 
2.5208
3216 
VC_0990 transcriptional activator RfaH, putative 814 69 1.29E-154 4.01E-153 
3.5603
6053 
VC_1008 sodium-type flagellar protein MotY 980 94 9.33E-201 3.10E-199 
3.3820
4909 
VC_1292 hypothetical protein 4296 714 2.68E-53 6.41E-52 
2.5889
9801 
VC_1455 transcriptional repressor RstR 96 0 0 0 Inf 
VC_1464 transcriptional repressor RstR 96 0 0 0 Inf 
VC_1616 glutaredoxin, putative 290 15 2.93E-114 8.38E-113 
4.2730
1849 
VC_1654 hypothetical protein 160 13 2.48E-38 5.32E-37 
3.6214
8838 
VC_1788 hypothetical protein 135 16 2.57E-34 5.16E-33 
3.0768
156 
VC_1822 PTS system, fructose-specific IIABC component 268 32 7.56E-104 2.13E-102 
3.0660
8919 
VC_1824 
PTS system, nitrogen regulatory IIA component, 
putative 900 140 5.47E-72 1.39E-70 
2.6844
9817 
VC_1828 conserved hypothetical protein 1246 77 0 0 
4.0163
0181 
Chromosome 2 
VC_A0029 transcriptional regulator, putative 96 21 8.07E-08 4.60E-07 
2.1926
4508 
VC_A0077 sulfate permease family protein 188 40 2.35E-22 2.27E-21 
2.2326
6076 
VC_A0080 GGDEF family protein 360 38 8.89E-121 1.72E-119 
3.2439
2558 
VC_A0106 hypothetical protein 92 20 1.44E-10 9.50E-10 
2.2016
3386 
VC_A0224 hypothetical protein 92 11 2.21E-16 1.78E-15 
3.0641
3034 
VC_A0233 hypothetical protein 199 37 4.92E-10 3.10E-09 
2.4271
7125 
VC_A0296 hypothetical protein 4114 502 2.33E-70 3.91E-69 
3.0347
8252 
VC_A0298 hypothetical protein 76 8 3.62E-16 2.89E-15 
3.2479
2751 
VC_A0310 hypothetical protein 174 2 0 0 
6.4429
435 
VC_A0321 hypothetical protein 544 27 5.53E-113 1.00E-111 
4.3325
7534 
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VC_A0329 hypothetical protein 93 8 7.91E-25 7.88E-24 
3.5391
5881 
VC_A0335 hypothetical protein 4685 516 2.46E-91 4.32E-90 
3.1826
0608 
VC_A0348 conserved hypothetical protein 694 31 1.05E-272 2.79E-271 
4.4845
9554 
VC_A0352 hypothetical protein 2113 316 3.36E-31 3.87E-30 
2.7412
963 
VC_A0359 plasmid stabilization element ParE, putative 1014 245 3.39E-18 2.89E-17 
2.0492
04 
VC_A0362 hypothetical protein 7734 1691 2.26E-69 3.76E-68 
2.1933
381 
VC_A0369 hypothetical protein 361 28 1.33E-76 2.27E-75 
3.6885
001 
VC_A0370 hypothetical protein 224 22 7.34E-52 1.06E-50 
3.3479
233 
VC_A0424 hypothetical protein 250 44 1.02E-15 8.12E-15 
2.5063
5267 
VC_A0429 hypothetical protein 2316 562 2.15E-15 1.68E-14 
2.0429
9322 
VC_A0432 hypothetical protein 75 10 2.61E-14 2.02E-13 
2.9068
906 
VC_A0434 hypothetical protein 3343 756 1.28E-25 1.32E-24 
2.1446
8522 
VC_A0448 hypothetical protein 104 14 1.04E-16 8.55E-16 
2.8930
848 
VC_A0466 hypothetical protein 2733 11 0 0 
7.9568
3813 
VC_A0503 conserved hypothetical protein 682 130 1.95E-18 1.69E-17 
2.3912
6012 
VC_A0515 hypothetical protein 3054 292 3.24E-92 5.75E-91 
3.3866
5979 
VC_A0531 sensor histidine kinase 336 47 1.36E-62 2.12E-61 
2.8377
2857 
VC_A0620 thiosulfate sulfurtransferase SseA, putative 125 30 3.14E-09 1.93E-08 
2.0588
9369 
VC_A0685 
iron(III) ABC transporter, periplasmic iron-
compound-binding protein 203 27 6.24E-37 7.90E-36 
2.9104
4842 
VC_A0686 iron(III) ABC transporter, permease protein 95 14 9.12E-29 9.99E-28 
2.7625
0069 
VC_A0687 iron(III) ABC transporter, ATP-binding protein 113 4 2.36E-239 5.97E-238 
4.8201
7896 
VC_A0713 hypothetical protein 73 6 2.46E-19 2.23E-18 
3.6048
6206 
VC_A0732 conserved hypothetical protein 152 3 0 0 
5.6629
6501 
VC_A0777 conserved hypothetical protein 263 50 3.00E-18 2.58E-17 
2.3950
628 
VC_A0874 hypothetical protein 1126 103 8.28E-79 1.44E-77 
3.4504
9058 
VC_A0879 hypothetical protein 2435 30 0 0 
6.3428
1546 
VC_A0892 hypothetical protein 101 24 1.25E-05 5.95E-05 
2.0732
4898 
VC_A0928 hypothetical protein 219 36 1.33E-17 1.12E-16 
2.6048
6206 
VC_A0945 
maltose ABC transporter, periplasmic maltose-
binding protein 119 24 3.76E-14 2.89E-13 
2.3098
5526 
VC_A0978 
amino acid ABC transporter, periplasmic amino 
acid-binding protein, putative 100 21 1.25E-08 7.49E-08 
2.2515
3877 
VC_A0997 hypothetical protein 65 11 1.84E-12 1.32E-11 
2.5629
3619 
VC_A1007 hypothetical protein 66 5 2.86E-31 3.32E-30 
3.7224
6602 
VC_A1028 maltoporin 114 28 3.05E-10 1.95E-09 
2.0255
3509 
 
Table 6.2 - Genes upregulated in 7PET relative to Classical (i.e., log2FC ≥ 2) at 30 ˚C. Genes that were 
previously identified as differentially-regulated between 7PET and Classical isolates at 30 ˚C [470] are indicated 
in blue. Two copies of rstR are present in the N16961 reference genome (Figure 4.2).  
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Gene ID Product 
Expressi
on.7PET 
Expressi
on.Cl pValue qValue log2Ratio 
Chromosome 1 
VC_0160 hypothetical protein 91 659 2.70E-37 5.68E-36 -2.85634 
VC_0198 hypothetical protein 44 712 0 0 -4.0163018 
VC_0204 conserved hypothetical protein 30 236 3.28E-85 8.65E-84 -2.9757525 
VC_0292 hypothetical protein 40 168 7.63E-07 6.72E-06 -2.0703893 
VC_0294 hypothetical protein 21 147 1.05E-16 1.54E-15 -2.8073549 
VC_0314 hypothetical protein 843 7664 
1.49E-
150 4.59E-149 -3.184493 
VC_0388 hypothetical protein 50 964 
1.23E-
251 4.34E-250 -4.2690331 
VC_0458 conserved hypothetical protein 31 171 2.14E-17 3.21E-16 -2.4636562 
VC_0485 pyruvate kinase I 101 464 1.10E-25 2.01E-24 -2.1997695 
VC_0621 hypothetical protein 85 416 3.70E-31 7.10E-30 -2.2910488 
VC_0713 hypothetical protein 768 6871 
1.12E-
135 3.34E-134 -3.1613419 
VC_0765 conserved hypothetical protein 69 351 2.38E-22 4.12E-21 -2.3468028 
VC_0824 TagD protein 99 765 
5.50E-
127 1.60E-125 -2.9499593 
VC_0829 toxin co-regulated pilus biosynthesis protein B 16 78 3.73E-24 6.62E-23 -2.2854022 
VC_0830 toxin co-regulated pilus biosynthesis protein Q 2 132 0 0 -6.0443941 
VC_0831 
toxin co-regulated pilus biosynthesis outer 
membrane protein C 20 109 4.16E-37 8.69E-36 -2.4462562 
VC_0832 toxin co-regulated pilus biosynthesis protein R 9 195 
3.98E-
282 1.47E-280 -4.4374053 
VC_0833 toxin co-regulated pilus biosynthesis protein D 4 182 0 0 -5.5077946 
VC_0834 toxin co-regulated pilus biosynthesis protein S 9 340 0 0 -5.2394659 
VC_0835 toxin co-regulated pilus biosynthesis protein T 13 156 
2.64E-
177 8.59E-176 -3.5849625 
VC_0837 toxin co-regulated pilus biosynthesis protein F 43 1484 0 0 -5.1090106 
VC_0838 TCP pilus virulence regulatory protein 5 66 5.95E-80 1.53E-78 -3.722466 
VC_0839 leader peptidase TcpJ 16 83 7.15E-18 1.08E-16 -2.3750394 
VC_0841 accessory colonization factor AcfC 26 330 
2.31E-
225 7.89E-224 -3.6658825 
VC_0843 TagE protein 39 2266 0 0 -5.8605299 
VC_0844 accessory colonization factor AcfA 14 968 0 0 -6.1115083 
VC_0939 hypothetical protein 16 97 1.19E-18 1.83E-17 -2.5999128 
VC_1233 conserved hypothetical protein 15 68 7.53E-09 7.86E-08 -2.1805722 
VC_1290 DNA polymerase III, epsilon subunit, putative 49 211 5.01E-24 8.86E-23 -2.1063893 
VC_1324 hypothetical protein 595 60038 0 0 -6.6568424 
VC_1325 
galactoside ABC transporter, periplasmic D-
galactose/D-glucose-binding protein 12 365 0 0 -4.9267902 
VC_1326 hypothetical protein 491 37233 0 0 -6.244715 
VC_1327 
galactoside ABC transporter, ATP-binding 
protein 8 80 3.10E-85 8.23E-84 -3.3219281 
VC_1456 cholera enterotoxin, B subunit 34 465 
4.56E-
184 1.50E-182 -3.7736241 
VC_1457 cholera enterotoxin, A subunit 27 462 0 0 -4.0968615 
VC_1459 accessory cholera enterotoxin 78 455 5.86E-40 1.27E-38 -2.5443205 
VC_1462 RstB2 protein 70 435 1.68E-49 3.94E-48 -2.6355886 
VC_1463 RstA2 protein 24 101 2.61E-19 4.12E-18 -2.073249 
VC_1554 
glycerophosphoryl diester phosphodiesterase, 
putative 73 296 1.08E-28 2.04E-27 -2.0196288 
VC_1569 hypothetical protein 18 86 4.68E-09 4.98E-08 -2.2563398 
VC_1593 GGDEF family protein 91 665 8.83E-71 2.22E-69 -2.8694159 
VC_1650 collagenase 56 320 4.66E-41 1.02E-39 -2.5145732 
VC_1772 hypothetical protein 1016 13882 0 0 -3.7722431 
VC_1774 conserved hypothetical protein 14 82 9.52E-32 1.84E-30 -2.5501971 
VC_1776 N-acetylneuraminate lyase, putative 23 111 2.25E-23 3.93E-22 -2.2708539 
VC_1780 hypothetical protein 271 7815 0 0 -4.8498811 
VC_1825 transcriptional regulator 31 135 4.04E-21 6.77E-20 -2.1226193 
VC_2083 zinc ABC transporter, permease protein 88 482 3.96E-65 9.82E-64 -2.4534577 
VC_2306 hypothetical protein 1285 7697 7.70E-44 1.74E-42 -2.5825279 
VC_2495 hypothetical protein 59 634 3.80E-73 9.70E-72 -3.425696 
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VC_2752 hypothetical protein 54 794 
1.24E-
143 3.78E-142 -3.8781077 
Chromosome 2 
VC_A0086 hypothetical protein 53 559 
2.81E-
117 5.29E-116 -3.398784 
VC_A0087 hypothetical protein 118 824 3.51E-43 4.67E-42 
-
2.8038575 
VC_A0128 ribose ABC transporter, ATP-binding protein 6 39 7.45E-21 6.97E-20 
-
2.7004397 
VC_A0130 
ribose ABC transporter, periplasmic D-ribose-
binding protein 21 147 8.92E-42 1.16E-40 
-
2.8073549 
VC_A0163 conserved hypothetical protein 26 142 1.99E-12 1.41E-11 
-
2.4493074 
VC_A0480 hypothetical protein 287 1287 2.26E-29 2.49E-28 
-
2.1648894 
VC_A0544 conserved hypothetical protein 114 665 1.09E-65 1.75E-64 
-
2.5443205 
VC_A0582 conserved hypothetical protein 36 156 2.10E-13 1.57E-12 
-
2.1154772 
VC_A0587 conserved hypothetical protein 36 206 4.04E-20 3.76E-19 
-
2.5165755 
VC_A0665 C4-dicarboxylate transporter, anaerobic 108 536 3.06E-43 4.11E-42 
-
2.3112017 
VC_A0670 hypothetical protein 230 186143 0 0 
-
9.6605618 
VC_A0671 hypothetical protein 38 223 4.11E-51 5.87E-50 
-
2.5529724 
VC_A0707 regulatory protein UhpC, putative 15 60 3.02E-12 2.13E-11 -2 
VC_A0743 conserved hypothetical protein 7 451 0 0 
-
6.0096287 
VC_A0744 glycerol kinase 45 186 4.20E-28 4.54E-27 
-
2.0473057 
VC_A0750 hypothetical protein 237 5266 0 0 
-
4.4737486 
VC_A0857 hypothetical protein 13 137 1.51E-30 1.71E-29 
-
3.3975924 
VC_A0914 
hemin ABC transporter, permease protein, 
putative 30 157 1.96E-30 2.21E-29 
-
2.3877302 
VC_A0915 
hemin ABC transporter, ATP-binding protein 
HutD 340 1652 9.95E-36 1.22E-34 -2.280607 
VC_A0986 conserved hypothetical protein 88 474 1.99E-53 2.93E-52 
-
2.4293116 
VC_A0989 conserved hypothetical protein 139 1238 
2.78E-
185 6.31E-184 
-
3.1548545 
VC_A1003 hypothetical protein 344 1856 5.02E-51 7.12E-50 
-
2.4317162 
VC_A1041 phosphomannomutase, putative 373 1896 1.10E-27 1.17E-26 
-
2.3457114 
VC_A1062 putrescine-ornithine antiporter 9 36 7.85E-08 4.49E-07 -2 
 
Table 6.3 - Genes upregulated in Classical relative to 7PET (i.e., log2FC ≥ 2) at 30 ˚C. Genes that were 
previously identified as differentially-regulated between 7PET and Classical isolates at 30 ˚C [470] are indicated 
in blue. rRNA loci have been deleted from these results. 
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In each sample, the vast majority of reads mapped to loci on chromosome 1 rather than 
chromosome 2 (Table 6.1), suggesting that chromosome 1 is more transcriptionally active than 
chromosome 2. A total of 110 genes were found to be significantly elevated in expression in 
7PET relative to Classical (67 on chromosome 1 and 43 on chromosome 2) and 82 genes were 
significantly elevated in expression in Classical relative to 7PET (58 on chromosome 1, 24 on 
chromosome 2) (Tables 6.2, 6.3). However, the overlap between these results and those of 
Beyhan and colleagues was limited. Behyan et al identified 270 genes that were elevated in 
expression in their Classical strain relative to their El Tor strain, and 252 genes that were 
elevated in their El Tor strain relative to their Classical strain. However, of these genes, just 11 
overlap with our results from 7PET, and 16 overlap with our Classical isolate (Tables 6.2, 6.3). 
This may reflect strain-specific differences, the differences in growth media between the 
experiments, or differences in sensitivity between microarray-based analyses and this RNA-
seq experiment.  
 
In spite of this, it is notable that the differential expression of genes encoded by CTXφ and 
VPI-1 between 7PET and Classical was recapitulated in our experiment. This included the 
expression of the rstR gene in 7PET (encoding the RstR repressor of CTXφ genes, and under 
“normal growth conditions”, this is the only CTXφ protein produced by lysogens [99]) and the 
expression of ctxAB, tcp, and acf virulence genes in Classical cultures under these in vitro 
conditions. This is consistent with previous studies discussed in Chapter 5 (section 5.3.8.2) 
which showed that genetic determinants such as PaphA and PtcpPH mutations drive 
overexpression of the ToxT regulon in Classical bacteria in vitro. Further experimentation and 
validation is required to determine whether the genes that were differentially regulated in this 
study but not in that of Beyhan et al are due to differences in culture conditions between these 
studies, or whether they reflect strain-specific variation in gene expression.  
 
We then determined the sets of genes that were differentially expressed by these strains when 
cultured at 37 ˚C, rather than at 30 ˚C. All other experimental conditions were kept constant 
with the 30 ˚C experiment. The results are illustrated in volcano plots (Figure 6.2) and 
significantly differentially regulated genes are listed in Tables 6.4 and 6.5.  
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Figure 6.2 – Volcano plots comparing gene expression in 7PET and Classical strains at 37 ˚C. Genes that 
were not detected in one strain or the other are not represented in these plots (log2FC = infinite). Genes which 
passed statistical thresholds described in section 2.1.18 are listed in Tables 6.4 and 6.5.  
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Gene ID Product 
Expression.7
PET 
Expressio
n.Cl pValue qValue 
log2Rati
o 
Chromosome 1 
VC_0175 deoxycytidylate deaminase-related protein 185 0 0 0 Inf 
VC_0176 transcriptional regulator, putative 105 0 0 0 Inf 
VC_0179 hypothetical protein 72 0 0 0 Inf 
VC_0180 conserved hypothetical protein 87 0 0 0 Inf 
VC_0181 conserved hypothetical protein 172 1 0 0 
7.42626
4755 
VC_0182 hypothetical protein 212 0 0 0 Inf 
VC_0183 hypothetical protein 131 0 0 0 Inf 
VC_0184 hypothetical protein 223 0 0 0 Inf 
VC_0185 transposase, putative 204 0 0 0 Inf 
VC_0375 hypothetical protein 236 25 1.22E-46 4.07E-45 
3.23878
686 
VC_0465 tyrosyl-tRNA synthetase 81 7 3.61E-110 
1.50E-
108 
3.53249
5081 
VC_0471 SprT protein, putative 88 8 5.14E-74 1.90E-72 
3.45943
1619 
VC_0490 conserved hypothetical protein 133 0 0 0 Inf 
VC_0491 hypothetical protein 99 0 0 0 Inf 
VC_0492 hypothetical protein 120 0 0 0 Inf 
VC_0493 hypothetical protein 130 0 0 0 Inf 
VC_0495 conserved hypothetical protein 164 0 0 0 Inf 
VC_0496 hypothetical protein 77 0 0 0 Inf 
VC_0502 type IV pilin, putative 345 0 0 0 Inf 
VC_0503 conserved hypothetical protein 175 0 0 0 Inf 
VC_0504 hypothetical protein 1705 0 0 0 Inf 
VC_0505 hypothetical protein 966 1 0 0 
9.91587
9379 
VC_0506 hypothetical protein 529 0 0 0 Inf 
VC_0507 hypothetical protein 359 0 0 0 Inf 
VC_0508 hypothetical protein 143 0 0 0 Inf 
VC_0509 hypothetical protein 112 0 0 0 Inf 
VC_0510 DNA repair protein RadC-related protein 104 0 0 0 Inf 
VC_0512 methyl-accepting chemotaxis protein 119 0 0 0 Inf 
VC_0516 phage integrase 110 0 0 0 Inf 
VC_0707 hypothetical protein 369 10 0 0 
5.20554
8911 
VC_0712 hypothetical protein 175 6 7.54E-206 
3.43E-
204 
4.86624
8611 
VC_1225 hypothetical protein 719 141 8.88E-31 2.61E-29 
2.35029
6608 
VC_1452 RstC protein 256 0 0 0 Inf 
VC_1572 hypothetical protein 76 16 2.03E-13 4.89E-12 
2.24792
7513 
VC_1578 hypothetical protein 108 3 0 0 
5.16992
5001 
VC_1616 glutaredoxin, putative 143 19 4.80E-33 1.42E-31 
2.91194
3823 
VC_1648 hypothetical protein 633 109 8.75E-27 2.50E-25 
2.53787
7365 
VC_1970 benzoate transport protein 524 78 3.61E-90 1.41E-88 
2.74802
0783 
VC_2327 hypothetical protein 1983 59 0 0 
5.07082
5913 
VC_2446 tRNA nucleotidyltransferase 222 15 6.09E-242 
2.93E-
240 
3.88752
5271 
VC_2545 inorganic pyrophosphatase 172 34 1.31E-22 3.55E-21 
2.33880
1913 
VC_2566 conserved hypothetical protein 1526 339 2.36E-26 6.63E-25 
2.17039
7784 
VC_2611 hypothetical protein 1410 291 1.92E-25 5.32E-24 
2.27660
4104 
VC_2613 phosphoribulokinase 87 15 2.27E-26 6.43E-25 
2.53605
29 
Chromosome 2 
VC_A0028 hypothetical protein 179 39 2.31E-11 2.93E-10 
2.19841
356 
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VC_A0070 
phosphate ABC transporter, periplasmic 
phosphate-binding protein 68 6 2.91E-53 8.46E-52 
3.50250
034 
VC_A0080 GGDEF family protein 162 21 3.38E-55 1.00E-53 
2.94753
258 
VC_A0168 hypothetical protein 164 36 7.49E-12 9.64E-11 
2.18762
7 
VC_A0315 hypothetical protein 799 8 0 0 
6.64205
169 
VC_A0321 hypothetical protein 83 2 1.87E-133 
7.60E-
132 
5.37503
943 
VC_A0323 conserved hypothetical protein 148 0 0 0 Inf 
VC_A0328 
biphenyl-2,3-diol 1,2-dioxygenase III-related 
protein 75 16 1.84E-09 2.04E-08 
2.22881
869 
VC_A0335 hypothetical protein 957 233 1.12E-10 1.35E-09 
2.03818
897 
VC_A0338 conserved hypothetical protein 63 6 1.75E-49 4.74E-48 
3.39231
742 
VC_A0348 conserved hypothetical protein 263 49 5.93E-16 9.35E-15 
2.42420
915 
VC_A0349 RelB protein 2128 479 1.46E-25 3.09E-24 
2.15140
059 
VC_A0515 hypothetical protein 448 67 1.02E-22 2.07E-21 
2.74126
573 
VC_A0527 conserved hypothetical protein 95 19 7.37E-14 1.06E-12 
2.32192
809 
VC_A0531 sensor histidine kinase 131 32 1.42E-15 2.17E-14 
2.03342
3 
VC_A0553 hypothetical protein 223 24 4.55E-46 1.19E-44 
3.21593
74 
VC_A0660 hypothetical protein 85 20 2.55E-08 2.66E-07 
2.08746
284 
VC_A0673 transcriptional regulator, LacI family 373 65 2.15E-39 5.35E-38 
2.52066
401 
VC_A0686 iron(III) ABC transporter, permease protein 84 21 1.24E-14 1.86E-13 2 
VC_A0698 hypothetical protein 102 18 4.29E-12 5.62E-11 
2.50250
034 
VC_A0719 sensor histide kinase 124 30 5.04E-12 6.54E-11 
2.04730
571 
VC_A0774 UDP-glucose 4-epimerase 105 17 7.89E-21 1.54E-19 
2.62678
268 
VC_A0879 hypothetical protein 159 26 4.26E-19 7.83E-18 
2.61244
324 
VC_A0924 conserved hypothetical protein 66 14 4.92E-14 7.16E-13 
2.23703
92 
VC_A0926 transcriptional regulator, AraC/XylS family 76 11 9.84E-28 2.17E-26 
2.78849
589 
VC_A0946 
maltose/maltodextrin ABC transporter, ATP-
binding protein 81 4 4.12E-157 
1.87E-
155 4.33985 
VC_A0994 hypothetical protein 93 17 6.80E-16 1.06E-14 
2.45169
597 
VC_A1061 hypothetical protein 127 25 3.09E-13 4.42E-12 
2.34482
85 
 
Table 6.4 - Genes upregulated in 7PET relative to Classical (i.e., log2FC ≥ 2) at 37 ˚C. Note that pathogenicity 
islands VSP-1 (VC_0174-0186) and VSP-2 (VC_0489-0517) are present and transcribed in 7PET isolates, but not 
in Classical isolates. rRNA and tRNA loci have been deleted from these results.  
 
Gene ID Product 
Expression
.7PET 
Expression
.Cl pValue qValue 
log2Rati
o 
Chromosome 1 
VC_0198 hypothetical protein 76 457 4.80E-13 1.15E-11 
-
2.58812
2842 
VC_0733 hypothetical protein 16 90 4.35E-07 7.64E-06 
-
2.49185
3096 
VC_0837 toxin co-regulated pilus biosynthesis protein F 47 235 3.41E-10 7.35E-09 
-
2.32192
8095 
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VC_0843 TagE protein 84 588 2.90E-27 8.39E-26 
-
2.80735
4922 
VC_0844 accessory colonization factor AcfA 61 253 1.80E-06 2.91E-05 
-
2.05225
6237 
VC_0939 hypothetical protein 37 157 4.23E-05 
0.000572
03 
-
2.08516
7383 
VC_1324 hypothetical protein 118 5072 0 0 
-
5.42569
5981 
VC_1326 hypothetical protein 161 4439 0 0 
-
4.78510
2115 
VC_1456 cholera enterotoxin, B subunit 17 92 2.44E-08 4.69E-07 
-
2.43609
9115 
VC_1457 cholera enterotoxin, A subunit 23 114 4.96E-07 8.62E-06 
-
2.30932
8058 
VC_2040 conserved hypothetical protein 5 89 7.88E-72 2.84E-70 
-
4.15380
5336 
Chromosome 2 
VC_A0245 PTS system, IIA component 14 66 7.39E-05 
0.000514
08 
-
2.23703
92 
VC_A0292 hypothetical protein 8 77 4.50E-13 6.26E-12 
-
3.26678
65 
VC_A0293 hypothetical protein 13 129 1.85E-23 3.81E-22 
-
3.31078
75 
VC_A0365 hypothetical protein 6 100 1.36E-49 3.74E-48 
-
4.05889
37 
VC_A0398 hypothetical protein 7 89 2.35E-25 4.91E-24 
-
3.66837
85 
VC_A0512 
anaerobic ribonucleoside-triphosphate 
reductase activating protein 21 102 2.68E-05 
0.000206
81 
-
2.28010
79 
VC_A0662 CbbY family protein 14 76 7.44E-07 7.14E-06 
-
2.44057
26 
VC_A0670 hypothetical protein 281 23993 0 0 
-
6.41589
96 
VC_A0899 hypothetical protein 18 182 3.46E-18 6.15E-17 
-
3.33786
96 
 
Table 6.5 - Genes upregulated in Classical relative to 7PET (i.e., log2FC ≤ 2) at 37 ˚C. Genes encoded on 
VPI-1 and CTXφ were up-regulated (VC_0809-VC_0848 and VC_1457-1465, respectively). 
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Once again, virulence genes that are members of the ToxT regulon were expressed in Classical 
at a higher level than in 7PET at 37 ˚C, consistent with the observations made at 30 ˚C. This 
included ctxAB, tcp and acf genes, and the tagE gene. It was also evident that at 37 ˚C, genes 
encoded by VSP-1 and VSP-2 were transcribed in 7PET (Table 6.4). These genes are absent 
from Classical V. cholerae and from MJD1402 (Figures 5.7, 5.22), and therefore their 
expression was detected as having an infinite log2(expression ratio). These genes were not 
determined to be significantly transcribed at 30 ˚C (Tables 6.2, 6.3). We also noted that in spite 
of rRNA depletion using RiboZero (Methods, section 2.2.18), rRNA loci were identified as 
being transcribed at significantly different levels in 7PET and Classical isolates (data not 
shown). This indicates that RiboZero depletion in these samples, or across the experiment more 
generally, was not totally efficient, and emphasises that this is a depletion rather than an 
elimination step. 
 
6.3.4 – Effect of temperature on transcriptome of Classical and 7PET isolates 
 
Using these data, a comparison was then performed to identify genes that were differentially 
expressed at different temperatures (i.e., comparing the 37 ˚C and 30 ˚C results for one strain 
to one another). At 37 ˚C, 122 genes were upregulated in 7PET relative to Classical (81 on 
chromosome 1, 41 on chromosome 2) and 245 genes were upregulated in Classical relative to 
7PET (154 on chromosome 1, 91 on chromosome 2). At 30 ˚C, 93 genes were upregulated in 
7PET relative to Classical (59 on chromosome 1, 34 on chromosome 2), and 105 genes were 
upregulated in Classical relative to 7PET (67 on chromosome 1, 38 on chromosome 2). Sixty-
two genes were upregulated in 7PET relative to Classical at both 37 and 30 ˚C (42 on 
chromosome 1, 20 on chromosome 2), and 32 genes were upregulated in Classical relative to 
7PET at both temperatures (21 on chromosome 1, 11 on chromosome 2). These results are 
summarised in Figure 6.3; the raw data are not shown. 
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Figure 6.3 – Volcano plot comparing genes expressed at 37 and 30 ˚C in Classical and 7PET strains. Genes 
that were not detected in one strain or the other are not represented in these plots (log2FC = infinite).  
 
One of the most striking expression differences amongst these data was the effect of 
temperature on the expression of a subset of genes on VPI-2 in Classical V. cholerae (Figure 
6.4). These genes encode sialidase and other enzymes required to catabolise and metabolise 
sialic acids (section 1.2.5). This difference in transcription is illustrated in Figure 6.4, and 
although at 30 ˚C there is a general increase in transcription of genes on VPI-2 in the Classical 
isolate, these sialic acid metabolism genes were specifically and dramatically up-regulated in 
comparison to their surrounding genes (Figure 6.4). It is important to note that neither VPI-2 
nor the nanH/sialidase gene clusters are considered canonically to be part of the ToxR or ToxT 
regulons – therefore, further investigation is required to determine whether or not the up-
regulation of virulence genes and sialidase genes at 30 ˚C in Classical V. cholerae are due to 
mechanisms or signals that are independent of one another.  
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Figure 6.4 – Upregulation of sialic acid metabolisms genes in Classical V. cholerae at 30 ˚C relative to 37 
˚C. All lanes scaled identically. 
 
There was also evidence that genes involved in V. cholerae virulence were up-regulated in 
Classical cultures at 30 ˚C relative to 37 ˚C under these in vitro conditions, exemplified by the 
ctxAB operon (illustrated in Figure 6.5). This is consistent with previous reports that have 
shown that culturing Classical V. cholerae at 30 ˚C induces virulence gene expression and the 
production both of CT and TCP, relative to culturing at 37 ˚C [91, 476–478]. The biological 
reason for this difference remains unclear. However, this has previously been shown not to be 
the case for 7PET bacteria, and this observation was recapitulated in our experiment – 
temperature variation did not cause statistically significant differential expression of virulence 
genes in cultures of 7PET V. cholerae.  
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Figure 6.5 – Illustration of ctxAB transcript levels in Classical V. cholerae at 30 ˚C. The ctxAB operon is 
transcribed at very high levels at 30 ˚C in comparison to the levels at 37 ˚C. All lanes scaled identically.  
 
6.3.5 – Selection of isolates for transcriptomic experiments 
 
These initial experiments established that RNA-seq approaches could be used successfully with 
V. cholerae at WSI, and provided initial information about the practicalities of designing such 
experiments under CL3 conditions. Informed by these results, attention was then turned to 
extending these comparative transcriptomics methodologies to broader biological questions – 
specifically, investigating whether pandemic and non-pandemic lineages of V. cholerae O1 
displayed different transcriptomic signatures when cultured under identical growth conditions.  
 
Eight whole-genome-sequenced V. cholerae isolates were selected for comparative 
transcriptomic analysis. A number of factors were considered in choosing these isolates, 
including the complement of virulence genes and genomic islands which they harboured, their 
serogroup, the presence and absence of important promoter mutations, and their membership 
of key phylogenetic lineages. These factors were established in the course of the research 
described in Chapter 5. The strains are detailed in Table 6.6, and their phylogenetic position is 
indicated in Figure 6.6.  
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ID Other name Serogroup Details 
MJD1402 NCTC 10256 O1 7PET. El Tor biotype. Toxigenic. Hong Kong, 1961 
MJD1403 MJD474 O1 7PET. El Tor biotype. Toxigenic. UK traveller returning from 
Somalia, 2017 
MJD1404 NCTC 10732 O1 Classical. Classical biotype. 1952 
MJD1405 NCTC 5596 O1 Classical. Classical biotype. Pre-1939 
MJD1406 A213 O1 Gulf Coast. El Tor biotype. Non-toxigenic. Georgia, 1984 
MJD1407 A219 O1 Gulf Coast. El Tor biotype. Toxigenic. Georgia, 1986 
MJD1408 MJD462 Non-O1 Related to MS-6. UK traveller returning from Thailand, 2017 
MJD1409 NCTC 9422 O1 Non-7PET. El Tor biotype. Non-toxigenic. Pre-1955 
Table 6.6 – Strains used in transcriptomic experiments. Each of these glycerol stocks were prepared from a 
single well-isolated colony taken from the original culture of each strain that was frozen at WSI. Isolation dates 
listed where known. Live isolates also listed in Table 2.1.  
 
Two 7PET isolates were included, one from wave 1 (MJD1402), and a recent travel-associated 
isolate that phylogenetic analysis has shown to be a member of wave 3 (MJD1043). Wave 1 
corresponds to the initial outbreak of the seventh cholera pandemic, and wave 3 to more recent 
pandemic cholera [234]. Both of these isolates are toxigenic, and harbour ctxB3 and ctxB7 
alleles of ctxB, respectively. Phylogenetic analysis demonstrated that MJD1403 is a member 
of the same sub-lineage of 7PET as the isolates which caused the Yemeni cholera epidemic in 
2017 – these isolates also harbour the ctxB7 variant [309].   
 
Two Classical isolates, MJD1404 and MJD1405, were included in this study. Both of these are 
toxigenic V. cholerae accessioned by NCTC, and harbour the ctxB1 variant of ctxB, as expected 
for Classical V. cholerae [479]. These two isolates were included in the analysis because 
although MJD1404 is closely-related to the O395 reference sequence (Figure 5.10), MJD1405 
harbours a wild-type PtcpPH allele (Figure 5.20). Given the importance of this promoter mutation 
in virulence gene regulation (section 5.3.8.2), this second Classical isolate was included in the 
experiment.  
 
Two V. cholerae O1 (A213, A219) that were members of the Gulf Coast lineage were included 
in these experiments. These were selected because they were non-toxigenic and toxigenic, 
respectively. Both originated from Georgia, USA, and were isolated in the 1980s. Their 
genome sequences were first reported in 2011 [234]. Like other members of the Gulf Coast 
lineage, these isolates harbour VPI-1 and VPI-2, but lack VSP-1 and VSP-2 (section 5.3.5). 
They are related to, but not identical to, strain 2740-80, the commonly-described representative 
of the Gulf Coast lineage [54, 189, 234]  
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Although this experiment was designed to explore whether there were differences in gene 
expression between 7PET and other V. cholerae O1, a single non-O1 isolate was included in 
this analysis. This non-toxigenic isolate was included because it is very closely related to MS-
6, a toxigenic serogroup O1 isolate that harbours VPI-1, VPI-2, and VSP-1 [440]. MS-6 and 
MJD1408 are more closely related to Gulf Coast and MX-2 lineages, and to recent non-7PET 
Chinese V. cholerae O1 [396] than they are to 7PET. By including this isolate, similarities in 
gene expression to that of Gulf Coast isolates might be detectable which are independent of 
serogroup, though such candidate results would need to be validated.  
 
The eighth strain included in the experiments was NCTC 9422, one of the non-pandemic El 
Tor V. cholerae O1 isolates characterised in Chapter 5 (section 5.3.7.2). This isolate is non-
toxigenic and lacks all of the canonical V. cholerae pathogenicity islands, and was included to 
determine the transcriptional profile exhibited by a serogroup O1 biotype El Tor isolate that is 
more distantly related to 7PET than the Gulf Coast isolates.  
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Figure 6.6 – Phylogenetic position of the live isolates chosen for this chapter research. Lineages are denoted 
as previously described [189]. The phylogeny presented here is the same as that used to generate Figure 5.1. 
 
It is important to state that the chosen isolates do not represent the totality of V. cholerae 
diversity, and were chosen for the specific reasons outlined above. However, this multi-strain 
transcriptomic experiment was in itself a pilot experiment, designed to determine whether or 
not lineage-specific signatures of gene expression could be detected. This was also the 
maximum number of isolates that could be handled safely in one working day from a practical 
perspective. In order to assay gene expression across multiple strains within the constraints of 
working at CL3, cultures were harvested for RNA extraction after a defined period of time 
post-inoculation (3 hr), rather than by monitoring optical density for each culture and stopping 
the experiment for each strain once a defined OD600 value had been reached.  
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6.3.6 – Assaying differential gene expression in eight strains 
 
Eight V. cholerae isolates were cultured at 37 ˚C in LB media, under identical conditions to 
those described in section 6.3.1. After 3 hr, cultures were harvested and RNA was subsequently 
isolated from snap-frozen cell pellets. All other conditions were kept identical to that of the 
pilot experiment (section 6.3.1). Sequencing data were analysed in the same way as was carried 
out in the pilot experiment, and genes that were statistically significantly differentially 
expressed were determined, pairwise, between each of the eight strains. These data have been 
summarised in Table 6.7.  
 
  X 
  1402 1403 1404 1405 1406 1407 1408 1409 
Y
 
1402 - 40/0 67/30 110/1077 60/11 55/14 61/55 409/1110 
1403  - 64/96 102/1119 49/72 42/140 1/237 369/1129 
1404   - 5/1058 43/54 47/77 44/118 259/1129 
1405    - 1045/82 1038/73 999/96 204/127 
1406     - 0/3 22/42 335/1110 
1407      - 24/40 272/1102 
1408       - 348/1077 
1409        - 
Table 6.7 – Summary numbers for differentially-expressed genes across 8-way experiment. Number of genes 
up-regulated in isolate X relative to isolate Y / number of genes up-regulated in isolate Y compared to isolate X. 
Note that genes which were present in only one of these isolates were excluded from these aggregate numbers.  
 
It was immediately apparent that MJD1405 and MJD1409 exhibited drastically different gene 
expression profiles to all other isolates - over 1,000 genes were expressed in these isolates 
relative to all other isolates in the experiment (Table 6.7). Moreover, gene expression in these 
two isolates was much more similar between one another than between these and other isolates, 
(Table 6.7). To investigate this using a complementary approach, a principal component 
analysis (PCA) of normalised transcripts for all 24 samples was performed to summarise the 
variation across all of the samples (Figure 6.7). Principal component 1 (PC1), explaining 57.3% 
of the variation amongst these 24 isolates, clearly separated both MJD1405 and MJD1409 from 
the rest of the experiment, and also showed that the three replicates for each of these isolates 
were dissimilar to one another (Figure 6.7). The variability within these replicates is unlikely 
to be explained by differences in growth stage – all cultures were harvested at the same time 
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post-inoculation, and OD600 values for each replicate were similar at the time of harvesting. It 
was therefore decided not to compare the data from these two strains to the others collected in 
this experiment.  
 
 
Figure 6.7 – PCA comparing all of the 24 sequenced samples in this experiment. The biological replicates of 
MJD1405 and MJD1409 were substantially different to the other strains in the experiment and to one another, 
separated by PC1. Ellipses added manually for illustrative purposes (Adobe Illustrator). 
 
PCA was then repeated after excluding replicates of MJD1405 and MJD1409, on eighteen 
samples in total (Figure 6.8). In this analysis, PC1 (explaining 26.3% of the variance amongst 
these replicates) clearly separated Classical isolate MJD1404 from the rest of the samples. 
However, there appeared to be limited separation of samples along PC2; replicates of different 
strains were mixed amongst one another, and the three replicates of each strain did not cluster 
with one another in every instance. This was a surprising result, as it had been hypothesised 
that isolates would cluster on the basis of their genotype or membership of genetic lineage. 
This may reflect variation within the experiment, or that each culture had reached a slightly 
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different growth phase stage at the time of harvesting. This variability meant that we were 
conservative in selecting genes for subsequent consideration or discussion in the absence of 
confirmatory experiments.  
 
 
 
Figure 6.8 – PCA of the 18 samples remaining after the exclusion of MJD1405 and MJD1409. The biological 
replicates of MJD1404, the Classical isolate remaining in the experiment, were clearly separated from the other 
samples in the experiment by PC1 and PC2. However, the remaining samples failed to resolve into clearly-
separated groups based on their genotype.  
 
It was decided to interrogate these data to identify potentially novel biological insights. For 
example, to our knowledge, this experiment is the first to compare the transcriptome of Gulf 
Coast isolates to those of either Classical or 7PET bacteria. Amongst the two Gulf Coast 
strains, just three genes were significantly differentially expressed (Table 6.7). These were 
VC_1865, VC_A0540, and one putative CDS of unknown function. Of these, only the product 
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of VC_A0540 has a known or predicted function (formate transporter). This lack of variability 
is consistent with one of the aims of this experiment – namely, to determine whether strains 
within a V. cholerae lineage have transcriptional profiles more similar to the profiles of other 
lineages.  
 
We interrogated the genes differentially expressed amongst Gulf Coast and 7PET isolates 
(Table 6.7), and immediately found it to be striking that multiple components of T6SS were 
up-regulated in Gulf Coast isolates in comparison to 7PET isolates. The macromolecular T6SS 
is an apparatus that enables V. cholerae to prey upon bacteria and eukaryotes, by secreting and 
injecting effector proteins into target cells (e.g., [480, 481]). Three such systems are usually 
encoded by three gene clusters in V. cholerae, and among the genes involved in producing 
T6SS is hcp, which encodes the Hcp protein (VC_1415, VC_A0017), and is considered to be a 
‘hallmark’ of T6SS function [482]. Hcp is thought to form hexameric rings that constitute the 
tube through which T6SS secrete effectors [483]. These hcp genes, and other genes encoding 
structural components of V. cholerae T6SS, were substantially differentially expressed in these 
isolates, exemplified in Figure 6.9. Examining transcription profiles across all replicates and 
strains also showed that MJD1408 exhibited a similar hcp transcription profile to Gulf Coast 
isolates (to which it is most closely related phylogenetically, Figure 6.6).  
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Figure 6.9 – The hcp gene (VC_A0017) is upregulated in Gulf Coast and a related strain of V. cholerae 
(MJD1408) relative to all other strains in this experiment. All tracks scaled identically.  
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6.4 – Discussion  
 
The design of these comparative experiments, and these initial data, lay the groundwork for 
future analyses that should begin to describe lineage-specific as well as strain-specific 
differences in gene expression amongst V. cholerae. These data have shown that genes which 
are highly over- or under-expressed can be identified, and have also highlighted the 
homogeneity of expression profiles within lineages and other closely-related V. cholerae. 
Characterising aspects of gene regulation that are hallmarks of a V. cholerae lineage should 
add to our understanding of the biological differences between pandemic and non-pandemic 
bacterial lineages. It is also notable that these data recapitulated some, but not all, of the 
previously-published differences in gene expression between Classical and 7PET V. cholerae 
[470]. The genes that were detected in both studies were highly differential-expressed in both 
studies, and this suggests that in spite of the differences in growth conditions between these 
experiments, any fundamental and dramatic lineage-specific gene expression patterns can still 
be detected (such as the hyperactivation of the ToxR regulon in Classical isolates grown in 
vitro). This is reinforced by the fact that the strains used in both experiments were different, 
though members of the same phylogenetic lineages. This suggests that this approach of 
comparing gene expression across lineages has merit, and although variation between 
experiments might influence expression patterns, dramatically-different expression profiles 
may still be detectable.  
 
However, these data also highlight the risks inherent in working with diverse bacteria under 
defined in vitro conditions. Variation in growth rates, auxotrophies, and the presence of 
mutations that lower fitness in vitro are all factors which could introduce confounding variation 
into experiments, including the large experiment described in this chapter. Such variations 
might also explain why replicate cultures of MJD1405 and MJD1409 did not resemble one 
another in PCA analyses (Figure 6.7). Nevertheless, these data show that observations such as 
differential expression of virulence genes and T6SS can be made in such an experiment, 
provided the magnitude of the signal in question is large enough to be detected and to be 
trustworthy. Additional experiments such as qRT-PCR and the construction of targeted 
mutants will still be required to validate results from transcriptomic experiments. It is also 
evident from these data that using this approach, dramatic differences in gene expression can 
be detected between strains and across growth conditions (Figures 6.5, 6.9). This lends itself 
to the development of genetic tools, such as fusions between differentially-regulated promoters 
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(e.g., Phcp, PctxAB, PnanH) and reporter genes such as gfp and lux, with which to identify cis and 
trans-factors involved in these differences in gene expression. Using the large collection of 
genome sequences now available to us, the distribution of any such factors, or variants of 
factors, can be easily determined across the sequenced V. cholerae species, such as was carried 
out in sections 3.4.9, 4.3.11, 5.3.3, and 5.3.8.  
 
The stark differences in T6SS gene expression in multiple V. cholerae were particularly 
intriguing because it has been shown that the 2740-80 Gulf Coast strain of V. cholerae O1 
constitutively expresses T6SS in vitro, whereas in 7PET bacteria, suitable inductive signals 
must be present for T6SS to be expressed (e.g., [50, 484]). Similarly, the O37 isolate V52 
expresses T6SS constitutively in vitro, and this strain has been used to study the biology of 
T6SS in V. cholerae [485, 486]. Crucially, although 2740-80 has been shown to express T6SS 
constitutively, neither of the Gulf Coast strains used in this analysis are identical to 2740-80 
[234]. This strongly suggests that the constitutive expression of T6SS is a feature of the Gulf 
Coast lineage. Moreover, MJD1408 is closely related to the Gulf Coast lineage (Figure 6.6), 
suggesting that this T6SS expression phenotype might be common to other related lineages 
within V. cholerae. Testing of additional isolates, including those that belong to MX-2 or 
resemble the Chinese V. cholerae O1 that are related to the Gulf Coast lineage (section 5.3.1), 
may be warranted.  
 
The VasH protein [487], the sigma factor RpoN [485], exposure to chitin, and quorum sensing 
[50, 484] are all factors which regulate the expression of T6SS in V. cholerae. VasH is different 
between N16961 and V52, and ectopic expression of VasHV52 can drive aspects of T6SS 
expression in N16961, but is not sufficient to activate full T6SS killing activity in vitro [487]. 
The VasH protein sequence has also been shown to be variable across non-O1/O139 V. 
cholerae [488, 489]. The constitutive expression of T6SS is an area of current research and 
although the mechanisms by which this expression is regulated constitutively in V52 remain 
unclear, the activity of the WigKR two-component system has recently been implicated in 
governing T6SS regulation in V52 [490]. In future work, it will be necessary to determine the 
variation of vasH amongst these isolates and across the V. cholerae phylogeny, and to 
determine whether introducing variation in this or other regulators can elicit a constitutive 
expression phenotype in 7PET or Classical isolates (or, indeed, if abolishing these regulators’ 
activity in Gulf Coast isolates can confer a 7PET-like T6SS expression phenotype in vitro).  
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Future experiments such as these should consider the utilisation of alternative growth 
conditions, to characterise further any gene expression differences that are lineage-specific. 
For instance, LB liquid media was used in all of these experiments. It would be worthwhile 
using minimal media supplemented with relevant carbon sources (e.g., glucose, chitin, etc), 
both to determine the ability of chosen strains to grow on these media, and to assess whether 
these nutritional stresses provoke differences in the transcriptome of these isolates and 
lineages.  
 
It will also be important to repeat these analyses using a panel of strains that includes the 
reference V. cholerae strains that are used by molecular biologists, to ascertain with confidence 
whether the previous work published on those reference strains describes the transcriptional 
behaviour of those strains, or of lineages more generally. Similarly, it is important to recognise 
that the gene expression data calculated in these experiments were generated by mapping to 
the N16961 reference genome. Differences in the expression of genes present in other isolates 
that are absent from N16961 will not be detectable using this approach. Producing closed 
genome assemblies for each strain being assayed will be an important next step in the 
optimisation of these large-scale transcriptomic assays.  
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Chapter 7 
 
Summary and future directions 
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7.1 – Summary of thesis findings 
 
In this thesis, I have used a combination of in silico and in vitro approaches to increase our 
understanding of the differences between pandemic and non-pandemic lineages of Vibrio 
cholerae. The initial thesis aims (section 1.5) were to study the evolution of 7PET 
longitudinally and across a large geography, and to characterise the non-7PET V. cholerae 
present in a country during a pandemic, alongside an external introduction of 7PET. From that 
baseline, the thesis then set out to investigate further the diversity of non-epidemic and non-
7PET V. cholerae, and the functional differences between pandemic and non-pandemic 
lineages of V. cholerae O1. This involved the detailed investigation of single fully-assembled 
genome sequences for important bacterial isolates, the collective examination of large numbers 
of genomes, and the design and execution of transcriptomic experiments. 
 
In Chapter 3, I presented a study of Argentinian V. cholerae which has increased our 
understanding of how 7PET evolves, and does not evolve, following its introduction into a 
country and population that was naïve to pandemic cholera caused by 7PET. These findings 
have also been actionable, contributing to changes in public health policies in Argentina 
(Chapter 3). Very minimal change in 7PET was observed, in terms of SNV accumulation, gene 
gain/loss, and recombination, though important conclusions were drawn from the observed 
variation in Inaba/Ogawa serotype and genotype, and the potentially-misleading conclusions 
that might be drawn from looking at phenotypic serotype variation alone. The clonality of 
7PET contrasted dramatically with that of the non-7PET V. cholerae from Argentina that were 
included in this thesis research. Many of these bacteria were isolated from suspected cholera 
cases, and the roles of virulence determinants other than CTXφ, such as T3SS, remains to be 
investigated. These non-7PET V. cholerae present in Argentina throughout the cholera 
epidemic are proposed to represent the population of V. cholerae that are truly endemic to 
Argentina, which may or may not cause symptoms that resemble clinical cholera.  
 
In Chapter 4, I illustrated the insights that can be gleaned from the study of high-quality closed 
genome assemblies. I presented novel and unique aspects of the genome biology of recently-
isolated V. cholerae O139, such as the presence of multiple ctxB alleles in the same genome, 
and cross-chromosomal duplications of VSP-1. I also described a genome assembly for non-
toxigenic V. cholerae O139 which occupies an unusual position in the V. cholerae phylogeny. 
Furthermore, as part of developing methods for work with V. cholerae at CL3, I assembled a 
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closed genome assembly for NCTC 30, which we believe to be the world’s oldest publicly-
available non-O1 V. cholerae. Using this genome sequence alongside complementary 
experimental methods, I confirmed the presence of a functional β-lactamase in this isolate 
(which pre-dates the introduction of antimicrobials as therapeutics), as well as the presence of 
a T3SS-2β element, and provided plausible explanations for the absence of flagella in this 
strain.  
 
Following this detailed characterisation of closed V. cholerae genome sequences, I proceeded 
to analyse specific, relevant genotypes and phenotypes across a set of 646 highly-diverse V. 
cholerae (Chapter 5). These included virulence determinants, antimicrobial resistance genes, 
and determinants of V. cholerae O1 biotypes, which are relevant to clinicians, to molecular 
microbiologists, and to those who study V. cholerae genomics. These data reinforced a number 
of previous findings, including the fact that very few plasmid replicons were detectable 
amongst diverse V. cholerae as well as within 7PET, and that T3SS virulence determinants are 
increasingly common amongst these diverse isolates, both those of clinical and environmental 
origin. This work also led to the first sequence of an historical IncA/C2 plasmid devoid of 
antimicrobial or heavy-metal resistance genes. This backbone may represent an “ancestral” 
IncA/C2 plasmid, and future work to perform phylogenetics of the many IncA/C plasmids 
being sequenced from V. cholerae and other species would be worthwhile.  
 
These data also highlighted inconsistencies amongst previous observations that had been 
considered to be dogma in V. cholerae biology. For instance, I identified numerous examples 
of V. cholerae pathogenicity islands present in non-pandemic isolates and lineages. 
Canonically, these elements have been described to be unique to epidemic and pandemic 
lineages, and this observation emphasises the fact that as we sequence additional members of 
this species, our definition of these truisms and our understanding of whether a mobile element 
is a ‘marker’ for a lineage will need to be refined. Similarly, by studying historical El Tor 
biotype V. cholerae O1, I have shown that the phenotypes associated with the classical biotype, 
and the mutations leading to these phenotypes, collectively only describe the Classical lineage 
– the El Tor biotype is broadly distributed amongst diverse V. cholerae, irrespective of 
serogroup. These results highlighted and emphasised that biotyping reactions are of limited 
utility in modern studies of V. cholerae, suggesting that the microbiological resources invested 
in biotyping might be better employed in other ways. However, this is wholly understandable 
in the context of how our understanding of V. cholerae and of cholera has developed and 
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evolved since the bacterium was first observed by Pacini. As our understanding has evolved, 
and as technologies with which to study V. cholerae have improved from biochemistry to 
whole-genome sequencing, the resolution at which we understand this pathogen has grown. 
These refinements to our understanding mean that current cholera control strategies, such as 
those of the GTFCC, now have the opportunity to effect meaningful change to global health.  
 
In Chapter 6, I describe transcriptomic experiments designed and executed in order to 
characterise lineage-specific differences in gene expression amongst V. cholerae O1. These 
were pilot experiments, designed both to optimise transcriptomic methodologies for use in 
CL3, and to discern robust differences in gene expression across V. cholerae lineages. These 
experiments have provided novel results as well as recapitulating the results from previous 
studies, which used different bacterial strains. These include apparent lineage-specific 
differences in T6SS regulation, and lineage-specific temperature-mediated differential 
expression of virulence and pathogenicity genes. The work presented in this chapter also 
highlights the difficulties in working with heterogenous bacteria, and the need to balance 
optimal experimental design with realistic practical considerations.  
 
7.2 – Future directions 
 
Cholera is an ancient disease, which we have failed to control to date, although efforts to do so 
are ongoing. It is clear from this thesis research, as well as from a growing body of literature, 
that taking a broad approach to sequencing V. cholerae – i.e., expanding focus from the 
exclusive sequencing of epidemics – is generating a wealth of genomic diversity for future 
analysis. Although the data in this thesis has advanced our understanding of the V. cholerae 
species as discussed above and in previous chapters, they also highlight open questions in this 
research area, and lay the groundwork by which to investigate these questions. In future 
projects, sequencing and functional research must not only focus on members of 7PET, but 
also on environmentally- and clinically-isolated V. cholerae irrespective of their serogroup and 
toxigenicity. Efforts should be invested in carrying out comprehensive studies of the 
pangenome of this species as a whole, alongside functional assays to determine the 
transcriptomic, biochemical, and metabolic differences amongst diverse V. cholerae. Particular 
attention should be paid to the clade of diverse isolates highlighted throughout this thesis 
(Chapters 4, 5). It is only by adopting such an holistic approach, aiming to capture all V. 
cholerae including those that do not appear to cause disease, that we will amass sufficient 
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genomic data and biological material with which to explore the question of what enables 
pandemic lineages to cause pandemics. 
 
In future work, it will be important to determine the significance of the lack of genomic 
variation amongst 7PET. It is unknown whether this lack of variation be explained 
mechanistically, and whether this is due to a reduced ability, or reduced opportunities, to 
participate in HGT. It is also unknown whether the pandemic lineage has fixed advantageous 
phenotypes by reducing genomic variation. This is a particularly relevant consideration 
because the reasons why 7PET can spread rapidly and to cause global pandemics are still 
uncertain. Further functional research into this area will be required to explain this observation. 
Similarly, the apparent lack of plasmids amongst V. cholerae, even amongst diverse isolates 
(Chapter 5), should also be studied in more detail. It is unknown why IncA/C plasmids are one 
of the very few plasmids that this species appears to be able to maintain. It will also be 
important to pursue this research avenue without assuming that databases of plasmid replicons 
contain all known Vibrio plasmids – it might be that genomic analyses fail to identify V. 
cholerae plasmids because the Plasmidfinder database simply lacks the replicon sequences for 
plasmids found in this species. Coupling genome sequencing to wet-lab bacteriology, and 
functional studies of plasmid dynamics and diversity, will expand our knowledge of HGT 
mechanisms and potential within this species.  
 
The role of T3SS in disease mediated by V. cholerae is also a research area with great potential. 
Although we found in this thesis that many clinically-isolated V. cholerae encoded T3SS in the 
absence of other canonical virulence factors, causal links between these systems and pathology 
in patients have not yet been proven. Considerable opportunity exists to exploit the genome 
sequences generated in this thesis to characterise in detail the diversity of T3SS systems in 
silico, as well as to avail of having access to live isolates of multiple T3SS+ V. cholerae to 
study the regulation of these systems, their mobility amongst different Vibrio spp., and their 
functionality in models of pathogenesis.  
 
The potential to discover new aspects of V. cholerae biology using this holistic approach – 
studying V. cholerae beyond 7PET – is exemplified by the transcriptomic studies set out in this 
thesis (Chapter 6). However, it is important to bear in mind that although it is logical and 
plausible that transcriptomic responses to stresses and signals would be more similar amongst 
members of the same lineage than across lineages, this remains an hypothesis and must be 
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tested in vitro and in vivo. The work in this thesis has set the stage for subsequent experiments 
to be refined and optimised, to test these hypotheses, and to expand our understanding of the 
V. cholerae species beyond that of 7PET and Classical lineages.  
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Sequencing data produced as part of this PhD have been, or will be, released into the European 
Nucleotide Archive under accession numbers PRJEB14661, ERP110583, and ERP118963.  
 
Name Serogroup Serotype Source Isolation date Country 
CCBT0190 O1 Ogawa Clinical 05/05/1992 Argentina 
CCBT0192 O1 Ogawa Environmental 05/05/1992 Argentina 
CCBT0187 O1 Ogawa Clinical 05/05/1992 Argentina 
CCBT0194 O1 Ogawa Clinical 05/05/1992 Argentina 
CCBT0264 O1 Inaba Clinical 05/05/1992 Argentina 
CCBT0258 O1 Ogawa Clinical 20/06/1997 Argentina 
CCBT0243 O1 Ogawa Clinical 05/05/1992 Argentina 
CCBT0253 O1 Ogawa Clinical 21/04/1992 Argentina 
CCBT0212 O1 Ogawa Clinical 21/04/1992 Argentina 
CCBT0247 O1 Ogawa Clinical 05/05/1992 Argentina 
CCBT0245 O1 Ogawa Clinical 05/05/1992 Argentina 
CCBT0246 O1 Ogawa Clinical 21/04/1992 Argentina 
CCBT0256 O1 Ogawa Clinical 24/02/1992 Argentina 
CCBT0235 O1 Ogawa Clinical 01/04/1992 Argentina 
CCBT0262 O1 Ogawa Clinical 05/05/1992 Argentina 
CCBT0231 O1 Ogawa Clinical 10/02/1992 Argentina 
CCBT0232 O1 Ogawa Clinical 12/03/1992 Argentina 
CCBT0255 O1 Ogawa Clinical 01/04/1992 Argentina 
CCBT0172 O1 Ogawa Clinical 10/02/1992 Argentina 
CCBT0249 O1 Ogawa Clinical 05/05/1992 Argentina 
CCBT0233 O1 Ogawa Clinical 01/04/1992 Argentina 
CCBT0062 O1 Ogawa Clinical 24/10/1992 Argentina 
CCBT0183 O1 Ogawa Clinical 05/05/1992 Argentina 
CCBT0189 O1 Ogawa Clinical 05/05/1992 Argentina 
CCBT0070 O1 Inaba Clinical 19/10/1992 Argentina 
CCBT0184 O1 Ogawa Clinical 05/05/1992 Argentina 
CCBT0071 O1 / Clinical 24/10/1992 Argentina 
CCBT0067 O1 Ogawa Clinical 19/10/1992 Argentina 
CCBT0257 O1 Ogawa Clinical 01/04/1992 Argentina 
CCBT0064 O1 Ogawa Clinical 01/09/1992 Argentina 
CCBT0345 O1 Ogawa Clinical 12/02/1993 Argentina 
CCBT0479 O1 Ogawa Clinical 03/03/1993 Argentina 
CCBT0097 O1 Ogawa Clinical 06/01/1993 Argentina 
CCBT0471 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0295 O1 Ogawa Clinical 22/01/1993 Argentina 
CCBT0379 O1 Ogawa Clinical 27/01/1993 Argentina 
CCBT0400 O1 Ogawa Clinical 22/01/1993 Argentina 
CCBT0450 O1 Ogawa Clinical 12/02/1993 Argentina 
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CCBT0317 O1 Ogawa Clinical 20/01/1993 Argentina 
CCBT0315 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0478 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0357 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0480 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0299 O1 Ogawa Clinical 22/01/1993 Argentina 
CCBT0477 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0390 / / Clinical 27/01/1993 Argentina 
CCBT0166 O1 Ogawa Clinical 22/12/1992 Argentina 
CCBT0224 O1 Ogawa Clinical 16/01/1993 Argentina 
CCBT0488 O1 Ogawa Environmental 20/01/1993 Argentina 
CCBT0340 O1 Ogawa Clinical 16/01/1993 Argentina 
CCBT0203 O1 Ogawa Clinical 26/03/1993 Argentina 
CCBT0461 O1 Ogawa Clinical 27/01/1993 Argentina 
CCBT0120 O1 Ogawa Clinical 06/01/1993 Argentina 
CCBT0396 O1 Ogawa Clinical 15/02/1993 Argentina 
CCBT0466 O1 Ogawa Clinical 27/01/1993 Argentina 
CCBT0098 O1 Ogawa Clinical 06/01/1993 Argentina 
CCBT0202 O1 Ogawa Clinical 15/03/1993 Argentina 
CCBT0341 O1 Ogawa Clinical 20/01/1993 Argentina 
CCBT0122 O1 Ogawa Clinical 13/01/1993 Argentina 
CCBT0123 O1 Ogawa Clinical 06/01/1993 Argentina 
CCBT0276 O1 Ogawa Clinical 08/03/1993 Argentina 
CCBT0418 O1 Ogawa Clinical 10/02/1993 Argentina 
CCBT0439 O1 Ogawa Clinical 27/01/1993 Argentina 
CCBT0388 O1 Ogawa Clinical 27/01/1993 Argentina 
CCBT0381 O1 Ogawa Clinical 27/01/1993 Argentina 
CCBT0473 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0428 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0423 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0424 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0285 O1 / Clinical 22/01/1993 Argentina 
CCBT0351 O1 Ogawa Clinical 05/02/1993 Argentina 
CCBT0132 O1 Ogawa Clinical 06/01/1993 Argentina 
CCBT0356 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0413 / / Clinical 27/01/1993 Argentina 
CCBT0175 O1 Ogawa Clinical 30/03/1993 Argentina 
CCBT0430 O1 Ogawa Clinical 05/02/1993 Argentina 
CCBT0292 O1 Ogawa Clinical 16/01/1993 Argentina 
CCBT0394 O1 Ogawa Clinical 27/01/1993 Argentina 
CCBT0436 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0318 O1 Ogawa Clinical 16/01/1993 Argentina 
CCBT0414 / / Clinical 27/01/1993 Argentina 
 
 264 
CCBT0337 O1 Ogawa Clinical 27/01/1993 Argentina 
CCBT0353 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0116 O1 Ogawa Clinical 06/01/1993 Argentina 
CCBT0442 O1 Ogawa Clinical 08/03/1993 Argentina 
CCBT0339 O1 Ogawa Clinical 16/01/1993 Argentina 
CCBT0213 O1 Ogawa Clinical 30/03/1993 Argentina 
CCBT0425 O1 Inaba Clinical 05/02/1993 Argentina 
CCBT0481 O1 Inaba Clinical 05/02/1993 Argentina 
CCBT0326 O1 Ogawa Clinical 16/01/1993 Argentina 
CCBT0144 O1 Ogawa Clinical 06/01/1993 Argentina 
CCBT0459 O1 Ogawa Clinical 08/03/1993 Argentina 
CCBT0308 O1 Ogawa Clinical 16/01/1993 Argentina 
CCBT0352 O1 Ogawa Clinical 08/03/1993 Argentina 
CCBT0321 O1 Ogawa Clinical 20/01/1993 Argentina 
CCBT0446 O1 Ogawa Clinical 05/02/1993 Argentina 
CCBT0261 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0327 O1 Ogawa Clinical 16/01/1993 Argentina 
CCBT0291 O1 Ogawa Clinical 16/01/1993 Argentina 
CCBT0226 O1 Ogawa Clinical 18/02/1993 Argentina 
CCBT0490 O1 Ogawa Clinical 20/01/1993 Argentina 
CCBT0393 O1 Ogawa Clinical 25/10/1993 Argentina 
CCBT0322 O1 Ogawa Clinical 20/01/1993 Argentina 
CCBT0294 O1 Ogawa Clinical 20/01/1993 Argentina 
CCBT0266 O1 Ogawa Clinical 20/01/1993 Argentina 
CCBT0323 O1 Ogawa Clinical 20/01/1993 Argentina 
CCBT0173 O1 Inaba Clinical 17/02/1992 Argentina 
CCBT0306 O1 Inaba Clinical 02/02/1993 Argentina 
CCBT0447 O1 Inaba Clinical 20/02/1996 Argentina 
CCBT0110 O1 Ogawa Clinical 01/12/1992 Argentina 
CCBT0432 O1 Ogawa Clinical 05/02/1993 Argentina 
CCBT0105 O1 Ogawa Clinical 28/12/1992 Argentina 
CCBT0163 O1 Ogawa Clinical 28/12/1992 Argentina 
CCBT0108 O1 Ogawa Clinical 25/11/1992 Argentina 
CCBT0333 O1 Ogawa Clinical 12/02/1993 Argentina 
CCBT0138 O1 Ogawa Clinical 13/01/1993 Argentina 
CCBT0376 O1 Ogawa Clinical 12/02/1993 Argentina 
CCBT0236 O1 Ogawa Clinical 13/01/1993 Argentina 
CCBT0278 O1 Ogawa Clinical 22/01/1993 Argentina 
CCBT0456 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0457 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0313 O1 Ogawa Clinical 22/01/1993 Argentina 
CCBT0148 O1 Ogawa Clinical 13/01/1993 Argentina 
CCBT0465 O1 Ogawa Clinical 12/02/1993 Argentina 
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CCBT0330 O1 Ogawa Clinical 22/01/1993 Argentina 
CCBT0154 O1 Ogawa Clinical 13/01/1993 Argentina 
CCBT0209 O1 Ogawa Clinical 30/03/1993 Argentina 
CCBT0085 O1 Inaba Clinical 09/04/1996 Argentina 
CCBT0050 O1 Inaba Clinical 24/04/1996 Argentina 
CCBT0089 O1 Inaba Clinical 03/06/1996 Argentina 
CCBT0055 O1 Inaba Clinical 03/06/1996 Argentina 
CCBT0088 O1 Inaba Clinical 30/05/1996 Argentina 
CCBT0052 O1 Inaba Clinical 03/06/1996 Argentina 
CCBT0095 O1 Inaba Clinical 03/06/1996 Argentina 
CCBT0047 O1 Inaba Clinical 06/06/1996 Argentina 
CCBT0057 O1 Inaba Clinical 06/06/1996 Argentina 
CCBT0083 O1 Inaba Clinical 06/06/1996 Argentina 
CCBT0051 O1 Inaba Clinical 28/05/1996 Argentina 
CCBT0059 O1 Inaba Clinical 28/02/1996 Argentina 
CCBT0041 O1 Inaba Clinical 03/06/1996 Argentina 
CCBT0048 O1 Inaba Clinical 28/05/1996 Argentina 
CCBT0046 O1 Inaba Clinical 03/06/1996 Argentina 
CCBT0075 O1 Inaba Clinical 03/06/1996 Argentina 
CCBT0487 O1 Ogawa Environmental 17/02/1994 Argentina 
CCBT0486 O1 Ogawa Clinical 15/02/1994 Argentina 
CCBT0003 O1 Ogawa Clinical 30/12/1996 Argentina 
CCBT0049 O1 Ogawa Clinical 03/06/1996 Argentina 
CCBT0091 O1 Ogawa Clinical 28/05/1996 Argentina 
CCBT0056 O1 Ogawa Clinical 03/06/1996 Argentina 
CCBT0092 O1 Ogawa Clinical 03/06/1996 Argentina 
CCBT0035 O1 Ogawa Clinical 06/01/1997 Argentina 
CCBT0017 O1 Ogawa Clinical 06/01/1997 Argentina 
CCBT0019 O1 Ogawa Clinical 06/01/1997 Argentina 
CCBT0010 O1 Inaba Clinical 10/02/1997 Argentina 
CCBT0022 O1 Ogawa Clinical 07/02/1997 Argentina 
CCBT0039 O1 Ogawa Clinical 07/02/1997 Argentina 
CCBT0040 O1 Ogawa Clinical 23/01/1997 Argentina 
CCBT0023 O1 Ogawa Clinical 07/02/1997 Argentina 
CCBT0029 O1 Ogawa Clinical 06/01/1997 Argentina 
CCBT0369 O1 Ogawa Clinical 21/01/1997 Argentina 
CCBT0014 O1 Ogawa Clinical 13/01/1997 Argentina 
CCBT0380 O1 Ogawa Clinical 07/02/1997 Argentina 
CCBT0028 O1 Ogawa Clinical 07/02/1997 Argentina 
CCBT0080 O1 Inaba Clinical 03/06/1996 Argentina 
CCBT0372 O1 Ogawa Clinical 21/01/1997 Argentina 
CCBT0373 / / / / Argentina 
CCBT0012 O1 Ogawa Clinical 08/11/1996 Argentina 
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CCBT0009 O1 Ogawa Clinical 13/03/1997 Argentina 
CCBT0037 O1 Ogawa Clinical 07/02/1997 Argentina 
CCBT0363 O1 Ogawa Clinical 21/01/1997 Argentina 
CCBT0002 O1 Ogawa Clinical 21/01/1997 Argentina 
CCBT0006 O1 Ogawa Clinical 13/01/1997 Argentina 
CCBT0032 O1 Ogawa Clinical 23/01/1997 Argentina 
CCBT0031 O1 Ogawa Clinical 07/02/1997 Argentina 
CCBT0013 O1 Ogawa Clinical 23/01/1997 Argentina 
CCBT0368 O1 Ogawa Clinical 07/02/1997 Argentina 
CCBT0364 O1 Ogawa Clinical 07/02/1997 Argentina 
CCBT0015 O1 Ogawa Clinical 07/02/1997 Argentina 
CCBT0021 / / / / Argentina 
CCBT0367 O1 Ogawa Clinical 23/01/1997 Argentina 
CCBT0374 O1 Ogawa Clinical 07/02/1997 Argentina 
CCBT0034 O1 Ogawa Clinical 07/02/1997 Argentina 
CCBT0016 O1 Ogawa Clinical 08/11/1996 Argentina 
CCBT0024 O1 Ogawa Clinical 07/02/1997 Argentina 
CCBT0030 O1 Ogawa Clinical 07/02/1997 Argentina 
CCBT0499 / / / / Argentina 
CCBT0365 O1 Ogawa Clinical 08/11/1996 Argentina 
CCBT0366 O1 Ogawa Clinical 08/11/1996 Argentina 
CCBT0371 O1 Ogawa Clinical 08/11/1996 Argentina 
CCBT0001 O1 Ogawa Clinical 07/02/1997 Argentina 
CCBT0038 O1 Ogawa Clinical 07/02/1997 Argentina 
CCBT0025 O1 Ogawa Clinical 07/02/1997 Argentina 
CCBT0036 O1 Ogawa Clinical 07/02/1997 Argentina 
CCBT0005 O1 Ogawa Clinical 23/01/1997 Argentina 
CCBT0011 / / / / Argentina 
CCBT0004 O1 Ogawa Clinical 23/01/1997 Argentina 
CCBT0027 O1 Ogawa Clinical 23/01/1997 Argentina 
CCBT0498 O1 Inaba Clinical 04/03/1996 Argentina 
CCBT0100 O1 Ogawa Clinical 13/11/1992 Argentina 
CCBT0103 O1 Ogawa Clinical 25/11/1992 Argentina 
CCBT0111 O1 Ogawa Clinical 25/11/1992 Argentina 
CCBT0104 O1 Ogawa Clinical 25/11/1992 Argentina 
CCBT0114 O1 Ogawa Clinical 25/11/1992 Argentina 
CCBT0331 O1 Ogawa Clinical 20/01/1993 Argentina 
CCBT0107 O1 Ogawa Clinical 25/11/1992 Argentina 
CCBT0409 O1 Ogawa Clinical 22/02/1993 Argentina 
CCBT0159 O1 Ogawa Clinical 28/12/1992 Argentina 
CCBT0164 O1 Ogawa Clinical 22/12/1992 Argentina 
CCBT0389 O1 Ogawa Clinical 12/02/1993 Argentina 
CCBT0272 O1 Ogawa Clinical 20/01/1993 Argentina 
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CCBT0199 O1 Ogawa Clinical 21/04/1992 Argentina 
CCBT0312 / / Clinical 28/01/1993 Argentina 
CCBT0489 O1 Ogawa Environmental 17/01/1994 Argentina 
CCBT0161 non-O1 / Environmental 01/12/1992 Argentina 
CCBT0344 O1 Ogawa Clinical 20/01/1993 Argentina 
CCBT0251 O1 Ogawa Clinical 21/04/1992 Argentina 
CCBT0470 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0463 O1 Ogawa Clinical 18/02/1993 Argentina 
CCBT0415 O1 Ogawa Clinical 22/02/1993 Argentina 
CCBT0483 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0283 O1 Ogawa Clinical 20/01/1993 Argentina 
CCBT0426 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0069 non-O1 / Environmental 13/11/1992 Argentina 
CCBT0416 O1 Ogawa Clinical 12/02/1993 Argentina 
CCBT0441 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0347 O1 Ogawa Clinical 27/01/1993 Argentina 
CCBT0410 O1 Ogawa Clinical 18/02/1993 Argentina 
CCBT0305 O1 Ogawa Clinical 20/01/1993 Argentina 
CCBT0375 O1 Ogawa Clinical 18/02/1993 Argentina 
CCBT0150 non-O1 / Environmental 29/12/1992 Argentina 
CCBT0383 O1 Ogawa Clinical 18/02/1993 Argentina 
CCBT0217 O1 Ogawa Clinical 20/01/1993 Argentina 
CCBT0128 O1 Ogawa Clinical 06/01/1993 Argentina 
CCBT0421 O1 Ogawa Clinical 22/02/1993 Argentina 
CCBT0109 O1 Ogawa Clinical 22/12/1992 Argentina 
CCBT0259 O1 Ogawa Clinical 06/01/1993 Argentina 
CCBT0160 O1 Ogawa Clinical 28/12/1992 Argentina 
CCBT0165 O1 Ogawa Clinical 22/12/1992 Argentina 
CCBT0384 O1 Ogawa Clinical 12/02/1993 Argentina 
CCBT0408 O1 Ogawa Clinical 22/02/1993 Argentina 
CCBT0336 O1 Ogawa Clinical 27/01/1993 Argentina 
CCBT0482 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0358 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0434 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0121 O1 Ogawa Clinical 06/01/1993 Argentina 
CCBT0127 O1 Ogawa Clinical 13/01/1993 Argentina 
CCBT0143 O1 Ogawa Clinical 13/01/1993 Argentina 
CCBT0286 non-O1 / Clinical 18/03/1996 Argentina 
CCBT0152 O1 Ogawa Environmental 19/01/1993 Argentina 
CCBT0147 O1 Ogawa Clinical 13/01/1993 Argentina 
CCBT0124 O1 Ogawa Clinical 13/01/1993 Argentina 
CCBT0125 O1 Ogawa Clinical 13/01/1993 Argentina 
CCBT0359 O1 Ogawa Clinical 02/03/1993 Argentina 
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CCBT0469 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0401 O1 Ogawa Clinical 18/02/1993 Argentina 
CCBT0449 O1 Ogawa Clinical 02/03/1993 Argentina 
VC005 non-O1 / Environmental 13/11/1992 Argentina 
CCBT0454 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0329 O1 Ogawa Clinical 20/01/1993 Argentina 
CCBT0451 O1 Ogawa Clinical 18/02/1993 Argentina 
CCBT0134 O1 Ogawa Environmental 19/01/1993 Argentina 
CCBT0476 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0241 O1 Ogawa Clinical 05/05/1992 Argentina 
CCBT0239 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0185 O1 Ogawa Environmental 21/04/1992 Argentina 
CCBT0349 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0182 O1 Ogawa Clinical 26/03/1993 Argentina 
CCBT0370 O1 Ogawa Environmental 10/05/1993 Argentina 
CCBT0468 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0265 O1 Ogawa Clinical 20/01/1993 Argentina 
CCBT0474 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0279 O1 Ogawa Clinical 22/01/1993 Argentina 
CCBT0435 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0271 O1 Ogawa Clinical 21/04/1992 Argentina 
VC007 non-O1 / Environmental 13/11/1992 Argentina 
CCBT0201 O1 Ogawa Clinical 21/04/1992 Argentina 
CCBT0215 O1 Ogawa Clinical 21/04/1992 Argentina 
CCBT0270 O1 Ogawa Clinical 22/01/1993 Argentina 
CCBT0404 O1 Ogawa Clinical 18/02/1993 Argentina 
CCBT0126 O1 Ogawa Environmental 19/01/1993 Argentina 
CCBT0142 O1 Ogawa Clinical 13/01/1993 Argentina 
CCBT0284 O1 Ogawa Clinical 22/01/1993 Argentina 
CCBT0429 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0440 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0484 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0200 O1 Ogawa Environmental 05/05/1992 Argentina 
CCBT0302 O1 Ogawa Clinical 22/01/1993 Argentina 
CCBT0398 O1 Ogawa Clinical 18/02/1993 Argentina 
CCBT0392 O1 Inaba Clinical 18/02/1993 Argentina 
CCBT0288 O1 Ogawa Clinical 22/01/1993 Argentina 
CCBT0275 O1 Ogawa Clinical 22/01/1993 Argentina 
CCBT0386 O1 Ogawa Clinical 18/02/1993 Argentina 
CCBT0198 O1 Ogawa Clinical 21/04/1992 Argentina 
CCBT0303 O1 Ogawa Clinical 20/01/1993 Argentina 
CCBT0492 O1 Ogawa Environmental 10/05/1993 Argentina 
CCBT0346 O1 Ogawa Clinical 12/02/1993 Argentina 
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CCBT0153 O1 Ogawa Environmental 19/01/1993 Argentina 
CCBT0467 O1 Ogawa Clinical 22/01/1993 Argentina 
CCBT0422 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0168 O1 Ogawa Clinical 21/04/1992 Argentina 
CCBT0420 O1 Ogawa Clinical 18/02/1993 Argentina 
CCBT0324 O1 Ogawa Clinical 03/02/1993 Argentina 
CCBT0133 O1 Ogawa Clinical 13/01/1993 Argentina 
CCBT0335 O1 Ogawa Clinical 12/02/1993 Argentina 
CCBT0139 O1 Ogawa Clinical 13/01/1993 Argentina 
CCBT0207 O1 Ogawa Clinical 05/05/1992 Argentina 
CCBT0417 O1 Ogawa Clinical 18/02/1993 Argentina 
CCBT0301 O1 Ogawa Clinical 22/01/1993 Argentina 
CCBT0156 O1 Ogawa Clinical 13/01/1993 Argentina 
CCBT0222 O1 Ogawa Clinical 22/01/1993 Argentina 
CCBT0412 O1 Ogawa Clinical 12/02/1993 Argentina 
CCBT0065 O1 Ogawa Clinical 21/04/1992 Argentina 
CCBT0225 O1 Ogawa Clinical 20/01/1993 Argentina 
CCBT0287 O1 Ogawa Clinical 22/01/1993 Argentina 
VC011 non-O1 / Clinical 21/04/1992 Argentina 
CCBT0178 O1 Ogawa Clinical 24/02/1992 Argentina 
CCBT0277 O1 Ogawa Clinical 22/01/1993 Argentina 
CCBT0068 O1 Ogawa Clinical 20/05/1992 Argentina 
CCBT0438 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0382 O1 Ogawa Clinical 18/02/1993 Argentina 
CCBT0157 O1 Ogawa Clinical 13/01/1993 Argentina 
CCBT0197 O1 Ogawa Clinical 05/05/1992 Argentina 
CCBT0348 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0460 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0350 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0296 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0355 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0458 O1 Ogawa Clinical 22/02/1993 Argentina 
CCBT0234 O1 Ogawa Clinical 01/04/1992 Argentina 
CCBT0297 O1 Ogawa Clinical 22/01/1993 Argentina 
CCBT0290 O1 Ogawa Clinical 20/01/1993 Argentina 
CCBT0195 O1 Ogawa Clinical 21/04/1992 Argentina 
CCBT0137 O1 Ogawa Clinical 13/01/1993 Argentina 
CCBT0307 O1 / Clinical 22/01/1993 Argentina 
CCBT0485 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0167 O1 Ogawa Clinical 21/04/1992 Argentina 
CCBT0211 O1 Ogawa Clinical 21/04/1992 Argentina 
CCBT0402 O1 Ogawa Clinical 12/02/1993 Argentina 
CCBT0186 O1 Ogawa Clinical 26/03/1993 Argentina 
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CCBT0158 O1 Ogawa Clinical 28/12/1992 Argentina 
CCBT0452 O1 Ogawa Clinical 12/02/1993 Argentina 
CCBT0181 O1 Ogawa Clinical 21/04/1992 Argentina 
CCBT0238 O1 Ogawa Clinical 21/04/1992 Argentina 
CCBT0268 O1 Ogawa Clinical 21/04/1992 Argentina 
CCBT0250 O1 Ogawa Clinical 21/04/1992 Argentina 
CCBT0196 O1 Ogawa Clinical 21/04/1992 Argentina 
CCBT0169 O1 Ogawa Clinical 21/04/1992 Argentina 
CCBT0248 O1 Ogawa Clinical 21/04/1992 Argentina 
CCBT0170 O1 Ogawa Clinical 21/04/1992 Argentina 
CCBT0433 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0300 O1 Ogawa Clinical 22/01/1993 Argentina 
CCBT0332 O1 Ogawa Clinical 22/01/1993 Argentina 
CCBT0455 O1 Ogawa Clinical 12/02/1993 Argentina 
CCBT0310 O1 Ogawa Clinical 20/01/1993 Argentina 
CCBT0437 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0204 O1 Ogawa Clinical 21/04/1992 Argentina 
CCBT0237 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0260 O1 Ogawa Clinical 13/01/1993 Argentina 
CCBT0360 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0273 O1 Ogawa Clinical 22/01/1993 Argentina 
CCBT0462 O1 Ogawa Clinical 12/02/1993 Argentina 
CCBT0338 O1 Ogawa Clinical 22/01/1993 Argentina 
CCBT0378 O1 Ogawa Clinical 18/02/1993 Argentina 
CCBT0228 O1 Ogawa Clinical 26/03/1993 Argentina 
CCBT0431 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0399 O1 Ogawa Clinical 05/02/1993 Argentina 
CCBT0171 O1 Ogawa Clinical 21/04/1992 Argentina 
CCBT0191 O1 Ogawa Clinical 05/05/1992 Argentina 
CCBT0267 O1 Ogawa Clinical 22/01/1993 Argentina 
CCBT0188 O1 Ogawa Environmental 05/05/1992 Argentina 
CCBT0475 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0254 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0361 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0407 O1 Ogawa Clinical 12/02/1993 Argentina 
CCBT0354 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0269 O1 Ogawa Clinical 21/04/1992 Argentina 
CCBT0342 O1 Ogawa Clinical 20/01/1993 Argentina 
CCBT0179 O1 Ogawa Clinical 01/04/1992 Argentina 
CCBT0145 O1 Ogawa Clinical 13/01/1993 Argentina 
CCBT0319 O1 Ogawa Clinical 20/01/1993 Argentina 
CCBT0280 O1 Ogawa Clinical 20/01/1993 Argentina 
CCBT0177 O1 Ogawa Clinical 21/04/1992 Argentina 
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CCBT0343 O1 Ogawa Clinical 22/01/1993 Argentina 
CCBT0395 O1 Ogawa Clinical 18/02/1993 Argentina 
CCBT0419 O1 Ogawa Clinical 18/02/1993 Argentina 
VC016 non-O1 / Environmental 13/11/1992 Argentina 
CCBT0244 O1 Ogawa Clinical 05/05/1992 Argentina 
CCBT0314 O1 Ogawa Clinical 22/01/1993 Argentina 
CCBT0219 O1 Ogawa Clinical 19/01/1993 Argentina 
CCBT0325 O1 Ogawa Clinical 19/09/1997 Argentina 
VC006 non-O1 / Environmental 13/11/1992 Argentina 
CCBT0387 O1 Ogawa Clinical 18/02/1993 Argentina 
CCBT0141 O1 Ogawa Environmental 19/01/1993 Argentina 
CCBT0130 non-O1 / Environmental 03/06/1996 Argentina 
CCBT0221 O1 Ogawa Clinical 20/01/1993 Argentina 
CCBT0311 O1 Ogawa Clinical 14/01/1993 Argentina 
CCBT0298 O1 Ogawa Clinical 22/01/1993 Argentina 
CCBT0453 O1 Ogawa Clinical 22/01/1993 Argentina 
CCBT0149 O1 Ogawa Clinical 01/12/1992 Argentina 
CCBT0464 O1 Ogawa Clinical 18/02/1993 Argentina 
CCBT0252 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0309 O1 Ogawa Clinical 22/01/1993 Argentina 
CCBT0397 O1 Ogawa Clinical 22/01/1993 Argentina 
CCBT0155 non-O1 / Environmental 11/02/2000 Argentina 
CCBT0293 O1 Ogawa Clinical 20/01/1993 Argentina 
CCBT0193 O1 Ogawa Clinical 05/05/1992 Argentina 
CCBT0316 O1 Ogawa Clinical 22/01/1993 Argentina 
CCBT0472 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0403 O1 Ogawa Clinical 12/02/1993 Argentina 
CCBT0405 O1 Ogawa Clinical 05/02/1993 Argentina 
CCBT0406 O1 Ogawa Clinical 12/02/1993 Argentina 
CCBT0391 O1 Ogawa Environmental 10/05/1993 Argentina 
CCBT0274 O1 Ogawa Clinical 03/02/1993 Argentina 
CCBT0328 O1 Ogawa Clinical 22/01/1993 Argentina 
CCBT0385 O1 Inaba Clinical 18/02/1993 Argentina 
CCBT0304 O1 Ogawa Clinical 22/01/1993 Argentina 
CCBT0206 O1 Ogawa Clinical 16/01/1993 Argentina 
CCBT0445 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0242 O1 Ogawa Clinical 21/04/1992 Argentina 
CCBT0263 O1 Ogawa Clinical 21/04/1992 Argentina 
CCBT0444 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0448 O1 Ogawa Clinical 18/02/1993 Argentina 
VC013 non-O1 / Environmental 13/11/1992 Argentina 
CCBT0362 O1 Ogawa Clinical 02/03/1993 Argentina 
CCBT0289 O1 Ogawa Clinical 22/01/1993 Argentina 
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CCBT0102 non-O1 / Environmental 12/04/2000 Argentina 
CCBT0042 non-O1 / Clinical 28/02/1996 Argentina 
CCBT0079 non-O1 / Clinical 22/04/1996 Argentina 
VC034 non-O1 / Clinical 12/05/1993 Argentina 
CCBT0082 non-O1 / Environmental 18/03/1996 Argentina 
CCBT0096 / / Environmental 14/06/1996 Argentina 
CCBT0084 
O1 (genomically non-
O1) Ogawa Clinical 26/04/1995 Argentina 
CCBT0086 non-O1 / Environmental 14/06/1996 Argentina 
CCBT0081 non-O1 / Clinical 18/04/1996 Argentina 
CCBT0007 non-O1 / Clinical 03/06/1996 Argentina 
CCBT0043 non-O1 / Clinical 28/05/1996 Argentina 
CCBT0493 non-O1 non-O139 / Clinical 15/04/2004 Argentina 
CCBT0500 
O1 (genomically non-
O1) Ogawa Clinical 04/02/1993 Argentina 
CCBT0090 non-O1 / Clinical 28/05/1996 Argentina 
CCBT0058 non-O1 / Clinical 17/04/1996 Argentina 
CCBT0053 non-O1 / Clinical 06/06/1996 Argentina 
VC012 non-O1 / Environmental 17/03/1992 Argentina 
CCBT0112 non-O1 / Environmental 15/07/1992 Argentina 
VC002 non-O1 / Environmental 17/03/1992 Argentina 
CCBT0106 non-O1 / Environmental 01/12/1992 Argentina 
VC001 non-O1 / Environmental 17/03/1992 Argentina 
CCBT0136 
O1 (genomically non-
O1) Ogawa Clinical 13/01/1993 Argentina 
CCBT0131 
O1 (genomically non-
O1) Ogawa Environmental 19/01/1993 Argentina 
CCBT0135 
O1 (genomically non-
O1) Ogawa Environmental 19/01/1993 Argentina 
CCBT0063 non-O1 / Clinical 01/09/1992 Argentina 
CCBT0119 non-O1 / Environmental 13/11/1992 Argentina 
CCBT0073 non-O1 / Environmental 13/11/1992 Argentina 
CCBT0054 non-O1 / Clinical 17/04/1996 Argentina 
CCBT0146 non-O1 / Environmental 29/12/1992 Argentina 
VC008 non-O1 / Clinical 28/01/1993 Argentina 
CCBT0129 non-O1 / Environmental 19/01/1993 Argentina 
CCBT0162 non-O1 / Environmental 01/12/1992 Argentina 
CCBT0045 non-O1 / Clinical 17/04/1996 Argentina 
CCBT0044 non-O1 / Clinical 17/04/1996 Argentina 
CCBT0033 non-O1 / Clinical 30/12/1996 Argentina 
CCBT0060 non-O1 / Environmental 13/11/1992 Argentina 
CCBT0094 non-O1 / Clinical 17/04/1996 Argentina 
CCBT0411 O1 (genomically O1) Ogawa Clinical 05/02/1993 Argentina 
CCBT0099 non-O1 / Environmental 01/12/1992 Argentina 
CCBT0491 / / Clinical 15/04/2004 Argentina 
VC024 non-O1 / Clinical 03/02/2000 Argentina 
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CCBT0443 non-O1 / Clinical 02/03/1993 Argentina 
CCBT0151 
O1 (genomically non-
O1) Ogawa Clinical 13/01/1993 Argentina 
VC010 non-O1 / Clinical 16/01/1993 Argentina 
CCBT0087 non-O1 / Clinical 18/04/1996 Argentina 
CCBT0008 
O1 (genomically non-
O1) Ogawa Environmental 19/01/1993 Argentina 
CCBT0018 non-O1 / Clinical 03/06/1996 Argentina 
CCBT0495 non-O1 non-O139 / Clinical 18/08/2005 Argentina 
CCBT0496 non-O1 / Clinical 02/05/1994 Argentina 
VC009 non-O1 / Clinical 20/01/1993 Argentina 
CCBT0093 non-O1 / Clinical 17/04/1996 Argentina 
CCBT0061 non-O1 / Clinical 16/10/1992 Argentina 
CCBT0072 non-O1 / Clinical 19/10/1992 Argentina 
CCBT0113 non-O1 / Clinical 19/10/1992 Argentina 
CCBT0494 non-O1 non-O139 / Clinical 17/12/2003 Argentina 
CCBT0101 non-O1 / Clinical 22/12/1992 Argentina 
CCBT0117 non-O1 / Environmental 29/12/1992 Argentina 
CCBT0026 non-O1 / Clinical 08/11/1996 Argentina 
CCBT0115 non-O1 / Clinical 16/10/1992 Argentina 
CCBT0020 non-O1 / Clinical 21/01/1997 Argentina 
CCBT0174 O1 (genomically O1) Ogawa Clinical 15/10/1997 Argentina 
CCBT0118 
non-O1 (genomically 
O1) / Clinical 28/05/1996 Argentina 
CCBT0077 non-O1 / Clinical 17/04/1996 Argentina 
CCBT0497 O1 (genomically O1) Ogawa Clinical 23/02/1998 Argentina 
CCBT0320 O1 (genomically O1) Ogawa Clinical 02/02/1993 Argentina 
Mex_175 non-O1 / Human 1993 - 1993 Guatemala 
Mex_01 non-O1 / Human 1991 Tabasco 
Mex_02 non-O1 / Human 1991 Tabasco 
Mex_03 non-O1 / Human 1991 Tabasco 
Mex_04 non-O1 / Human 1991 Tabasco 
Mex_05 non-O1 / Human 1992-93 Campeche 
Mex_06 non-O1 / Water well 1992-93 Campeche 
Mex_07 non-O1 / Water well 1992-93 Campeche 
Mex_08 non-O1 / Water well 1992 Campeche 
Mex_09 non-O1 / Human June 1991 Hidalgo 
Mex_10 non-O1 /  June1991  
Mex_11 non-O1 / Human July 1991 Chiapas 
Mex_12 non-O1 / Human July 1991 Puebla 
Mex_13 non-O1 / Human July 1991 Hidalgo 
Mex_14 non-O1 / Human July 1991 Hidalgo 
Mex_15 non-O1 / Human July 1991 Hidalgo 
Mex_16 non-O1 / Human August 1991 Puebla 
Mex_17 non-O1 / Human July 1991 Hidalgo 
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Mex_18 non-O1 / Human July 1991 Veracruz 
Mex_19 non-O1 / Human July 1991 Hidalgo 
Mex_20 non-O1 / Environmental August 1991 INDRE 
Mex_21 non-O1 / Human July 1991 Veracruz 
Mex_22 non-O1 / Human August 1991 Yucatan 
Mex_23 non-O1 / Human August 1991 Hidalgo 
Mex_24 non-O1 / Human August 1991 Veracruz 
Mex_25 non-O1 / Human July 1991 Bosay 
Mex_26 non-O1 / Human June1991 Hidalgo 
Mex_27 non-O1 / Human August 1991 Chiapas 
Mex_28 non-O1 / Human August 1991 Campeche 
Mex_29 non-O1 / Human February 1992 INDRE 
Mex_30 non-O1 / Human August 1991 Guerrero 
Mex_31 non-O1 / Human August 1991 Chiapas 
Mex_32 non-O1 / Human June 1991 Hidalgo 
Mex_33 non-O1 / Human August 1991 INDRE 
Mex_34 non-O1 / Human August 1991 INDRE 
Mex_35 non-O1 / Fish August 1991 Veracruz 
Mex_36 non-O1 / Human July 1991 Veracruz 
Mex_37 non-O1 / Environmental July 1991 Veracruz 
Mex_39 non-O1 / Human 
September 
1991 Leon 
Mex_40 non-O1 / Human August 1991 INDRE 
Mex_38 non-O1 / Human August 1991 Hidalgo 
Mex_41 non-O1 / Human 
September 
1991 Guanajuato 
Mex_42 non-O1 / Human August 1991 Yucatan 
Mex_43 non-O1 / Human February 1992 Guanajuato 
Mex_44 non-O1 / Human March 1992 Michoacan 
Mex_45 non-O1 / Human 
September 
1991 Chiapas 
Mex_46 non-O1 / Human August 1991 Zacatecas 
Mex_47 non-O1 / Human 
September 
1991 Chiapas 
Mex_48 non-O1 / Human 
September 
1991 Guanajuato 
Mex_49 non-O1 / Human August 1991 Hidalgo 
Mex_50 non-O1 / Human August 1991 Zacatecas 
Mex_51 non-O1 / Water 1992 Tabasco 
Mex_52 non-O1 / Human 1992 Tabasco 
Mex_53 non-O1 / Human 1992 Tabasco 
Mex_54 non-O1 / Human 1992 Tabasco 
Mex_55 non-O1 / Human 1992 Tabasco 
Mex_56 non-O1 / Human 1992 Tabasco 
Mex_57 non-O1 / Human 1992 Tabasco 
Mex_58 non-O1 / Human 1992 Tabasco 
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Mex_59 non-O1 / Human 1992 Tabasco 
Mex_60 non-O1 / Human 1993 Tabasco 
Mex_61 non-O1 / Human 1993 Tabasco 
Mex_62 non-O1 / Human 1992 Tabasco 
Mex_63 non-O1 / Human 1992 Tabasco 
Mex_64 non-O1 / Human 1993 Tabasco 
Mex_65 non-O1 / Human 1992 Tabasco 
Mex_66 non-O1 / Human 1992 Tabasco 
Mex_67 non-O1 / Water well 1992-93 Campeche 
Mex_68 non-O1 / Water well 1992-93 Campeche 
Mex_69 non-O1 / Water well 1992-93 Campeche 
Mex_70 non-O1 / Water well 1992-93 Campeche 
Mex_71 non-O1 / Water well 1992-93 Campeche 
Mex_72 non-O1 / Water well 1992-93 Campeche 
Mex_73 non-O1 / Water well 1992-93 Campeche 
Mex_74 non-O1 / Human 1991 Tabasco 
Mex_75 non-O1 / Human 1991 Tabasco 
Mex_76 non-O1 / Human 1991 Tabasco 
Mex_77 non-O1 / Human 1991 Tabasco 
Mex_78 non-O1 / Human 1991 Tabasco 
Mex_79 non-O1 / Human 1991 Tabasco 
Mex_80 non-O1 /    
Mex_81 non-O1 /    
Mex_82 non-O1 /    
Mex_83 non-O1 /   Campeche 
Mex_84 non-O1 /  apr-oct 1993  
Mex_85 non-O1 /  apr-oct 1993  
Mex_88 non-O1 / Food 1993 Hermosillo 
Mex_89 non-O1 / Water 1993 Hermosillo 
Mex_90 non-O1 / Food 1993 Hermosillo 
Mex_91 non-O1 / Fish 1993 Hermosillo 
Mex_92 non-O1 / Fish 1993 Hermosillo 
Mex_93 non-O1 / Fish 1993 Hermosillo 
Mex_94 non-O1 / Water 1993 Hermosillo 
Mex_95 non-O1 / Fish 1993 Hermosillo 
Mex_96 non-O1 / Water 1993 Hermosillo 
Mex_97 non-O1 / Fish 1993 Hermosillo 
Mex_98 non-O1 / Fish 1993 Hermosillo 
Mex_99 non-O1 / Fish 1993 Hermosillo 
Mex_100 non-O1 / Fish 1993 Hermosillo 
Mex_101 non-O1 / Shrimp 1993 Hermosillo 
Mex_102 non-O1 / Fish 1993 Hermosillo 
Mex_103 non-O1 / Fish 1993 Hermosillo 
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Mex_104 non-O1 / Fish 1993 Hermosillo 
Mex_105 non-O1 / Fish 1993 Hermosillo 
Mex_106 non-O1 / Fish 1993 Hermosillo 
Mex_107 non-O1 / Sewage 1993 Hermosillo 
Mex_108 non-O1 / Sewage 1993 Hermosillo 
Mex_109 non-O1 / Sewage 1993 Hermosillo 
Mex_110 non-O1 / Septic tank 1993 Hermosillo 
Mex_111 non-O1 / Sewage 1993 Hermosillo 
Mex_179 non-O1 / Sewage 1993 Hermosillo 
Mex_178 non-O1 / Sewage 1993 Hermosillo 
Mex_112 non-O1 / Sewage 1993 Hermosillo 
Mex_113 non-O1 / Sewage 1993 Hermosillo 
Mex_115 non-O1 / Dam 1993 Hermosillo 
Mex_114 non-O1 / Dam 1993 Hermosillo 
Mex_116 non-O1 / Dam 1993 Hermosillo 
Mex_117 non-O1 / Sewage 1993 Hermosillo 
Mex_118 non-O1 / Sewage 1993 Hermosillo 
Mex_119 non-O1 / Sewage 1993 Hermosillo 
Mex_120 non-O1 / Sewage 1993 Hermosillo 
Mex_121 non-O1 / Sewage 1993 Hermosillo 
Mex_176 non-O1 / Sewage 1993 Hermosillo 
Mex_122 non-O1 / Sewage 1993 Hermosillo 
Mex_123 non-O1 / Sewage 1993 Hermosillo 
Mex_124 non-O1 / Sewage 1993 Hermosillo 
Mex_125 non-O1 / Sewage 1993 Hermosillo 
Mex_177 non-O1 / Sewage 1993 Hermosillo 
Mex_126 non-O1 / Sewage 1993 Hermosillo 
Mex_127 non-O1 /  apr-oct 1993 Mexico 
Mex_128 non-O1 /   Mexico 
Mex_129 non-O1 /   Mexico 
Mex_130 non-O1 /   Mexico 
Mex_131 non-O1 /   Mexico 
Mex_132 non-O1 /   Mexico 
Mex_133 non-O1 /   Mexico 
Mex_134 non-O1 /   Mexico 
Mex_135 non-O1 /   Mexico 
Mex_136 non-O1 /   Mexico 
Mex_137 non-O1 /   Mexico 
Mex_138 non-O1 /   Mexico 
Mex_139 non-O1 /   Mexico 
Mex_141 non-O1 /   Mexico 
Mex_142 non-O1 /   Mexico 
Mex_143 non-O1 /   Mexico 
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Mex_144 non-O1 /   Mexico 
Mex_145 non-O1 / Human 1992 - 1993 Guatemala 
Mex_146 non-O1 / Human 1992 - 1993 Guatemala 
Mex_147 non-O1 / Human 1992 - 1993 Guatemala 
Mex_148 non-O1 / Human 1992 -1993 Guatemala 
Mex_174 non-O1 / Human 1992 - 1993 Guatemala 
Mex_149 non-O1 / Human 1992 - 1993 Guatemala 
Mex_173 non-O1 / Human 1992 - 1993 Guatemala 
Mex_151 non-O1 / Human 1992 - 1993 Guatemala 
Mex_152 non-O1 / Human 1992 - 1993 Guatemala 
Mex_172 non-O1 / Human 1992 - 1993 Guatemala 
Mex_153 non-O1 / Human 1992 - 1993 Guatemala 
Mex_171 non-O1 / Human 1992 - 1993 Guatemala 
Mex_154 non-O1 / Human 1992 - 1993 Guatemala 
Mex_170 non-O1 / Human 1992 - 1993 Guatemala 
Mex_155 non-O1 / Human 1992 - 1993 Guatemala 
Mex_169 non-O1 / Human 1992 - 1993 Guatemala 
Mex_156 non-O1 / Human 1992 - 1993 Guatemala 
Mex_168 non-O1 / Human 1992 - 1993 Guatemala 
Mex_157 non-O1 / Human 1992 - 1993 Guatemala 
Mex_158 non-O1 / Human 1992 - 1993 Guatemala 
Mex_167 non-O1 / Human 1992 - 1993 Guatemala 
Mex_159 non-O1 / Human 1992 - 1993 Guatemala 
Mex_160 non-O1 / Human 1992 - 1993 Guatemala 
Mex_161 non-O1 / Human 1992 - 1993 Guatemala 
Mex_162 non-O1 / Human 1992 - 1993 Guatemala 
Mex_163 non-O1 / Human 1992 - 1993 Guatemala 
Mex_164 non-O1 / Human 1992 - 1993 Guatemala 
Mex_165 non-O1 / Human 1992 - 1993 Guatemala 
Mex_86 non-O1 /    
Mex_87 non-O1 /    
NCTC_30 Non-O1 / / 1916 
See table 
5.2 
NCTC_3661 O1 / / 1931 
See table 
5.2 
NCTC_4693 O1 / / Pre-1936 
See table 
5.2 
NCTC_4711 Non-O1/O139 / / Pre-1936 
See table 
5.2 
NCTC_4714 Non-O1/O139 / / 1934 
See table 
5.2 
NCTC_4715 Non-O1/O139 / / 1934 
See table 
5.2 
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NCTC_4716 Non-O1/O139 / / 1932 
See table 
5.2 
NCTC_5395 O1 / / 1938 
See table 
5.2 
NCTC_5596 O1 / / Pre-1939 
See table 
5.2 
NCTC_6585 O1 / / Pre-1944 
See table 
5.2 
NCTC_7258 O1 / / Pre-1948 
See table 
5.2 
NCTC_7260 O1 / / Pre-1948 
See table 
5.2 
NCTC_7270 O1 / / Pre-1948 
See table 
5.2 
NCTC_8021 O1 / / Pre-1950 
See table 
5.2 
NCTC_8039 O1 / / Pre-1950 
See table 
5.2 
NCTC_8040 O1 / / Pre-1950 
See table 
5.2 
NCTC_8041 O1 / / Pre-1950 
See table 
5.2 
NCTC_8042 Non-O1/O139 / / Pre-1950 
See table 
5.2 
NCTC_8050 O1 / / Pre-1950 
See table 
5.2 
NCTC_8367 O1 / / Pre-1952 
See table 
5.2 
NCTC_8457 O1 / / 1930 
See table 
5.2 
NCTC_9420 O1 / / Pre-1955 
See table 
5.2 
NCTC_9421 O1 / / Pre-1955 
See table 
5.2 
NCTC_9422 O1 / / Pre-1955 
See table 
5.2 
NCTC_9423 O1 / / Pre-1955 
See table 
5.2 
NCTC_10255 O1 / / 1961 
See table 
5.2 
NCTC_10256 O1 / / 1961 
See table 
5.2 
NCTC_10732 O1 / / 1952 
See table 
5.2 
NCTC_10733 O1 / / 1952 
See table 
5.2 
NCTC_10954 O1 / / 1973 
See table 
5.2 
NCTC_11090 O1 / / Pre-1950 
See table 
5.2 
NCTC_11348 Non-O1/O139 / / Pre-1981 
See table 
5.2 
NCTC_11500 Non-O1/O139 / / Pre-1983 
See table 
5.2 
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NCTC_11643 Non-O1/O139 / / Pre-1985 
See table 
5.2 
NCTC_12946 O139 / / 1993 
See table 
5.2 
 
